U.S. patent application number 14/284283 was filed with the patent office on 2014-11-27 for reprogramming immortalized b cells.
This patent application is currently assigned to CELLULAR DYNAMICS INTERNATIONAL, INC.. The applicant listed for this patent is CELLULAR DYNAMICS INTERNATIONAL, INC.. Invention is credited to Sarah Jane DICKERSON, Amanda MACK, Michael MILLER, Deepika RAJESH, James THOMSON.
Application Number | 20140349397 14/284283 |
Document ID | / |
Family ID | 45560057 |
Filed Date | 2014-11-27 |
United States Patent
Application |
20140349397 |
Kind Code |
A1 |
THOMSON; James ; et
al. |
November 27, 2014 |
REPROGRAMMING IMMORTALIZED B CELLS
Abstract
Methods and composition for providing induced pluripotent stem
(iPS) cells are provided. For example, in certain aspects methods
including reprogramming B lymphocytes transformed by episomal
vectors such as Epstein-Barr virus-based vectors are described.
Furthermore, the invention provides induced pluripotent stem cells
essentially free of exogenous elements and having B cell
immunoglobin variable region rearrangement.
Inventors: |
THOMSON; James; (Madison,
WI) ; RAJESH; Deepika; (Madison, WI) ;
DICKERSON; Sarah Jane; (Madison, WI) ; MACK;
Amanda; (Madison, WI) ; MILLER; Michael;
(Madison, WI) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
CELLULAR DYNAMICS INTERNATIONAL, INC. |
Madison |
WI |
US |
|
|
Assignee: |
CELLULAR DYNAMICS INTERNATIONAL,
INC.
Madison
WI
|
Family ID: |
45560057 |
Appl. No.: |
14/284283 |
Filed: |
May 21, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13197529 |
Aug 3, 2011 |
8765470 |
|
|
14284283 |
|
|
|
|
61441885 |
Feb 11, 2011 |
|
|
|
61370615 |
Aug 4, 2010 |
|
|
|
Current U.S.
Class: |
435/366 |
Current CPC
Class: |
C12N 2501/606 20130101;
C12N 2800/108 20130101; C12N 2501/727 20130101; C12N 2710/16243
20130101; C12N 2501/115 20130101; C12N 2501/15 20130101; C12N
2510/00 20130101; C12N 5/0696 20130101; C12N 2501/235 20130101;
C12N 15/63 20130101; C12N 2501/602 20130101; C12N 2501/603
20130101; C12N 2501/06 20130101; C12N 2501/608 20130101; C12N
2506/11 20130101; C12N 2501/605 20130101; C12N 2501/604 20130101;
C12N 2510/04 20130101; C12N 15/85 20130101 |
Class at
Publication: |
435/366 |
International
Class: |
C12N 5/074 20060101
C12N005/074 |
Claims
1.-16. (canceled)
17. A human iPS cell having a genome that comprises an incomplete
set of B cell immunoglobin variable region genes compared with an
embryonic stem cell, wherein the iPS cell is essentially free of
exogenous genetic elements.
18. The human iPS cell of claim 17, wherein the genome comprises a
selected genetic marker.
19. The human iPS cell of claim 18, wherein the selected genetic
marker is a genetic marker of a selected disease.
20. The human iPS cell of claim 17, wherein the genome is derived
from an immortalized B cell.
21. The human iPS cell of claim 20, wherein the human iPS cell has
a normal karyotype.
22. A differentiated cell, tissue, or organ derived from the human
iPS cell of claim 17.
Description
[0001] This application is a continuation of U.S. application Ser.
No. 13/197,529, filed Aug. 3, 2011, which claims priority to U.S.
Application No. 61/370,615, filed on Aug. 4, 2010 and U.S.
Application Ser. No. 61/441,885 filed on Feb. 11, 2011, the entire
contents of each of which are hereby incorporated by reference.
BACKGROUND OF THE INVENTION
[0002] 1. Field of the Invention
[0003] The present invention relates generally to the field of
molecular biology and stem cells. More particularly, it concerns
reprogramming of somatic cells, especially transformed B cells.
[0004] 2. Description of Related Art
[0005] Induced pluripotent stem cells, commonly abbreviated as iPS
cells or iPSCs, are a type of pluripotent stem cell artificially
derived from a non-pluripotent cell, typically an adult somatic
cell. Induced pluripotent stem cells are believed to be identical
to natural pluripotent stem cells, such as embryonic stem (ES)
cells in many respects, for example in terms of the expression of
certain stem cell genes and proteins, chromatin methylation
patterns, doubling time, embryoid body formation, teratoma
formation, viable chimera formation, and potency and
differentiability, but the full extent of their relation to natural
pluripotent stem cells is still being assessed.
[0006] In humans, iPS cells are commonly generated from dermal
fibroblasts. However, the requirement for skin biopsies and the
need to expand fibroblast cells for several passages in vitro make
it a cumbersome source for generating patient-specific stem cells.
Moreover, previous methods for reprogramming of human somatic cells
are inconvenient because they need to obtain somatic cells directly
from a human subject, or maintain the cells in a labor-intensive
cell culture system. Therefore, there is a need to develop methods
to induce pluripotent stem cells from alternative sources which are
simple, convenient, and easily accessible.
SUMMARY OF THE INVENTION
[0007] Generation of patient-specific induced pluripotent cells
(iPSCs) holds great promise for regenerative medicine. Epstein-Barr
virus (EBV) immortalized lymphoblastoid B cell lines (LCLs) can be
generated from a minimal amount of blood and are banked worldwide
as cellular reference material for immunological or genetic
analysis for pedigreed study populations. As demonstrated in
Examples, iPSCs were generated from two LCLs (LCL-iPSCs) via a
feeder-free episomal method using a cocktail of transcription
factors and small molecules. LCL-derived iPSCs exhibited normal
karyotype, expressed pluripotency markers, lost oriP/EBNA-1
episomal vectors, generated teratomas, retained donor identity and
differentiated in vitro into hematopoietic, cardiac, neural and
hepatocyte lineages. Significantly, although the parental LCLs
express viral EBNA-1 and other EBV latency related elements for
their survival, their presence was not detectable in LCL-iPSCs.
Thus, reprogramming LCLs could offer an unlimited source for
patient-specific iPSCs especially for EBV related diseases.
[0008] Therefore, certain aspects of the present invention overcome
a major deficiency in the art by providing novel methods for
producing induced pluripotent stem cells (iPS cells) from
immortalized somatic cells, as well as iPS cells provided
therefrom. Accordingly, in a first embodiment there is provided a
method that comprises reprogramming one or more somatic cells that
have been immortalized by virtue of one or more episomal vector
elements, therefore producing iPS cells. In certain aspects, the
immortalized somatic cells comprise lymphoblastoid cells or
immortalized peripheral blood mononuclear cells. An immortalized
peripheral blood mononuclear cell may be derived from a lymphocyte
(different types of T cells and/or B cells), a monocyte or a
macrophage. For example, the immortalized somatic cells, in
particularly lymphoblastoid cells, may be derived from a cell
population comprising B cells, for example, by EBV (Epstein-Barr
virus) transformation. Any of the episomal vector elements
disclosed herein may comprise EBV elements. The EBV elements may
include an oriP replication origin and/or a gene encoding EBNA-1 or
derivatives thereof.
[0009] In a particular aspect, there may be provided a method for
producing induced pluripotent stem cells (iPS cells) from
immortalized B cells. The method may comprise obtaining
immortalized B cells that have been immortalized by virtue of one
or more immortalizing Epstein-Barr virus (EBV) elements. The method
may further comprise reprogramming the immortalized B cells by
effecting expression of exogenous reprogramming factors therein,
thereby producing iPS cells. It has been discovered that
immortalizing EBV elements may not be required in iPS cells for
long term proliferation and storage, therefore the method may
further comprise removing the EBV elements from the iPS cells or
isolating or enriching iPS cells that are essentially free of the
EBV elements. Thus, iPS cells essentially free of EBV elements but
derived from immortalized B cells may be obtained.
[0010] There may be at least two approaches to obtain immortalized
B cells. One approach may be to immortalize B cells with
Epstein-Barr virus (EBV) elements. Such B cells prior to
immortalization may have been obtained from a blood sample. The
blood sample may have a volume of from at least about 0.01 to about
5 mL, more particularly about 0.1 to 0.5 mL, or any number or range
derivable therein. For example, the immortalizing EBV elements may
comprise inducible exogenous reprogramming expression cassettes.
Thus, reprogramming the immortalized B cells may comprise inducing
the expression of inducible exogenous reprogramming expression
cassettes. In other aspects, the immortalized B cells may be
obtained from an established lymphoblastoid cell line. For
reprogramming, the method may comprise introducing one or more
reprogramming episomal vector elements into the immortalized B
cells, such as EBV elements.
[0011] To increase reprogramming efficiency, the immortalized B
cells may be cultured in the absence of a feeder layer. In further
aspects, the method may comprise contacting the immortalized B
cells with one or more signaling inhibitors including a glycogen
synthase kinase 3 (GSK-3) inhibitor, a mitogen-activated protein
kinase kinase (MEK) inhibitor, a transforming growth factor beta
(TGF-.beta.) receptor inhibitor, leukemia inhibitory factor (LIF),
a p53 inhibitor, an NF-kappa B inhibitor, or a combination thereof.
The reprogramming method may also comprise contacting the
immortalized B cells with fibroblast growth factor (FGF). The
reprogramming method as described in certain aspects of the
invention may obviate the need of Pax-5 inhibition or C/EBP.alpha.
overexpression in repreogramming mature B cells. Thus, the
reprogramming may not include the introduction of an inhibitory
nucleotide specific for Pax-5 into the immortalized B cells or
expression of exogenous C/EBP.alpha. in the immortalized B cells.
The method may further comprise differentiating the iPS cells into
cardiac cells, hematopoietic cells, neural cells, or hepatocytes in
vitro.
[0012] For reprogramming B cells to produce iPS cells, there may be
provided a method of immortalizing B cells, and effecting exogenous
expression of one or more reprogramming factors in the immortalized
B cells. In a further embodiment, there may also be provided a
method for producing iPS cells, comprising the steps of: a)
transforming B cells with an EBV-based episomal vector to produce
an immortalized cell line; and b) effecting exogenous expression of
one or more reprogramming factors in the immortalized cell line,
thereby producing iPS cells.
[0013] Reprogramming of immortalized B cells may comprise
introducing reprogramming episomal vectors into the immortalized B
cells. In alternative embodiments, reprogramming may comprise
inducing the expression of reprogramming expression cassettes
comprised in the episomal vectors for immortalization. The
reprogramming factors may be reprogramming expression cassettes
comprised in a separate episomal vector different from the
EBV-based episomal vector for immortalization. Alternatively, the
reprogramming factors may be reprogramming expression cassettes
comprised in the EBV-based episomal vector, therefore saving the
step of introducing separate reprogramming vectors and simplifying
the process. The reprogramming expression cassettes may be under
the control of an inducible promoter. In this particular aspect,
effecting exogenous expression of reprogramming factors may
comprise activating the inducible promoter.
[0014] As described below, there may be provided methods comprising
isolating or enriching iPS cells that are essentially free of
episomal vector elements (episomal vector elements for
immortalization or reprogramming or both) or removing episomal
vector elements from iPS cells so produced. Episomal vector
elements for immortalization or reprogramming may be the same or
different entities.
[0015] Certain aspects of the invention are novel at least because
the initial immortalized cells depend on genes expressed by
episomal vector elements for long-term proliferation to provide a
sustained cell source; however, after converting into iPS cells,
the episomal vector elements are no longer needed as the iPS cells
are naturally proliferative and immortal. Therefore, in certain
embodiments, the iPS cells so produced may be essentially free of
exogenous genetic elements, particularly episomal vector elements:
for example, the iPS cells may be essentially free of DNA, RNA or
protein of EBNA-1, EBV latency-related elements such as EBNA-2,
LMP-2A, lytic gene such as BZLF-1, and/or EBV-encoded small RNAs
(EBERs).
[0016] Such iPS cells may be produced with or without additional
steps for enriching or selecting cells essentially free of episomal
vector elements during or after reprogramming. For example,
enriching or selecting the iPS cell essentially free of episomal
vector elements may include having the episomal vector elements
removed to minimize the effects of exogenous genetic elements. In
other aspects, the episomal vector elements may be lost from iPS
progeny cells after long term proliferation.
[0017] In one embodiment, there may be methods comprising isolating
or enriching the iPS cells that are essentially free of episomal
vector elements. For example, the method may comprise cloning
individual iPS cells and selecting for a clonal colony that has the
episomal vector elements removed. To facilitate the selection, the
method may comprise effecting expression of a selectable marker
and/or screenable marker comprised in the episomal vector elements.
In some aspects, the selectable and/or screenable marker is under
the control of an externally responsive regulatory element, such as
an inducible promoter. An inducing agent, such as estrogen or
tetracycline, may effect expression of such a selectable and/or
screenable marker, which indicates the presence of the episomal
vector elements.
[0018] A selectable marker and/or screenable marker may be used in
certain aspects of the invention for various purposes. Any
selectable or screenable marker known in the art are included. The
selectable maker may be further defined as an antibiotic resistance
gene or a suicide gene. The screenable marker may be further
defined as a reporter gene that expresses a fluorescent,
luminescent or bioluminescent protein or a reporter gene that
expresses a cell surface marker, an epitope, or chloramphenicol
acetyl transferase (CAT). For example, the antibiotic resistance
gene may be a gene that confers resistance to puromycin,
blasticidin, neomycin, tetracycline, or ampicillin. The suicide
gene may be Herpes simplex virus thymidine kinase gene (HSV-tk).
The reporter gene may express a protein such as a green fluorescent
protein (GFP), red fluorescent protein (RFP), blue fluorescent
protein (BFP), yellow fluorescent protein (YFP), luciferase or
beta-galactosidase.
[0019] In another embodiment, the episomal vector elements in the
iPS cells may be removed by methods comprising effecting expression
of an episomal mutant gene that increases the loss of the episomal
vector elements from the iPS cells. For example, the episomal
mutant gene is an EBNA-1 (Epstein-Barr virus nuclear antigen 1)
dominant negative mutant. For example, EBNA-1 dominant negative
mutants may be derivatives of EBNA-1 such as ND450-641 and
ND450-618 (Kirchmaier and Sugden, 1997).
[0020] In certain aspects, the method comprises introducing an
expression cassette comprising the episomal mutant gene into the
iPS cells. In other aspects, the method may comprise effecting the
expression of the episomal mutant gene comprised in the episomal
vector elements. For example, the episomal mutant gene may be under
the control of an inducible promoter. The method may comprise
activating such a promoter when the episomal removal is desired,
thereby the episomal mutant gene would be expressed.
[0021] In a further embodiment, the episomal vector elements in the
iPS cells may be removed by methods comprising contacting the iPS
cells with one or more agents capable of removing the episomal
vector elements. Particularly, the episomal vector elements
comprise viral elements, for example, EBV elements. The removal
agents may be anti-viral agents, or more particularly, anti-EBV
agents. Without being bound by theory, the anti-viral agents or
anti-EBV agents may inhibit replication or proliferation of
episomal vector elements; or in other aspects, because the episomal
vector elements may be spontaneously lost from iPS cells with cell
growth/division, some examples of these agents may specifically
inhibit or kill cells which still retain the vector elements,
thereby enriching cells essentially free of the vector
elements.
[0022] For example, the anti-viral agents comprise nucleic acid
analogs or G-quadruplex-specific compounds. Nucleic acid analogs
may be Acyclovir ([9-(2-hydroxyethoxymethyl)guanine]),
E-5-(2-bromovinyl)-2'-deoxyuridine,
1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine,
1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-methyluracil,
beta-L-5-Iododioxolane uracil, and/or 3'-azido-3'-deoxythymidine.
G-quadruplex-specific compounds may be TMPyP3, TMPyP4, and/or
BRACO-19.
[0023] For example, the anti-EBV agents may comprise Hsp90
inhibitors, c-Myc inhibitors, or EBNA-1 inhibitors. The EBNA-1
inhibitor may be further defined as a fusion protein comprising a
protein transduction domain fused to an EBNA-1 mutant protein that
increases the loss of the EBV vector elements. A particular example
of the fusion protein may be a derivative of EBNA-1 that functions
dominant-negatively fused to the Tat protein to facilitate protein
transduction.
[0024] As describe above, the immortalized somatic cells may be
lymphoblastoid cells derived from a cell population comprising B
cells. The B cells may have been immortalized by EBV
transformation. The cell population may comprise immature B cells.
In a further aspect, the cell population may comprise mature B
cells. The B cell-containing cell population may be obtained from a
source such as a blood sample, blood components, bone marrow, lymph
node, spleen, fetal liver, or umbilical cord. The source may be of
a selected subject or a selected population. The somatic cells may
be from a subject having a selected disease or disorder, for
example, a patient having an EBV infection or a patient in need of
transplantation.
[0025] The method may further comprise obtaining B cells from any B
cell-containing source, such as a blood sample. Due to the high
reprogramming efficiency of the present method and high
proliferation capacity of immortalized cells, the iPS cell
production methods may involve the use of a unprecedentedly small
amount of blood sample from a selected subject, for example, at
least, about, or at most 0.001, 0.002, 0.003, 0.004, 0.005, 0.006,
0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.06, 0.07, 0.08,
0.09, 0.1, 0.2, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2,
2.5, 3, 4, 5, 6, 7, 8, 9, 10 mL, or any range derivable therein.
The method may also include selecting a subject, particularly a
patient. The selected subject or patient may have a selected
genetic marker.
[0026] In certain aspects, the iPS cells may be produced or the
reprogramming may comprise culturing cells in the presence of a
feeder layer, such as mouse embryonic fibroblast (MEF) cells. In
other aspects, as the presence of MEFs may result in uncontrolled
proliferation of undesired cells, it may be advantageous to
reprogram in the absence of a feeder layer. For example, iPS cells
may be produced in the presence of a matrix component. The matrix
component may comprise Matrigel.TM., fibronectin, RetroNectin.RTM.
(a fragment of fibronectin), CellStart.TM., collagen or any
component that could replace a feeder layer.
[0027] In further aspects, the invention involves reprogramming the
immortalized somatic cells. For example, reprogramming may comprise
effecting the expression of one or more reprogramming factors in
the cells, for example, the reprogramming factors may be
reprogramming expression cassettes comprises in the immortalizing
episomal vector elements; and/or introducing one or more
reprogramming factors into the cells, for example, via additional
episomal vector elements.
[0028] Reprogramming factors may effect the expression of Sox and
Oct, for example, by using ectopic expression or protein
transduction. Sox and Oct are thought to be central to the
transcriptional regulatory hierarchy that specifies ES cell
identity. For example, Sox may be Sox1, Sox2, Sox3, Sox15, or
Sox18, preferably Sox2; Oct may be Oct4. Additional factors may
increase the reprogramming efficiency, like Nanog, Lin28, Klf4,
c-Myc, L-Myc, SV40 Large T antigen, or Esrrb. Specific sets of
reprogramming factors may be a set comprising Sox2, Oct4, Nanog
and, optionally, Lin-28; or comprising Sox2, Oct4, Klf and,
optionally, c-Myc; or Sox2, Oct4, Nanog and, SV40 Large T
antigen.
[0029] In a particular aspect, the episomal vector elements for
immortalization may comprise one or more reprogramming expression
cassettes comprising an Oct gene and a Sox gene. The reprogramming
expression cassettes may further comprise a Nanog gene, a Lin28
gene, a Klf gene, a Myc gene, or an SV40 large T antigen gene. The
reprogramming expression cassettes may be under the control of an
externally controllable regulatory element, such as an inducible
promoter or a conditional operator. This aspect may save the step
of introducing reprogramming factors after immortalization. A Myc
gene may be a c-Myc, N-Myc, or L-Myc.
[0030] In other aspects, the reprogramming factors may comprise one
or more reprogramming expression cassettes comprising an Oct gene
and a Sox gene. The reprogramming expression cassettes may further
comprise a Nanog gene, a Lin28 gene, or a Klf gene.
[0031] For direct reprogramming, the reprogramming factors may
comprise one or more reprogramming proteins comprising a Sox
protein and an Oct protein. The reprogramming proteins may further
comprise a Nanog protein, a Lin28 protein, a Klf protein, a Myc
protein, or an SV40 large T antigen protein. To assist the
intracellular delivery, the reprogramming proteins may be operably
linked to a protein transduction domain.
[0032] For enhancement of reprogramming, reprogramming may further
comprise contacting the cells with one or more cell signaling
regulators, such as a glycogen synthase kinase 3 (GSK-3) inhibitor,
a mitogen-activated protein kinase kinase (MEK) inhibitor, a
transforming growth factor beta (TGF-.beta.) receptor inhibitor,
leukemia inhibitory factor (LIF), a p53 inhibitor, an NF-kappa B
inhibitor, or a combination thereof. Those regulators may include
small molecules, inhibitory nucleotides, expression cassettes or
protein factors. In particular aspects, reprogramming of
immortalized mature B cells may comprise reprogramming in the
presence of a combination of signaling inhibitors, while obviating
the use of a Pax-5 inhibitory nucleotide molecule and exogenous
expression of C/EBP.alpha..
[0033] For reprogramming immortalized cells derived from B cells,
especially mature B cells, B cell development regulators such as a
C/EBP.alpha. enhancer and/or a Pax-5 inhibitor may or may not be
used in reprogramming. An important finding is that preemptive
inhibition of Pax-5 is not required to reprogram LCLs. It
automatically is inhibited/down-regulated during the reprogramming
process but it is not necessary to preemptively down regulate it
for reprogramming to occur. Therefore, externally added Pax-5
inhibitors or C/EBP.alpha. enhancer (C/EBP.alpha. down-regulates
Pax-5) may not be used prior to or during reprogramming of
immortalized B cells.
[0034] For example, the Pax-5 inhibitor may be any inhibitory
nucleotide, such as antisense RNA, small interfering RNA,
ribozymes, or an expression cassette expressing Pax-5 inhibiting
nucleotide molecules. The Pax-5 inhibitor may also be a
glucocorticoid like Prednisolone sodium succinate, SN38, or SU11274
to down-regulate Pax-5 expression. Glucocorticoids have also been
described in the literature to induce the expression of
C/EBP.alpha.. Similarly, B cell development regulators may also
include inhibitors of Blimp1, Oct2 and Bob-1, which may or may not
be used in reprogramming of B cells.
[0035] Overexpression of C/EBP.alpha. may be achieved through an
expression cassette for expressing C/EBP.alpha. or induced by small
molecule treatment. It has also been reported that C/EBP.alpha. may
directly or indirectly (through EBF) downregulate Pax-5, although
the exact mechanism is not currently known.
[0036] Nucleotides of these B cell development regulators such as
C/EBP.alpha. enhancer and/or a Pax-5 inhibitor may be comprised in
the episomal vector elements and may be removed after pluripotency
has been established.
[0037] In alternative embodiments, reprogramming of lymphoblastoid
cells or immortalized B cells may be performed without the use of
Pax-5-specific inhibitory nucleotides and/or exogenous expression
of C/EBP.alpha..
[0038] In accordance with any of the above methods, certain aspects
of the invention may provide an iPS cell or a differentiated cell,
tissue, or organ derived therefrom. For clinical application or
research of the iPS cells, the methods may further comprise
differentiating the iPS cells to a differentiated cell, for
example, a cardiomyocyte, a hematopoietic cell, a myocyte, a
neuron, a fibroblast, a pancreatic cell, a hepatocyte, or an
epidermal cell. In a further aspect, a differentiated cell, tissue
or organ, which has been differentiated from the iPS cell
population as described above, may be disclosed. The tissue may
comprise nerve, bone, gut, epithelium, muscle, cartilage or cardiac
tissue; the organ may comprise brain, spinal cord, heart, liver,
kidney, stomach, intestine or pancreas. In certain aspects, the iPS
cells and differentiated cell, tissue or organ may be used in
tissue transplantation, drug screening or developmental research to
replace embryonic stem cells.
[0039] There may also be provided an iPS cell comprising a genome
comprising an incomplete set of V, D, and J segments of
immunoglobulin variable region genes compared with an embryonic
stem cell, which may be a human cell. In a particular aspect, the
iPS cell may be essentially free of integrated, exogenous viral
elements. In a further aspect, the iPS cell may be essentially free
of episomal vector elements. In a yet further aspect, the iPS cell
may be essentially free of any exogenous genetic elements. In a
particular aspect, there may be provided a human iPS cell having a
genome that comprises an incomplete set of B cell immunoglobin
variable region genes compared with an embryonic stem cell. The iPS
cell may be essentially free of exogenous genetic elements or EBV
elements. The genome of the iPS cell may comprise a selected
genetic marker, such as a genetic marker of a selected disease,
like a particular cancer, acquired immunodeficiency syndrome (AIDS)
or Human immunodeficiency virus (HIV) infection or a neurological
disease. In a particular aspect, the genome of the IPS cell may be
derived from an immortalized B cell. In certain aspects, the iPS
cell may or may not have a normal karyotype. There may also be
provided a differentiated cell, tissue, or organ derived from the
iPS cell.
[0040] In a still further aspect, an iPS cell that comprises a
genome derived from a somatic cell that has been immortalized by
virtue of one or more episomal vector elements may also be
disclosed. Such immortalized cell may be a lymphoblastoid cell. In
particular, the iPS cell may be essentially free of episomal vector
elements.
[0041] There may also be provided an iPS cell that comprises a
genome comprising an incomplete set of B cell immunoglobin variable
region genes compared with an embryonic stem cell, wherein the iPS
cells is essentially free of exogenous genetic elements. The genome
may comprise a selected genetic marker, such as a genetic marker of
a selected disease. Such iPS cells may be immortal, have a normal
karyotype, no exogenously introduced oncogenes or telomerase, and a
B cell rearrangement, and/or carry a specific genetic marker for
one or more diseases. Any differentiated derivatives from such iPS
cells may also be provided.
[0042] Embodiments discussed in the context of methods and/or
compositions of the invention may be employed with respect to any
other method or composition described herein. Thus, an embodiment
pertaining to one method or composition may be applied to other
methods and compositions of the invention as well.
[0043] As used herein the terms "encode" or "encoding" with
reference to a nucleic acid are used to make the invention readily
understandable by the skilled artisan; however, these terms may be
used interchangeably with "comprise" or "comprising"
respectively.
[0044] As used herein the specification, "a" or "an" may mean one
or more. As used herein in the claim(s), when used in conjunction
with the word "comprising", the words "a" or "an" may mean one or
more than one.
[0045] The use of the term "or" in the claims is used to mean
"and/or" unless explicitly indicated to refer to alternatives only
or the alternatives are mutually exclusive, although the disclosure
supports a definition that refers to only alternatives and
"and/or." As used herein "another" may mean at least a second or
more.
[0046] Throughout this application, the term "about" is used to
indicate that a value includes the inherent variation of error for
the device, the method being employed to determine the value, or
the variation that exists among the study subjects.
[0047] Other objects, features and advantages of the present
invention will become apparent from the following detailed
description. It should be understood, however, that the detailed
description and the specific examples, while indicating preferred
embodiments of the invention, are given by way of illustration
only, since various changes and modifications within the spirit and
scope of the invention will become apparent to those skilled in the
art from this detailed description.
BRIEF DESCRIPTION OF THE DRAWINGS
[0048] The following drawings form part of the present
specification and are included to further demonstrate certain
aspects of the present invention. The invention may be better
understood by reference to one or more of these drawings in
combination with the detailed description of specific embodiments
presented herein.
[0049] FIGS. 1A-1B: Exemplary EBV-based episomal vectors having
reprogramming expression cassettes.
[0050] FIGS. 2A-2B: Tra-1-60 live staining to confirm iPS status at
40 days post transfection. A LCL was transfected with reprogramming
factors and placed on a matrix (Matrigel and Retronectin) in the
CHALP medium for 15 days, followed by mTeSR-1 medium for 25 days
(FIG. 2A). Staining with Tra-1-60 in FIG. 2B confirmed the presence
of iPS cells.
[0051] FIGS. 3A-3B: Tra-1-60 live staining to confirm iPS status at
46 days post transfection. A LCL was transfected with reprogramming
factors and placed on a matrix (Matrigel) in the CHALP medium for
15 days, followed by mTeSR-1 medium for 31 days (FIG. 3A). Staining
with Tra-1-60 in FIG. 3B confirmed the presence of iPS cells.
[0052] FIGS. 4A-4B: Tra-1-60 live staining to confirm iPS status at
29 days post transfection. A LCL was transfected with reprogramming
factors and placed on a matrix (Matrigel) in the CHALP medium for
20 days, followed by mTeSR-1 medium for 9 days (FIG. 4A). Staining
with Tra-1-60 in FIG. 4B confirmed the presence of iPS cells.
[0053] FIGS. 5A-5B: Tra-1-60 live staining to confirm iPS status at
48 days post transfection. A LCL was transfected with reprogramming
factors and placed on a matrix (Matrigel) in the CHALP medium for
15 days, followed by mTeSR-1 medium for 33 days (FIG. 5A). Staining
with Tra-1-60 in FIG. 5B confirmed the presence of iPS cells.
[0054] FIGS. 6A-6D: Transfection of reprogramming factors inhibits
Pax-5 expression. FIG. 6A: Pax-5 isotype control. Representatitve
flow cytometic staining of LCL-2 cells with PE conjugated Pax-5
antibody isotype control. The background staining is approximately
0.4%. FIG. 6B: Pax-5 of LCL-1 untransfected cells. Representatitve
flow cytometic staining of LCL-2 post transfection control (with no
DNA) with PE conjugated Pax-5. The Pax-5 expression staining is
approximately 56.2%. FIG. 6C: Pax-5 staining of LCL-2 cells
transfected with reprogramming factors. Representative flow
cytometic staining of LCL-2 cells transfected with reprogramming
plasmids p36-p34-p31 with PE conjugated Pax-5 antibody. The Pax-5
expression staining is approximately 8.2%. FIG. 6D: Pax-5
inhibition by reprogramming factors. Levels of Pax-5 inhibition of
LCL-1 and LCL-2 cell lines transfected with various combinations of
reprogramming plasmids.
[0055] FIGS. 7A-7F: Derivation and characterization of LCL-iPSCs.
FIG. 7A: The scheme for reprogramming human lymphoblastoid cell
lines (LCLs). Morphology of a LCL culture, cells during
reprogramming and LCL-iPSC colonies are shown. Images were captured
using 40.times., 20.times. and 10.times. magnification,
respectively. FIG. 7B: The average number of Tra-1-60 positive
colonies form after nucleofection of LCL-1 (i) and LCL-2 (ii) with
various combinations of reprogramming factors. The abbreviations
used for the reprogramming factors are as follows: O=OCT4, S=SOX2,
N=NANOG, K=KLF4, c-m=c-MYC, L-m=L-MYC, T=SV40 Large T antigen and
L=LIN28. FIG. 7C: Characterization of LCL-iPS lines. i. Brightfield
(left panel) and Tra-1-60 staining (right panel) of a
representative LCL-derived iPS line (LCL-iPS2a), confirms uniform
expression of the pluripotent surface marker, Tra-1-60. Images were
taken using 10.times. magnification. ii. Flow cytometric analysis
of hESC pluripotency markers OCT4 (left panel, OCT4: black line and
isotype control: red line), SSEA-4 (middle panel, SSEA4: red line
and isotype control: black line) and Tra-1-81 (right panel,
Tra-1-81: red line and isotype control: black line) of a
representative LCL derived iPS line, LCL-iPS1b. iii. Karyotype
analysis of each LCL-iPS line was performed after 11 passages
(WiCell Research Institute) and found to be normal; a
representative image of LCL-iPS2b is shown. iv. RT-PCR analysis of
H1 (hESC line), LCL-1, LCL-2 and two representative LCL-iPS clones
from each donor lines for expression of hES cell-marker genes
DNMT3B, LEFTB, NODAL, REX1, ESG1, GDF3, and UTF1. GAPDH was used as
positive loading control for each sample and cDNA made in the
absence of reverse transcriptase (no RT) was used to verify genomic
DNA did not contaminate the RNA samples. FIG. 7D: Hematoxylin and
eosin (H&E) staining of teratomas derived from immunodeficient
mice injected with LCL-iPS2a show tissues representing all three
embryonic germ layers, endoderm (goblet cells, left panel),
ectoderm (neural rosettes, middle panel) and mesoderm (cartilage,
right panel). All H&E images were captured using 40.times.
magnification. FIG. 7E: RT-PCR analysis of RNA from LCL-iPSCs for
the expression of reprogramming vector genes. Forward primers for
three reprogramming genes of interest (OCT4, NANOG and c-Myc) and
reverse primers for IRES2 were utilized. GAPDH was used as a
positive loading control for each sample and cDNA made in the
absence of Reverse Transcriptase (no RT) was used to verify genomic
DNA did not contaminate the RNA samples. A reprogramming vector was
included as a positive control for each PCR reaction (+ control).
FIG. 7F: PCR analysis of genomic DNA confirms no integration of the
transgenes. Forward primers for three reprogramming genes of
interest (OCT4, NANOG and c-Myc) and reverse primers for the IRES
were utilized. GAPDH was used as a positive loading control for
each sample and a reprogramming vector was included as a positive
control for each PCR reaction (+ control).
[0056] FIGS. 8A-8E: Analysis of LCL-iPSCs for reprogramming and
viral elements and trilineage differentiation of LCL-iPSCs. FIG.
8A: RT-PCR analysis of H1 (hESC line), LCL-1, LCL-2 and two
representative LCL-iPS clones from each donor line for expression
of EBV genes: EBNA-1, EBNA-2, LMP-2A and BZLF-1. GAPDH was used as
positive loading control for each sample and cDNA made in the
absence of Reverse Transcriptase (no RT) was used to verify genomic
DNA did not contaminate the RNA samples. FIG. 8B: PCR analysis of
genomic DNA (gDNA) reveals an absence of EBV DNA in LCL-iPSCs. gDNA
PCR analysis of H1 (hESC line), LCL-1, LCL-2 and two representative
LCL-iPSCs from each donor line was performed to detect EBV
sequences encoding: EBNA-1, oriP, EBNA-2 and BZLF-1. GAPDH was used
as a positive loading control for each sample. FIG. 8C:
Immunohistochemistry was performed on LCL-1, LCL-2 and two
representative LCL-iPS clones from each donor line using an
anti-EBNA-1 antibody to detect EBNA-1 protein expression (brown).
Images were captured using 40.times. magnification. FIG. 8D:
Trilineage in vitro differentiation. i. Quantification of
alpha1-antitrypsin expressing hepatocyte precursors derived from
LCL-iPSCs by flow cytometry. ii. Cardiac induction of LCL-iPSCs was
performed and quantification of cardiac troponin T (cTNT)-positive
cardiomyocytes at day 14 by flow cytometry. iii. Neural cultures
from LCL-iPS2b immunostained for the presence of .beta.3-tubulin.
Image captured using 20.times. magnification. iv. Quantification of
.beta.3-tubulin and nestin co-expressing neural precursors from
neural induced LCL-iPSCs by flow cytometry. v. Megacult cultures of
HPCs derived from LCL-iPS2a cells stained for the presence of
megakaryocytes and proplatelets, image captured at 40.times.
magnification (left panel). HPCs derived LCL-iPS2b expanded in the
presence of GM-CSF and stained for the presence of monocytes,
neutrophils and macrophages, image captured at 20.times.
magnification (right panel). vi. Quantification of Colony Forming
Units (CFU) to demonstrate the presence of erythroid (CFU-E/BFU-E),
myeloid comprising macrophage (CFU-M), granulocyte (CFU-G), and
granulocyte-macrophage (CFU-GM), and multipotent comprising
granulocyte-erythroid-macrophage-megakaryocyte (CFU-GEMM) colonies
from all four LCL-iPSCs. vii. In vitro differentiation into
LCL-iPSCs to cells to hematopoietic progenitor cells (HPCs) via a
defined serum-free embryoid body (EB) differentiation protocol for
12 days. The percentage of single positive CD34, CD45, CD43, CD41,
CD235a and double positive CD34/CD43, CD45/CD43, CD34/45 cells was
quantified by flow cytometry. FIG. 8E: Each B-cell has a single
productive immunoglobulin gene rearrangement respectively that is
unique in both length and sequence. Polymerase chain reaction (PCR)
assays with specific primers for the joining region and all three
of the conserved framework regions (FR1, FR2 and FR3) were used to
amplify immunoglobulin heavy chain (IgGH) gene rearrangements
according to the BIOMED-2 Concerted Action protocol. DNA from a
normal or polyclonal B cell population produces a bell-shaped curve
of amplicon products (Gaussian distribution), whereas clonal
rearrangements are identified as prominent, single-sized products
by capillary electrophoresis and GeneScanning
DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS
I. Introduction
[0057] Patient-specific induced pluripotent stem cells (iPSCs) can
serve as a useful model to understand the etiology of disease and
facilitate the development of novel therapeutic interventions
(Yamanaka, 2007). Recently, iPSCs free of exogenous DNA have been
generated by delivering reprogramming factors via multiple methods
including oriP/EBNA-1 (Epstein-Barr nuclear antigen-1) based
episomal plasmids (Yu et al., 2009) in the presence or absence of
small molecules (Lin et al., 2009; Okita and Yamanaka, 2010; Okita
et al., 2010), via piggyBAC transposons (Woltjen et al., 2009),
minicircles (Jia et al., 2010), proteins (Zhou et al., 2009) or by
a cocktail of RNAs (Warren et al., 2010) predominantly using
fibroblasts. However, these methods still have relatively low
reprogramming efficiency and are thus limited in applications.
[0058] Peripheral blood is a more tractable source for
reprogramming compared with fibroblasts derived from invasive skin
biopsies. Human B cells from as little as 0.5 mL blood can be
transformed in vitro by EBV to generate lymphoblastoid cell lines
(LCLs) (Amoli et al., 2008). A number of major facilities currently
manage collections of LCLs for the international research community
(Amoli et al., 2008). B lymphocytes can transdifferentiate to
macrophages (Cobaleda, 2010; Cobaleda and Busslinger, 2008) or
hematopoietic precursor cells (HPCs) by down-regulation of Pax-5
expression (Cobaleda and Busslinger, 2008). Murine B cells have
been reprogrammed to generate iPSCs via viral transduction of
OCT3/4, SOX2, KLF4, and c-MYC in the presence (Hanna et al., 2008)
or absence of Pax-5 inhibition (Wada et al., 2011).
[0059] Certain aspects of the present invention provide a method
for preparing iPS cells by reprogramming of somatic cells,
particularly somatic cells immortalized by virtue of episomal
vector elements. For example, reprogramming of lymphoblastoid cells
(e.g., EBV-transformed B cells) and iPS cells derived therefrom are
included. Immortalized somatic cells, such as lymphoblastoid cells,
may depend on episomal vector elements for long-term proliferation;
however, after reprogramming to an established pluripotent state,
the reprogrammed cells have a normal karyotype and are no longer
dependent on the episomal vector elements, particularly EBV
expressed genes, for their proliferation. Such immortalized cells
may include any lymphoblastoid cell lines already available or in
storage, or immortalized cells derived from a specific living
subject.
[0060] Generating pluripotent or multipotent cells by somatic cell
reprogramming using the methods of the present invention has at
least the following advantages. First, the methods of the present
invention allow one to generate autologous pluripotent cells, which
are cells specific to a patient. The use of autologous cells in
cell therapy offers a major advantage over the use of
non-autologous cells, which are likely to be subject to
immunological rejection. In contrast, autologous cells are unlikely
to elicit significant immunological responses (See Munsie et al.,
2000). Second, the methods of the present invention allow one to
generate pluripotent cells from a novel sustainable and easy source
of immortalized somatic cells without using embryos, oocytes and/or
nuclear transfer technology. Not intended to limit the scope, the
present invention involves reprogramming of immortalized cells such
as EBV-transformed B cells, but not B cells directly from a
subject, therefore reducing the volume of a sample such as a blood
sample needed for reprogramming.
[0061] The inherent plasticity of B cells, their receptivity to
oriP/EBNA-1 plasmids, ease of generating LCLs, and availability of
banked collections of LCLs may be additional advantages for
reprogramming immortalized B cells or LCLs using oriP/EBNA-1 based
episomal vectors. As shown in Examples, LCL-derived iPSCs
demonstrated the characteristics of pluripotent stem cells with a
normal karyotype, retained the genetic identity of the parental
LCLs, maintained the clonal signature of the rearranged IgG locus
and lost expression of the episomal reprogramming genes as well as
viral EBNA-1, EBNA-2, LMP-2A and BZLF-1 genes, leading to
self-sustained LCL-iPSCs essentially free of exogenous
reprogramming and viral elements.
[0062] In additional aspects, the resulting iPS cells provided may
have the episomal vector elements removed or lost during cell
division to minimize the effect of such exogenous elements.
Therefore, an immortal cell with a normal karyotype, no exogenously
introduced oncogenes or telomerase, and optionally carrying a
specific genetic marker for a disease may be provided. Until this
invention, it is highly unlikely that the existing EBV transformed
B-cell lines would be utilized to study a genetic predisposition
for a particular disease with the EBV viral genes still present, as
that would likely interfere with or confound the results when
specific tissues are generated and studied. However, by removing
those episomal elements, the resulting iPS cells generated from the
B cell lines would be useful for the purpose of studying a
particular disease in specific cells or tissues derived from the
iPS cells.
[0063] In further aspects, somatic cells from a living subject may
be obtained for immortalization by episomal vector elements
followed by reprogramming into iPS cells. For example, a cell
population comprising B cells from a small volume of blood may be
transformed with EBV and then the transformed B cells may undergo
reprogramming. In particular aspects, the episomal vector elements,
like the EBV vectors, may comprise inducible reprogramming
expression cassettes. Therefore, as an alternative to introducing
reprogramming factors into immortalized cells, the reprogramming
cassettes in the episomal vector in the immortalized cells may be
induced for reprogramming.
[0064] Some aspects of the invention provide methods of
reprogramming transformed B cells and provide iPS cells derived
from such B cells. In a further aspect, these iPS cells may be
essentially free of exogenously integrated genetic elements. A
particular advantage of these aspects lies in rearranged and
reduced V, D, J gene segments of immunoglobulin genes from B cells
which may be retained in reprogrammed progeny cells and the absence
of integration of foreign genes. This could serve as a specific
characteristic or "bar code" of different clonal populations of B
cell-derived iPS cells, and also help to differentiate those iPS
cells from pluripotent stem cells which have not undergone V(D)J
recombination. The absence of genetic integration is important for
the future use of iPS cells without the risks of oncogenic
transformation and of developing dysfunction, etc. Further
embodiments and advantages of the invention are described
below.
[0065] "Reprogramming" is a process that confers on a cell a
measurably increased capacity to form progeny of at least one new
cell type, either in culture or in vivo, than it would have under
the same conditions without reprogramming. More specifically,
reprogramming is a process that confers on a somatic cell a
pluripotent potential. This means that after sufficient
proliferation, a measurable proportion of progeny have the
phenotypic characteristics of the new cell type if essentially no
such progeny could form before reprogramming; otherwise, the
proportion having characteristics of the new cell type is
measurably more than before reprogramming. Under certain
conditions, the proportion of progeny with characteristics of the
new cell type may be at least about 1%, 5%, 25% or more in order of
increasing preference.
[0066] The term "corresponds to" is used herein to mean that a
polynucleotide sequence is homologous (i.e., is identical, not
strictly evolutionarily related) to all or a portion of a reference
polynucleotide sequence, or that a polypeptide sequence is
identical to a reference polypeptide sequence. In
contradistinction, the term "complementary to" is used herein to
mean that the complementary sequence is homologous to all or a
portion of a reference polynucleotide sequence. For illustration,
the nucleotide sequence "TATAC" corresponds to a reference sequence
"TATAC" and is complementary to a reference sequence "GTATA".
[0067] A "gene," "polynucleotide," "coding region," "sequence,"
"segment," "fragment," or "transgene" which "encodes" a particular
protein, is a nucleic acid molecule which is transcribed and
optionally also translated into a gene product, e.g., a
polypeptide, in vitro or in vivo when placed under the control of
appropriate regulatory sequences. The coding region may be present
in either a cDNA, genomic DNA, or RNA form. When present in a DNA
form, the nucleic acid molecule may be single-stranded (i.e., the
sense strand) or double-stranded. The boundaries of a coding region
are determined by a start codon at the 5' (amino) terminus and a
translation stop codon at the 3' (carboxy) terminus. A gene can
include, but is not limited to, cDNA from viral, prokaryotic or
eukaryotic mRNA, genomic DNA sequences from viral, prokaryotic or
eukaryotic DNA, and synthetic DNA sequences. A transcription
termination sequence will usually be located 3' to the gene
sequence.
[0068] The term "cell" is herein used in its broadest sense in the
art and refers to a living body which is a structural unit of
tissue of a multicellular organism, is surrounded by a membrane
structure which isolates it from the outside, has the capability of
self replicating, and has genetic information and a mechanism for
expressing it. Cells used herein may be naturally-occurring cells
or artificially modified cells (e.g., fusion cells, genetically
modified cells, etc.).
[0069] As used herein, the term "stem cell" refers to a cell that
is capable of self-renewal through mitotic cell division and
differentiation into a diverse range of specialized cell types
(i.e., pluripotent). Typically, stem cells can regenerate an
injured tissue. Stem cells herein may be, but are not limited to,
embryonic stem (ES) cells, induced pluripotent stem (iPS) cells, or
tissue stem cells (also called tissue-specific stem cell, or
somatic stem cell). Any artificially produced cell which can have
the above-described abilities (e.g., fusion cells, reprogrammed
cells, or the like used herein) may be a stem cell.
[0070] "Embryonic stem (ES) cells" are pluripotent stem cells
derived from early embryos. An ES cell was first established in
1981, which has also been applied to production of knockout mice
since 1989. In 1998, a human ES cell was established, which is
currently becoming available for regenerative medicine.
[0071] Unlike ES cells, tissue stem cells have a limited
differentiation potential. Tissue stem cells are present at
particular locations in tissues and have an undifferentiated
intracellular structure. Therefore, the pluripotency of tissue stem
cells is typically low. Tissue stem cells have a higher
nucleus/cytoplasm ratio and have few intracellular organelles. Most
tissue stem cells have low pluripotency, a long cell cycle, and
proliferative ability beyond the life of the individual. Tissue
stem cells are separated into categories, based on the sites from
which the cells are derived, such as the dermal system, the
digestive system, the bone marrow system, the nervous system, and
the like. Tissue stem cells in the dermal system include epidermal
stem cells, hair follicle stem cells, and the like. Tissue stem
cells in the digestive system include pancreatic (common) stem
cells, liver stem cells, and the like. Tissue stem cells in the
bone marrow system include hematopoietic stem cells, mesenchymal
stem cells, and the like. Tissue stem cells in the nervous system
include neural stem cells, retinal stem cells, and the like.
[0072] "Induced pluripotent stem cells," commonly abbreviated as
iPS cells or iPSCs, refer to a stem cell having properties similar
to those of an ES cell, and specifically a cell having pluripotency
and proliferative capacity. An iPS cell is artificially prepared
from a non-pluripotent cell, typically an adult somatic cell or
terminally differentiated cell, such as a fibroblast, a
hematopoietic cell, a myocyte, a neuron, an epidermal cell, or the
like, by effecting exogenous expression of certain genes referred
to as reprogramming factors.
[0073] "Pluripotency" refers to a stem cell that has the potential
to differentiate into all cells constituting one or more tissues or
organs, or preferably, any of the three germ layers: endoderm
(interior stomach lining, gastrointestinal tract, the lungs),
mesoderm (muscle, bone, blood, urogenital), or ectoderm (epidermal
tissues and nervous system). "Pluripotent stem cells" used herein
refer to cells that can differentiate into cells derived from any
of the three germ layers, for example, direct descendants of
totipotent cells or induced pluripotent cells.
[0074] The term "somatic cell" refers to any cell except an ES
cell, an iPS cell, or other cells which retain their
undifferentiated, pluripotent state. Specific examples of somatic
cells include, for example, (i) tissue stem cells (somatic stem
cells), such as neural stem cells, hematopoietic stem cells,
mesenchymal stem cells and the like, (ii) tissue progenitor cells,
and (iii) differentiated cells, such as lymphocytes, epithelial
cells, muscle cells, fibroblasts and the like. The kind of the
somatic cell used for the preparation method of the present
invention is not particularly limited and any somatic cell can be
suitably used.
[0075] A "vector" or "construct" (sometimes referred to as gene
delivery or gene transfer "vehicle" or "cassette") refers to a
macromolecule or complex of molecules comprising a polynucleotide
to be delivered to a host cell, either in vitro or in vivo. A
vector can be a linear or a circular molecule.
[0076] The term "episomal vector" refers to an extra-chromosomal
DNA molecule which autonomously replicates and maintains itself. In
certain cases, it is circular and double-stranded. Any episomal
vector that has such properties can be used for the preparation
method of the present invention, without particular limitation.
[0077] By "expression construct" or "expression cassette" is meant
a nucleic acid molecule that is capable of directing transcription.
An expression construct includes, at the least, a promoter or a
structure functionally equivalent to a promoter. Additional
elements, such as an enhancer, and/or a transcription termination
signal, may also be included.
[0078] The term "exogenous," when used in relation to a protein,
gene, nucleic acid, or polynucleotide in a cell or organism refers
to a protein, gene, nucleic acid, or polynucleotide which has been
introduced into the cell or organism by artificial or natural
means, or in relation to a cell refers to a cell which was isolated
and subsequently introduced to other cells or to an organism by
artificial or natural means. An exogenous nucleic acid may be from
a different organism or cell, or it may be one or more additional
copies of a nucleic acid which occurs naturally within the organism
or cell. An exogenous cell may be from a different organism, or it
may be from the same organism. By way of a non-limiting example, an
exogenous nucleic acid is in a chromosomal location different from
that of natural cells, or is otherwise flanked by a different
nucleic acid sequence than that found in nature.
[0079] By "operably linked" with reference to nucleic acid
molecules is meant that two or more nucleic acid molecules (e.g., a
nucleic acid molecule to be transcribed, a promoter, and an
enhancer element) are connected in such a way as to permit
transcription of the nucleic acid molecule. "Operably linked" with
reference to peptide and/or polypeptide molecules is meant that two
or more peptide and/or polypeptide molecules are connected in such
a way as to yield a single polypeptide chain, i.e., a fusion
polypeptide, having at least one property of each peptide and/or
polypeptide component of the fusion. The fusion polypeptide is
preferably chimeric, i.e., composed of heterologous molecules.
[0080] The term "regulatory elements" refers collectively to
promoter regions, polyadenylation signals, transcription
termination sequences, upstream regulatory domains, origins of
replication, internal ribosome entry sites ("IRES"), enhancers,
splice junctions, and the like, which collectively provide for the
replication, transcription, post-transcriptional processing and
translation of a coding sequence in a recipient cell. Not all of
these control elements need always be present so long as the
selected coding sequence is capable of being replicated,
transcribed and translated in an appropriate host cell.
[0081] The term "promoter" is used herein in its ordinary sense to
refer to a nucleotide region comprising a DNA regulatory sequence,
wherein the regulatory sequence is derived from a gene which is
capable of binding RNA polymerase and initiating transcription of a
downstream (3' direction) coding sequence.
[0082] By "enhancer" is meant a nucleic acid sequence that, when
positioned proximate to a promoter, confers increased transcription
activity relative to the transcription activity resulting from the
promoter in the absence of the enhancer domain.
II. Sources of Cells for Reprogramming
[0083] The medical potential of cellular reprogramming for
regenerative medicine is enormous, and hence efforts are ongoing to
identify the ideal cell type that exhibits plasticity with a
minimal amount of manipulation. Certain aspects of the invention
provide methods and cells used for reprogramming somatic cells
(e.g., blood cells, more particularly, B cells) immortalized by the
virtue of episomal vector elements, particularly EBV elements. The
cells to be reprogrammed may be lymphoblastoid cells, for example,
EBV-transformed B cells, either established or derived from a blood
sample. The source of B cells may be a small blood sample from a
living or diseased subject, for example, a human.
[0084] Blood is a convenient and accessible source of human
material amenable to reprogramming to generate induced, pluripotent
stem (iPS) cells. Multiple labs have successfully derived iPS cells
from cord blood, for example. More specifically, iPS cells have
been generated from T cells, monocytes, and pools of myeloid
progenitors including CD34.sup.+ cells that comprise blood.
Unfortunately, reprogramming human blood cells by methods that do
not rely on retro- or lenti-viral based systems are currently
inefficient. One such method involves a plasmid-based approach that
relies on the oriP replicon from Epstein-Barr virus (EBV) to
facilitate retention and replication of plasmids within transfected
host cells. For example, cells may be transfected with oriP-based
plasmids encoding combinations of reprogramming factors whereby the
oriP replicon allows sufficient time for expression of the key
reprogramming elements. The plasmids are then lost naturally from
host cells at a rate of roughly 5-8% per cell division to generate
iPS cells free of exogenous DNA (Nanbo et al., 2007).
[0085] Debate exists with regard to the maturation state of the
blood cell and its correlation with reprogramming. For example,
hematopoietic stem cell progenitors expressing CD34 have been
perceived as desirable candidates based on the efficiency of iPS
clone generation. This hypothesis has not been carefully tested to
include differences among CD34+ cells derived from cord blood,
mobilized/non-mobilized peripheral blood, and bone marrow
collectively. Furthermore, CD34.sup.+ cells represent only a small
fraction (0.01%) of the total population of peripheral blood
mononuclear cells (PBMCs). Therefore, acquiring enough starting
material from 1 mL of blood to generate multiple clones poses a
challenge since the efficiency of reprogramming without the
integration of DNA in blood cells is also low (<0.01%). B cells,
on the other hand, represent a larger fraction of the PBMC
population (roughly 20%) and it is contemplated that they could be
more receptive to reprogramming.
[0086] In certain aspects of the invention, methods may be provided
to immortalize a B cell-containing cell population by episomal
vector elements and to reprogram resulting immortalized B cells
subsequently. To save the need to introduce reprogramming
expression cassettes separately, the episomal vector elements may
comprise inducible reprogramming expression cassettes. In certain
aspects, the methods may be provided to reprogram established
transformed B cells, like lymphoblastoid cells.
[0087] A. Reprogramming of Transformed B Cells
[0088] Reprogramming of transformed B cells may be provided in
certain aspects, for example, by using reprogramming expression
cassettes or reprogramming proteins. Additional reprogramming
factors for B cells such as Pax-5 inhibitors and C/EBP.alpha.
enhancers may be used to enhance reprogramming based on the lineage
specification status of the original B cells. In certain
embodiments, Pax-5 inhibitors and C/EBP.alpha. enhancers may not be
needed even for reprogramming mature B cells.
[0089] The generation of B-lymphocytes from hematopoietic stem
cells is controlled by multiple transcription factors regulating
distinct developmental aspects. Ikaros and PU.1 act in parallel
pathways to control the development of lymphoid progenitors in part
by regulating the expression of essential signaling receptors
(F1t3, c-Kit, and IL-7R.alpha.). The generation of the earliest B
cell progenitors depends on the activation of E2A and EBF
transcription factors, which coordinately activate the B cell gene
expression program and immunoglobulin heavy-chain gene
rearrangements to prime the onset of B-lymphopoiesis.
[0090] Pax-5 restricts the developmental options of lymphoid
progenitors to the B cell lineage by repressing the transcription
of lineage-inappropriate genes and simultaneously activating the
expression of B-lymphoid signaling molecules. B cells exhibit
plasticity during the earliest stages of B cell development. IL7,
in combination with the three transcription factors E2A, EBF1, and
Pax-5 (Kirchmaier and Sugden, 1997; Kennedy et al., 2003) play a
key role in B cell differentiation. E2A and EBF1 activate the
expression of B lymphoid genes at the onset of B cell development
but the commitment to the lineage is controlled by Pax-5, which
possesses the dual capacity of repressing the transcription of
B-lineage-inappropriate genes and activating the expression of
B-cell-specific genes (Mack and Sugden, 2008; Wendtner et al.,
2003).
[0091] As the cells express Pax-5, pro-B cells can only
differentiate along their unidirectional path to mature B cells.
Pax-5-/- knock-out pro-B cells behave as multipotent progenitors
because they express multi-lineage genes that allow them to be
programmed into most of the hematopoietic lineages under the
appropriate conditions.
[0092] The recent conversion of mature B cells into induced
pluripotent stem cells (iPSCs) by forced expression of
transcription factors Oct3/4, Sox2, Klf4, and c-Myc in combination
with Pax-5 downregulation can be considered as a
transdifferentiation process, that involves the generation of early
progenitors from mature cells (Delecluse et al., 1999). This
conversion involves the transition to a cellular state that reveals
re-activation of genes related to stem cell renewal and maintenance
and an incomplete repression of lineage-specific transcription
factors and incomplete epigenetic remodeling.
[0093] Committed CD19.sup.+ B cells can also be transdifferentiated
into macrophages by retroviral expression of the myeloid
transcription factor C/EBP.alpha. (Delecluse et al., 1998; Hettich
et al., 2006) in the presence of myeloid cytokines. The
C/EBP.alpha.-induced conversion of committed B cells into
macrophages happens via non-physiological cellular intermediates
expressing markers belonging to both B cells and macrophages in a
classical transdifferentiation manner.
[0094] Several other transcription factors have been identified to
play important roles in regulating gene expression during B cell
development, similar to the role of Pax-5, including Blimp1, Oct2
and Bob-1. Blimp1 is a critical transcriptional regulator of plasma
cell differentiation. It is a repressor that is required for
terminal differentiation of B cells and monocyte/macrophages. Oct2
is a B cell specific transcription factor which plays an important
role in late B cell development. Bob-1 is a coactivator of Oct2 and
Pax-5 (BSAP).
[0095] B. Lymphoblastoid Cells
[0096] Lymphoblastoid cell lines (LCLs) may be established by in
vitro transformation of lymphocytes (such as any types of T cells
or B cells) by episomal vector elements such as Epstein-Barr virus
(EBV) or EBV-derived episomal vector elements. Transformation of
peripheral B lymphocytes by Epstein-Barr virus (EBV) is a method of
choice for generating LCLs. This method has been in use for the
last two decades with a high success rate. With a somatic mutation
rate of 0.3% and ease of cell maintenance, lymphoblastoid cells are
still the preferred choice of storage for patients' genetic
material.
[0097] Lymphoblastoid cell lines (LCLs) may also be obtained by
immortalization of lymphocytes by virtue of non-EBV episomal
vector. For example, lymphoblastoid cells may be established from
Marek's Disease Virus (MDV) infection of T cells, primarily CD4'
cells (Parcells et al., 1999).
[0098] C. Additional Source of Immortalized Cells
[0099] Biologists have chosen the word immortal to designate cells
that are not limited by the Hayflick limit (where cells no longer
divide because of DNA damage or shortened telomeres). The Hayflick
limit is the number of times a normal cell population will divide
before it stops, presumably because the telomeres reach a critical
length. The term immortalization was applied to cells that
expressed the telomere-lengthening enzyme telomerase, and thereby
avoided apoptosis (programmed cell death). Normal stem cells and
germ cells can also be said to be immortal.
[0100] Immortal cells can be created by induction of oncogenes or
loss of tumor suppressor genes. One way to induce immortality is
through viral-mediated induction of the large T-antigen, commonly
introduced through Simian Vacuolating virus 40 (SV40). SV40 large T
antigen (SV40 TAg) is a hexamer protein that is an oncogene derived
from the polyomavirus SV40 which is capable of transforming a
variety of cell types.
[0101] In certain aspects of the invention, there may be provided
somatic cells immortalized by virtue of episomal vector elements.
Such episomal vector elements may express EBV genes for
transformation of lymphocytes as described above, or express
transgenes such as telomerase, or oncogenes for immortalization of
any somatic cells.
[0102] The somatic cells may be terminally differentiated cells, or
tissue stem cells, including, but not limited to, fibroblasts,
hematopoietic cells, mesenchymal cells, keratinocytes,
hematopoietic cells, liver cells, stomach cells, or neural stem
cells. The somatic cells may be from a tissue cell bank or from a
selected human subject, specifically, a live human. Genomes from
progeny of these somatic cells will be considered to be derived
from these somatic cells of a certain source, such as a selected
human individual.
III. Episomal Vector Elements and Removal
[0103] The success in the establishment of iPS cells allows us to
avoid bioethical problems attributed to ES cells, and this success
is a major step towards realization of regenerative medicine free
from immunological rejection. However, conventional methods for
preparing iPS cells involve gene transduction via a retrovirus
vector or another similar vector, a lentivirus vector. Such a viral
vector may cause mutation of an endogenous gene, or may cause
activation of an endogenous oncogene since the viral vector
mediates the integration of a gene into a random position of the
host cell's chromosomes. In view of future use of iPS cells in
regenerative medicine, use of such a viral vector has the risks of
oncogenic transformation and of developing dysfunction, etc. For
that reason, an extremely important development toward future
application of iPS cells are methods for preparing iPS cells
without genome integrating reprogramming factors.
[0104] Episomal vector elements, including EBV or variants thereof,
may be provided for immortalization of somatic cells, such as
lymphocytes. In further aspects, episomal vector elements in the
iPS cells may be removed after reprogramming.
[0105] Any episomal vector that has such properties can be used for
the preparation method of the present invention, without particular
limitation. Specifically, examples of the episomal vector include
episomal vectors based on viruses, for example, an episomal vector
based on a mouse polyomavirus (Gassmann et al., 1995); an episomal
vector based on a BK virus, a kind of human polyomaviruses (De
Benedetti and Rhoads, 1991); an episomal vector based on an
Epstein-Barr virus (Margolskee et al., 1988); and an episomal
vector based on a bovine papilloma virus (BPV) (Ohe et al., 1995).
Inter alia, an episomal vector based on a BK virus and an episomal
vector based on Epstein-Barr virus are suitably used for human
cells.
[0106] Each of these vectors contains a replication origin (ori)
derived from the corresponding virus. A "replication factor" binds
to such a replication origin (ori), thereby triggering vector
replication. The term "replication factor" as used herein refers to
an indispensable factor for replication, which binds to the ori,
thereby triggering nucleic acid replication. The "replication
factors" corresponding to the respective virus-based episomal
vectors illustrated above are the large T antigen of a mouse
polyomavirus, the large T antigen of a BK virus, EBNA-1 of an EBV
virus, and E1 and E2 of a BPV, respectively.
[0107] An episomal vector containing a base sequence called S/MAR
(scaffold/matrix attachment region) can also be used suitably for
the preparation method of the present invention. This episomal
vector contains at least one S/MAR and at least one viral or
eukaryotic replication origin (ori). Unlike other episomal vectors
described above, this episomal vector does not require any
replication factor corresponding to the on for replication.
Specifically, such an episomal vector is exemplified by the
episomal vector containing, as an S/MAR, the upstream region (about
2 kbs) of the human interferon beta gene, which is described in
Piechaczek et al. (1999).
[0108] In addition, there is known a system in which two kinds of
adenovirus vectors introduced into cells produce a circular
episomal vector within the cells (Leblois et al., 2000). The
episomal vector obtained by using this system can also be used for
the preparation method of the present invention. This system is
based on the Cre-loxP system. More specifically, in the system, one
adenovirus vector expresses Cre, and the other adenovirus vector
contains a gene construct required for serving as an episomal
vector, the gene construct being inserted into the region flanked
by two loxP sites of the vector. The region flanked by the two loxP
sites is excised by Cre, forming a circular DNA. When the region
flanked by the two loxP sites is designed to carry a replication
origin and a replication factor gene (for example, the oriP
sequence and the gene encoding EBNA-1, which are a replication
origin of and a replication factor gene of an Epstein-Barr virus,
respectively) in addition to an expression unit, a formed circular
DNA is maintained as an episome in cells.
[0109] B. Episomal Vector Backbone
[0110] These reprogramming methods may also make use of
extra-chromosomally replicating vectors (i.e., episomal vectors),
which are vectors capable of replicating episomally to make iPS
cells essentially free of exogenous vector or viral elements (see
U.S. Publication No. 20100003757, incorporated herein by reference;
Yu et al., 2009). A number of DNA viruses, such as adenoviruses,
Simian vacuolating virus 40 (SV40), EBV or bovine papilloma virus
(BPV), or budding yeast ARS (Autonomously Replicating
Sequences)-containing plasmids replicate extra-chromosomally or
episomally in mammalian cells. These episomal plasmids are
intrinsically free from all these disadvantages (Bode et al., 2001)
associated with integrating vectors. For example, a lymphotrophic
herpes virus-based vector comprising EBV elements as defined above
may replicate extra-chromosomally and help deliver reprogramming
factors to somatic cells.
[0111] For example, the plasmid-based approach used in the
invention may extract robust elements necessary for the successful
replication and maintenance of an EBV element-based system without
compromising the system's tractability in a clinical setting as
described in detail below. The essential EBV elements are oriP and
EBNA-1 or their variants or functional equivalents. An additional
advantage of this system is that these exogenous elements will be
lost with time after being introduced into cells, leading to
self-sustained iPS cells essentially free of exogenous
elements.
[0112] The use of plasmid- or liposome-based extra-chromosomal
vectors, e.g., oriP-based vectors, and/or vectors encoding a
derivative of EBNA-1 permit large fragments of DNA to be introduced
to a cell and maintained extra-chromosomally, replicated once per
cell cycle, partitioned to daughter cells and elicit substantially
no immune response. In particular, EBNA-1, the only viral protein
required for the replication of the oriP-based expression vector,
does not elicit a cellular immune response because it has developed
an efficient mechanism to bypass the processing required for
presentation of its antigens on MHC class 1 molecules (Levitskaya
et al., 1997). Further, EBNA-1 can act in trans to enhance
expression of the cloned gene, inducing expression of a cloned gene
up to 100-fold in some cell lines (Langle-Rouault et al., 1998;
Evans et al., 1997). Finally, the manufacture of such oriP-based
expression vectors is inexpensive.
[0113] Other extra-chromosomal vectors include other lymphotrophic
herpes virus-based vectors. Lymphotrophic herpes virus is a herpes
virus that replicates in a lymphoblast (e.g., a human B
lymphoblast) and becomes a plasmid for a part of its natural
life-cycle. Herpes simplex virus (HSV) is not a "lymphotrophic"
herpes virus. Exemplary lymphotrophic herpes viruses include, but
are not limited to EBV, Kaposi's sarcoma-associated herpesvirus
(KSHV), Herpes virus saimiri (HVS) and Marek's disease virus (MDV).
Also other sources of episome-base vectors are contemplated, such
as yeast ARS, adenovirus, SV40, or BPV.
[0114] To circumvent potential problems from viral gene delivery,
two groups this year reported on a collaboration that has succeeded
in transposon-based approaches for producing pluripotency in human
cells without using viral vectors (Woltjen et al., 2009; Kaji et
al., 2009). Stable iPS cells were produced in both human and mouse
fibroblasts using virus-derived 2A peptide sequences to create a
multicistronic vector incorporating the reprogramming factors,
delivered to the cell by the piggyl)ac transposon vector. The
2A-linked reprogramming factors, not required in the established
iPS cell lines, were then removed. These strategies could be
similarly applied to immortalize and/or reprogram somatic cells in
certain aspects of the present invention.
[0115] C. Epstein-Barr Virus-Based Vector Elements
[0116] The Epstein-Barr virus (EBV), also called Human herpesvirus
4 (HHV-4), is a gamma herpes virus of the human herpes family
(which includes Herpes simplex virus, Vacricella-zoster virus and
Cytomegalovirus), and is one of the most common viruses in
humans.
[0117] EBV maintains its genome extra-chromosomally and works in
collaboration with host cell machinery for efficient replication
and maintenance (Lindner and Sugden, 2007), relying solely on two
essential features for its replication and its retention within
cells during cell division (Yates et al. 1985; Yates et al. 1984).
One element, commonly referred to as oriP, exists in cis and serves
as the origin of replication. The other factor, EBNA-1, functions
in trans by binding to sequences within oriP to promote replication
and maintenance of the plasmid DNA. Therefore, the EBNA-1 protein
is essential for maintenance of the virus genome.
[0118] When EBV infects B-lymphocytes in vitro, lymphoblastoid cell
lines eventually emerge that are capable of indefinite growth. The
growth transformation of these cell lines is the consequence of
viral protein expression. EBV genes such as EBNA-2, EBNA-3A,
EBNA-3C, EBNA-LP and/or LMP-1 may be comprised in EBV vectors for
transformation in certain aspects of the present invention.
[0119] 1. OriP
[0120] OriP is the site at or near which DNA replication initiates
and is composed of two cis-acting sequences approximately 1
kilobase pair apart known as the family of repeats (FR) and the
dyad symmetry (DS).
[0121] FR is composed of 21 imperfect copies of a 30 by repeat and
contains 20 high affinity EBNA-1-binding sites. When FR is bound by
EBNA-1, it both serves as a transcriptional enhancer of promoters
in cis up to 10 kb away (Reisman and Sugden, 1986; Yates, 1988;
Sugden and Warren, 1989; Wysokenski and Yates, 1989; Gahn and
Sugden, 1995; Kennedy and Sugden, 2003; Altmann et al., 2006), and
contributes to the nuclear retention and faithful maintenance of FR
containing plasmids (Langle-Rouault et al., 1998; Kirchmaier and
Sugden, 1995; Wang et al., 2006; Nanbo et al., 2007). The efficient
partitioning of oriP plasmids is also likely attributable to FR.
While the virus has evolved to maintain 20 EBNA-1-binding sites in
FR, efficient plasmid maintenance requires only seven of these
sites, and can be reconstituted by a polymer of three copies of DS,
having a total of 12 EBNA-1-binding sites (Wysokenski and Yates,
1989).
[0122] The dyad symmetry element (DS) is sufficient for initiation
of DNA synthesis in the presence of EBNA-1 (Aiyar et al., 1998;
Yates et al., 2000), and initiation occurs either at or near DS
(Gahn and Schildkraut, 1989; Niller et al., 1995). Termination of
viral DNA synthesis is thought to occur at FR, because when FR is
bound by EBNA-1 it functions as a replication fork barrier as
observed by 2D gel electrophoresis (Gahn and Schildkraut, 1989;
Ermakova et al., 1996; Wang et al., 2006). Initiation of DNA
synthesis from DS is limited to once-per-cell-cycle (Adams, 1987;
Yates and Guan, 1991), and is regulated by the components of the
cellular replication system (Chaudhuri et al., 2001; Ritzi et al.,
2003; Dhar et al., 2001; Schepers et al., 2001; Zhou et al., 2005;
Julien et al., 2004). DS contains four EBNA-1-binding sites, albeit
with lower affinity than those found in FR (Reisman et al., 1985).
The topology of DS is such that the four binding sites are arranged
as two pairs of sites, with 21 by center-to-center spacing between
each pair and 33 by center-to-center spacing between the two
non-paired internal binding sites (Baer et al., 1984; Rawlins et
al., 1985).
[0123] The functional roles of the elements within DS have been
confirmed by studies of another region of the EBV genome, termed
Rep*, which was identified as an element that can substitute for DS
inefficiently (Kirchmaier and Sugden, 1998). Polymerizing Rep*
eight times yielded an element as efficient as DS in its support of
replication (Wang et al., 2006). Biochemical dissection of Rep*
identified a pair of EBNA-1-binding sites with a 21 by
center-to-center spacing critical for its replicative function
(ibid). The minimal replicator of Rep* was found to be the pair of
EBNA-1-binding sites, as replicative function was retained even
after all flanking sequences in the polymer were replaced with
sequences derived from lambda phage. Comparisons of DS and Rep*
have revealed a common mechanism: these replicators support the
initiation of DNA synthesis by recruiting the cellular replicative
machinery via a pair of appropriately spaced sites, bent and bound
by EBNA-1.
[0124] There are other extra-chromosomal plasmids that replicate in
mammalian cells that are unrelated to EBV and in some ways appear
similar to the zone of initiation within the Raji strain of EBV.
Hans Lipps and his colleagues have developed and studied plasmids
that contain "nuclear scaffold/matrix attachment regions" (S/MARs)
and a robust transcriptional unit (Piechaczek et al., 1999; Jenke
et al., 2004). Their S/MAR is derived from the human
interferon-beta gene, is A/T rich, and operationally defined by its
association with the nuclear matrix and its preferential unwinding
at low ionic strength or when embedded in supercoiled DNA (Bode et
al., 1992). These plasmids replicate semiconservatively, bind
origin recognition complex (ORC) proteins, and support the
initiation of DNA synthesis effectively and randomly throughout
their DNA (Schaarschmidt et al., 2004). They are efficiently
maintained in proliferating hamster and human cells without drug
selection and when introduced into swine embryos can support
expression of GFP in most tissues of fetal animals (Manzini et al.,
2006).
[0125] 2. EBNA-1
[0126] As a replication factor, Epstein Barr nuclear antigen 1
(EBNA-1) is a DNA-binding protein that binds to FR and DS of oriP
or Rep* to facilitate replication and faithful partitioning of the
EBV plasmid to daughter cells independent of, but in concert with,
cell chromosomes during each cell division.
[0127] The 641 amino acids (AA) of EBNA-1 have been categorized
into domains associated with its varied functions by mutational and
deletional analyses. Two regions, between AA40-89 and AA329-378 are
capable of linking two DNA elements in cis or in trans when bound
by EBNA-1, and have thus been termed Linking Region 1 and 2 (LR1,
LR2) (Middleton and Sugden, 1992; Frappier and O'Donnell, 1991; Su
et al., 1991; Mackey et al., 1995). Fusing these domains of EBNA-1
to GFP homes the GFP to mitotic chromosomes (Marechal et al., 1999;
Kanda et al., 2001). LR1 and LR2 are functionally redundant for
replication; a deletion of either one yields a derivative of EBNA-1
capable of supporting DNA replication (Mackey and Sugden, 1999;
Sears et al., 2004). LR1 and LR2 are rich in arginine and glycine
residues, and resemble the AT-hook motifs that bind A/T rich DNA
(Aravind and Landsman, 1998), (Sears et al., 2004). An in vitro
analysis of LR1 and LR2 of EBNA-1 has demonstrated their ability to
bind to A/T rich DNA (Sears et al., 2004). When LR1, containing one
such AT-hook, was fused to the DNA-binding and dimerization domain
of EBNA-1, it was found to be sufficient for DNA replication of
oriP plasmids, albeit less efficiently than the wild-type EBNA-1
(ibid).
[0128] In specific embodiments of the invention, an episomal vector
may contain both oriP and a version of EBNA-1 competent to support
plasmid replication and its proper maintenance during cell
division. The highly repetitive sequence within the amino-terminal
one-third of wild-type EBNA-1 and a 25 amino-acid region that has
demonstrated toxicity in various cells are dispensable for the
trans-acting function of EBNA-1 associated with oriP (Yates et al.
1985; Kennedy et al. 2003). Therefore, an exemplary derivative, the
abbreviated form of EBNA-1, known as deltaUR1, could be used
alongside oriP within this plasmid-based system. More examples of
EBNA-1 derivatives that can activate transcription from an
extra-chromosomal template are known (see, for example, Kirchmaier
and Sugden, 1997, and Kennedy and Sugden, 2003, both incorporated
herein by reference).
[0129] A derivative of EBNA-1 used in the invention is a
polypeptide which, relative to a corresponding wild-type
polypeptide, has a modified amino acid sequence. The modifications
include the deletion, insertion or substitution of at least one
amino acid residue in a region corresponding to the unique region
(residues about 65 to about 89) of LR1 (residues about 40 to about
89) in EBNA-1, and may include a deletion, insertion and/or
substitution of one or more amino acid residues in regions
corresponding to other residues of EBNA-1, e.g., about residue 1 to
about residue 40, residues about 90 to about 328 ("Gly-Gly-Ala"
repeat region), residues about 329 to about 377 (LR2), residues
about 379 to about 386 (NLS), residues about 451 to about 608 (DNA
binding and dimerization), or residues about 609 to about 641, so
long as the resulting derivative has the desired properties, e.g.,
dimerizes and binds DNA containing an on corresponding to oriP,
localizes to the nucleus, is not cytotoxic, and activates
transcription from an extrachromosomal vector but does not
substantially activate transcription from an integrated template.
Substitutions include substitutions which utilize the D rather than
L form, as well as other well known amino acid analogs, e.g.,
unnatural amino acids such as .alpha.-disubstituted amino acids,
N-alkyl amino acids, lactic acid, and the like.
[0130] 3. Other EBV Genes
[0131] In certain aspects of the invention, the episomal vector
elements may comprise one or more transforming genes, such as those
derived from EBV, for example, EBNA-1, EBNA-2, EBNA-3A, EBNA-3C,
EBNA-LP or LMP-1.
[0132] EBV infection in vitro converts primary human B cells into
continuously proliferating lymphoblastoid cell lines (LCLs). In
EBV-transformed LCLs, EBV expresses six nuclear proteins [EBV
nuclear antigens (EBNAs) EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C,
and EBNA-LP], three integral membrane proteins (LMP-1, LMP-2A, and
LMP-2B), two small nonpolyadenylated RNAs (EBER1 and EBER2), and
BamA rightward transcripts. Six of these viral latency proteins,
EBNA-1, EBNA-2, EBNA-3A, EBNA-3C, EBNA-LP, and LMP-1, have been
shown to be required for the transformation phenotype through
reverse genetic experiments. EBV vectors for transformation may
include one or more of these EBV transforming genes in certain
aspects of the present invention.
[0133] EBV nuclear antigen 2 (EBNA-2) is a viral protein associated
with Epstein-Barr virus. EBNA-2 is the main viral transactivator,
switching transcription from the Wp promoters used initially after
infection to the Cp promoter. The LMP-1 and LMP-2A/2B promoters are
activated by EBNA-2 in B cells (Zimber-Strobl et al., 1991). It is
known to bind the host RBP-JK protein that is a key player in the
Notch pathway. c-Myc gene expression is induced by EBNA-2 mediated
enhanced transcriptional initiation and EBNA-2 is essential for
EBV-mediated growth transformation.
[0134] EBNA-3A, EBNA-3B, and EBNA-3C, which are arranged in tandem
in the EBV genome, are encoded by genes that are similar in
structure, leading to the proposal that the EBNA-3 genes may have
arisen from a tandem triplication of an ancestral gene. The
N-terminal amino acids of EBNA-3A, EBNA-3B, and EBNA-3C mediate
interaction with a sequence-specific DNA-binding protein, RBP-JK.
Reverse genetic experiments with recombinant EBVs indicate that
EBNA-3A and EBNA-3C are essential for the EBV-mediated conversion
of primary B cells into LCLs, whereas EBNA-3B is dispensable.
EBNA-3C binds to and regulates cell cycle proteins, including Rb
(Parker et al., 1996) and cyclin A (Knight and Robertson,
2004).
[0135] Latent membrane protein 1 (LMP-1) is one of the viral gene
products that are essential for B cell transformation, and is
essential for LCL proliferation (Kilger et al, 1998) and exhibits
antiapoptotic properties namely through activating the NF-.kappa.B
pathway (Cahir-McFarland et al. 2000 and 2004). LMP-1 is an
integral membrane protein composed of a short cytoplasmic
amino-terminal domain, six hydrophobic transmembrane domains, and a
cytoplasmic carboxy-terminal domain. It has been demonstrated that
LMP-1 acts as a constitutively active receptor that mimics
activated CD40, a member of the tumor necrosis factor receptor
family. The cytoplasmic carboxy terminus of LMP-1 plays a critical
role in EBV-induced B-cell transformation through its binding to a
tumor necrosis factor receptor-associated factor (TRAF) and a tumor
necrosis factor receptor-associated death domain (TRADD)
protein.
[0136] The LMP-1 (BNLF1) gene contains three exons that are located
within the BamHI-N region of the EBV genome. Two open reading
frames (ORFs) have been identified based on nucleotide sequences
and mRNA mapping of B95-8 strain EBV. A transcript starting from
the ED-L1 promoter, which is located upstream of the first exon,
encodes the first ORF. This ORF encodes full-length LMP-1 (386
amino acids) that is abundantly expressed in lymphoblastoid cell
lines. Another transcript starting from the ED-L1A promoter, which
is located within the first intron of the LMP-1 gene, encodes the
second ORF. The translation initiation site of this second ORF is
methionine-129 of full-length LMP-1, and the ORF thus encodes an
amino-terminally truncated form of the LMP-1 protein. The truncated
LMP-1 (258 amino acids) consists of the fifth and sixth
transmembrane domains and the cytoplasmic carboxy terminus of
full-length LMP-1, and is expressed during lytic infection and
reactivation of B cells (Hudson et al., 1985).
[0137] EBV nuclear antigen leader protein (EBNA-LP, or EBNA-4)
plays a critical role in EBV induced B cell transformation. It is
one of the first EBV latency proteins expressed after infection of
primary B cells with EBV, suggesting it is required for cell
activation and important for cell cycle progression during this
time. Further evidence to support this claim is that EBNA-LP
cooperates with EBNA-2 to activate transcription of cyclinD2
(Sinclair et al, 1994), as well as coactiving viral proteins
including LMP-1 (Harada and Kieff, 1997).
[0138] D. Additional Episomal Vector Elements
[0139] In certain aspects, the episomal vector of the present
invention contains an expression cassette for the gene encoding a
nuclear reprogramming factor and/or for the gene encoding a
replication factor. The promoter used for the expression unit may
be any promoter used for mammalian cells, and includes, for
example, a CAG promoter, a CMV promoter, a beta-actin promoter, an
SV40 promoter, a PGK promoter and a MuLV LTR promoter. By inserting
the gene (DNA) to be expressed downstream of such a promoter,
expression of the gene product is achieved in cells. A plurality of
genes can be expressed under the control of one promoter by using
IRES (Internal Ribosome Entry Site). The IRES to be used is not
particularly limited, and includes human HCV-derived IRES and
picornavirus-derived IRES, for example.
[0140] In further aspects, the expression cassettes in the episomal
vectors may be under the control of one or more externally
controllable promoters. In certain aspects, the reprogramming
expression cassettes may be induced to express reprogramming
factors after immortalization. For example, the replication factor
expression cassette may be induced for replication of episomal
vector elements comprising immortalization genes or reprogramming
factors for immortalization or reprogramming and may be turned off
for later removal of episomal vector elements, thus inhibiting
replication. The episomal vector may also comprise dominant
negative mutants of replication factors, which interfere with the
replication of episomal vectors and lead to their eventual loss
from the host cells. The episomal vector may also comprise suicidal
factors, which may be induced to kill the cells which retain the
episomal vectors.
[0141] The episomal vector can carry a marker gene for isolating or
enriching cells having the episomal vector introduced therein or
for later vector removal. The marker gene is not particularly
limited as long as it can be used for selecting cells having the
episomal vector introduced therein, but a drug resistance gene is
suitably used. Examples of drugs used for cell selection include,
for example, neomycin (geneticin (G418)), hygromycin, puromycin,
zeocin and blasticidin.
[0142] E. Vector Loss or Removal
[0143] In certain embodiments, the method may further comprising a
step to select or enrich for cells with loss of episomal vector
elements. For examples, in the absence of selection for cells
comprising vectors, vector elements would be lost gradually from
progeny cells. The selection may also comprise selection or
enrichment based on marker gene expression.
[0144] In further embodiments, the method may comprise a vector
removal step. The vector removal step is to remove episomal vectors
from iPS cells. The vector removal step may be unnecessary because
the number of copies of the introduced episomal vector may
spontaneously diminish from the iPS cells during cell growth, thus
resulting in its removal from the population of iPS cells. If
episomal vectors remain in iPS cells, however, the undifferentiated
state of the cells could become unstable or conversely the cells
could lose the ability to differentiate. Therefore, it is preferred
to conduct the vector removal step. Moreover, if episomal vectors
remain for a long period of time, a foreign gene could become
chromosomally integrated spontaneously thus resulting in a similar
problem as is present for retroviral mediated gene integration.
Therefore, it is preferred to conduct the vector removal step also
in order to reduce the possibility of spontaneous chromosomal
integration of a foreign gene, thereby reducing the risk of
cellular oncogenic transformation and subsequent cellular
dysfunction. The method for eliminating episomal vectors is not
particularly limited, and non-limiting methods are provided
below.
[0145] 1. Cloning by Limiting Dilution
[0146] As described above, the presence of episomal vectors
spontaneously decrease over time in conjunction with cell division.
A population consisting only of iPS cells without episomal vectors
can be obtained by continued culturing so as to enable cell
division and by selecting for single clones utilizing the process
of limiting dilution.
[0147] 2. Use of Retroviral Promoter
[0148] While it is often the case that retroviral promoters do not
drive gene expression in undifferentiated cells (Gorman et al.,
1985), residual gene expression from such promoters has been
reported (Yu et al. 2009). Many reports show that a retroviral
vector becomes inactivated in undifferentiated cells (for example,
Pannell et al., 2000). Therefore, when an episomal vector carrying
the gene encoding a replication factor downstream of a retroviral
promoter is employed, for example, the expression of the
replication factor stops or is greatly limited after reprogramming
of somatic cells into iPS cells. As a result, such an episomal
vector loses the ability to replicate, and a population consisting
only of iPS cells without the vectors is gradually formed. The gene
ligated downstream of a retroviral promoter is not limited to the
gene encoding a replication factor, and may be a gene encoding a
nuclear reprogramming factor, but the gene encoding a replication
factor is preferred from the viewpoint of suppressing vector
replication.
[0149] 3. Use of drug-regulated gene expression system Expression
of a target gene product can be regulated by switching medium
conditions between the presence and absence of a specific drug.
When this system is employed so that the expression of a
replication factor is suspended by addition of a specific drug to
the medium, the expression of the replication factor is inhibited,
the episomal vector loses the ability to replicate, and then a
population consisting only of iPS cells without the episomal
vectors is gradually formed. The drug used for the drug-regulated
gene expression system is not particularly limited, and any drug
can be suitably used as long as it can help to realize such a
system.
[0150] As a non-limiting example, the Tet-Off system is such a
known system. In the Tet-Off system, the episomal vector carrying
the gene encoding a replication factor can be designed so that the
expression of the replication factor is suspended by addition of
tetracycline (or any suitable analog thereof) to the medium.
Specifically, for example, the primary vector used by in the
examples can be modified to express tTA (tet-regulated
transcriptional activator) under CMV promoter control, and to carry
the gene encoding a replication factor (large T antigen) downstream
of the tTA-regulated tetO (Tet operator sequence) promoter. The
replication origin (ori) and the neomycin resistance gene in this
vector remain unchanged. When such an episomal vector is employed,
addition of tetracycline to medium after iPS cell selection
inhibits the expression of the replication factor, the episomal
vector loses the ability to replicate, and then a population
consisting only of iPS cells without episomal vectors is gradually
formed.
[0151] It is also possible to employ the Tet-On system, which is
regulated in an opposite manner to the Tet-Off system, that is, in
which the expression of the replication factor is suspended by
removal of tetracycline from medium. In the case of employing the
Tet-On system, medium with tetracycline should be used until iPS
cells are formed, at which time this medium should be replaced with
medium without tetracycline. The Tet-Off system and the Tet-On
system are commercially available from Clontech.
[0152] A similar drug-regulated strategy may also apply to the
conditional expression of suicidal genes, dominant negative mutants
or other episomal removal agents from the episomal vectors.
[0153] 4. Use of Herpesvirus-Derived Thymidine Kinase
[0154] The episomal vector is prepared so as to carry the
herpesvirus-derived thymidine kinase gene in addition to the gene
encoding a replication factor and/or the gene encoding a nuclear
reprogramming factor. In this case, iPS cells which stop expressing
the thymidine kinase due to loss of episomal vectors are allowed to
selectively survive by addition of ganciclovir or aciclovir to
medium after iPS cell selection. Thus, a population consisting only
of iPS cells without episomal vectors can be obtained.
IV. Cell Reprogramming
[0155] In certain aspects of the invention, immortalized somatic
cells may be reprogrammed to prepare iPS cells. Reprogramming may
comprise increasing expression of one or more endogenous
reprogramming factors or introducing one or more reprogramming
factors in nucleic acid or protein form. In further aspects,
signaling regulators such as small molecules may also be used to
enhance reprogramming efficiency. Culturing conditions such as
feeder-free conditions may also be used to facilitate
reprogramming.
[0156] A. Reprogramming Factors
[0157] The generation of iPS cells is dependent upon the use of
reprogramming factors. The following factors or combinations
thereof could be used in the methods disclosed in the present
invention. In certain aspects, nucleic acids encoding Sox and Oct
(preferably Oct3/4) will be included into the reprogramming vector.
For example, one or more reprogramming vectors may comprise
expression cassettes encoding Sox2, Oct4, Nanog and optionally
Lin28, or expression cassettes encoding Sox2, Oct4, Klf4 and
optionally c-Myc, or expression cassettes encoding Sox2, Oct4, and
optionally Esrrb, or expression cassettes encoding Sox2, Oct4,
Nanog, Lin28, K.sub.1f4, c-Myc, and optionally SV40 Large T
antigen. Nucleic acids encoding these reprogramming factors may be
comprised in the same expression cassette, different expression
cassettes, the same reprogramming vector, or different
reprogramming vectors.
[0158] Oct4 and certain members of the Sox gene family (Sox1, Sox2,
Sox3, and Sox15) have been identified as crucial transcriptional
regulators involved in the induction process whose absence makes
induction impossible. Additional genes, however, including certain
members of the Klf family (Klf1, Klf2, Klf4, and Klf5), the Myc
family (c-Myc, L-Myc, and N-Myc), Nanog, and Lin28, have been
identified to increase the induction efficiency.
[0159] Oct4 (Pou5f1) is one of the family of octamer ("Oct")
transcription factors, and plays a crucial role in maintaining
pluripotency. The absence of Oct4 in Oct4' cells, such as
blastomeres and embryonic stem cells, leads to spontaneous
trophoblast differentiation, and presence of Oct4 thus gives rise
to the pluripotency and differentiation potential of embryonic stem
cells. Various other genes in the "Oct" family, including Oct4's
close relatives, Oct1 and Oct6, fail to elicit induction, thus
demonstrating the exclusiveness of Oct4 to the induction
process.
[0160] The Sox family of genes is associated with maintaining
pluripotency similar to Oct4, although it is associated with
multipotent and unipotent stem cells in contrast with Oct4, which
is exclusively expressed in pluripotent stem cells. While Sox2 was
the initial gene used for induction by Yamanaka et al., Jaenisch et
al., and Thompson et al., other genes in the Sox family have been
found to work as well in the induction process. Sox1 yields iPS
cells with a similar efficiency as Sox2, and genes Sox3, Sox15, and
Sox18 also generate iPS cells, although with decreased
efficiency.
[0161] In embryonic stem cells, Nanog, along with Oct4 and Sox2, is
necessary in promoting pluripotency. Therefore, it was surprising
when Yamanaka et al. reported that Nanog was unnecessary for iPS
cell generation although Thomson et al. has reported it is possible
to generate iPS cells with Nanog as one of the factors.
[0162] Lin28 is an mRNA binding protein expressed in embryonic stem
cells and embryonic carcinoma cells associated with differentiation
and proliferation. Thomson et al. demonstrated it is a factor in
iPS generation, although it is unnecessary.
[0163] Klf4 of the Klf family of genes was initially identified by
Yamanaka et al. and confirmed by Jaenisch et al. as a factor for
the generation of mouse iPS cells and was demonstrated by Yamanaka
et al. as a factor for generation of human iPS cells. However,
Thompson et al. reported that Klf4 was unnecessary for generation
of human iPS cells and in fact failed to generate human iPS cells.
Klf2 and Klf4 were found to be factors capable of generating iPS
cells, and related genes Klf1 and Klf5 did as well, although with
reduced efficiency.
[0164] The Myc family of genes are proto-oncogenes implicated in
cancer. Yamanaka et al. and Jaenisch et al. demonstrated that c-Myc
is a factor implicated in the generation of mouse iPS cells and
Yamanaka et al. demonstrated it was a factor implicated in the
generation of human iPS cells. However, Thomson et al. and Yamanaka
et al. reported that c-Myc was unnecessary for generation of human
iPS cells. Usage of the "Myc" family of genes in induction of iPS
cells is troubling for the eventuality of iPS cells as clinical
therapies, as 25% of mice transplanted with c-Myc-induced iPS cells
developed lethal teratomas. N-Myc and L-Myc can also contribute
toward iPS cell generation, exhibiting similar efficiency to c-Myc.
SV40 large T antigen may be used to reduce or prevent the
cytotoxcity that may occur when c-Myc is expressed.
[0165] The reprogramming proteins used in the present invention can
be substituted by protein homologs with about the same
reprogramming functions. Nucleic acids encoding those homologs
could also be used for reprogramming. Conservative amino acid
substitutions are preferred--that is, for example,
aspartic-glutamic as polar acidic amino acids;
leucine/isoleucine/methionine/valine/alanine/glycine/proline as
non-polar or hydrophobic amino acids; lysine/arginine/histidine as
polar basic amino acids; acids; serine/threonine as polar or
uncharged hydrophilic amino acids. Conservative amino acid
substitution also includes groupings based on side chains. For
example, a group of amino acids having aliphatic side chains is
glycine, alanine, valine, leucine, and isoleucine; a group of amino
acids having aliphatic-hydroxyl side chains is serine and
threonine; a group of amino acids having amide-containing side
chains is asparagine and glutamine; a group of amino acids having
aromatic side chains is phenylalanine, tyrosine, and tryptophan; a
group of amino acids having basic side chains is lysine, arginine,
and histidine; and a group of amino acids having sulfur-containing
side chains is cysteine and methionine. For example, it is
reasonable to expect that replacement of a leucine with an
isoleucine or valine, an aspartate with a glutamate, a threonine
with a serine, or a similar replacement of an amino acid with a
structurally related amino acid will not have a major effect on the
properties of the resulting polypeptide. Whether an amino acid
change results in a functional polypeptide can readily be
determined by assaying the specific activity of the
polypeptide.
[0166] B. Reprogramming Signaling Inhibitors
[0167] In certain aspects of the invention, during at least part of
the reprogramming process, the cell may be maintained in the
presence of one or more signaling inhibitors which inhibit a signal
transducer involved in a signaling cascade, e.g., in the presence
of a MEK inhibitor, a GSK-3 inhibitor, a TGF-.beta. receptor
inhibitor, both a MEK inhibitor and a GSK-3 inhibitor, both a GSK-3
inhibitor and a TGF-.beta. receptor inhibitor, both a MEK inhibitor
and a TGF-.beta. receptor inhibitor, a combination of all three
inhibitors, or inhibitor of other signal transducers within these
same pathways. In certain aspects, ROCK inhibitors, such as HA-100
or H-1152, or myosin II ATPase inhibitors, such as blebbistatin,
may be used to facilitate clonal expansion of reprogrammed cells
and resulting iPS cells.
[0168] High concentration of FGF, in combination with specific
reprogramming medium such as conditioned human ES cell culture
medium or serum-free defined N2B27 medium, may also be used to
increase reprogramming efficiency. Externally added FGF, signaling
inhibitors or any other chemicals (e.g., .beta.-mercaptoethanol)
used herein may be at an amount of at least, about or at most 0.1,
1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80,
90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900
ng/mL, at least, about, or at most 0.05, 0.1, 0.2, 0.2, 0.3, 0.4,
0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10,
20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700,
800, 900 .mu.M, 1, 2, 3, 4, 5, 6, 7, 8, 9, mM, or any range
derivable therein, or any concentration effective for improving
episomal reprogramming. In specific embodiments, high concentration
of FGF may be used, for example, about 40 to 200 ng/mL, or more
particularly, about 100 ng/mL. More details of the methods for
reprogramming cells with signaling inhibitors have been disclosed
in U.S. Application No. 61,258,120 incorporated herein by
reference.
[0169] In certain embodiments, in addition to introducing the cells
with one or more reprogramming factors (e.g. two, three or more, as
described herein) by episomal vector elements, the cells are
treated with a reprogramming medium comprising: a MEK inhibitor, a
TGF-.beta. receptor inhibitor, a GSK-3 inhibitor, and optionally
Leukemia inhibitory factor (LIF). The use of such molecules may
result in improved reprogramming efficiency and kinetics, thereby
facilitating iPS cell identification in the primary reprogramming
culture, thus preserving iPS cell clonality.
[0170] It will be understood that in these aspects and embodiments,
other signaling inhibitors which inhibit a signaling component of
the same signaling pathway (e.g. ERK1 or ERK2 cascade) may be
substituted where desired for the MEK inhibitor. This may include
inhibition of an upstream stimulus of the MAPK pathway, in
particular through the FGF receptor (Ying, 2008). Likewise, the
GSK-3 inhibitor may be substituted where desired for other
inhibitors of GSK-3-related signaling pathways, such as insulin
synthesis and Wnt/.beta.-catenin signaling; LIF may be substituted
where desired for other activators of Stat3 or gp130 signaling.
[0171] Such a signaling inhibitor, e.g., a MEK inhibitor, a GSK-3
inhibitor, a TGF-.beta. receptor inhibitor, may be used at an
effective concentration of at least or about 0.02, 0.05, 0.1, 0.2,
0.5, 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150,
200, 500 to about 1000 .mu.M, or any range derivable therein.
[0172] Inhibitors may be provided or obtained by those skilled in
the art by conventional means or from conventional sources (see
also WO2007113505).
[0173] 1. Glycogen Synthase Kinase 3 Inhibitor
[0174] Glycogen synthase kinase 3 (GSK-3) is a serine/threonine
protein kinase that mediates the addition of phosphate molecules on
certain serine and threonine amino acids in particular cellular
substrates. The phosphorylation of these other proteins by GSK-3
usually inhibits the target protein (also called the "substrate").
As mentioned, GSK-3 is known for phosphorylating and thus
inactivating glycogen synthase. It has also been implicated in the
control of cellular response to damaged DNA and Wnt signaling.
GSK-3 also phosphorylates Ci in the Hedgehog (Hh) pathway,
targeting it for proteolysis to an inactive form. In addition to
glycogen synthase, GSK-3 has many other substrates. However, GSK-3
is unusual among the kinases in that it usually requires a "priming
kinase" to first phosphorylate a substrate.
[0175] The consequence of GSK-3 phosphorylation is usually
inhibition of the substrate. For example, when GSK-3 phosphorylates
another of its substrates, the NFAT family of transcription
factors, these transcription factors cannot translocate to the
nucleus and are therefore inhibited. In addition to its important
role in the Wnt signaling pathway, which is required for
establishing tissue patterning during development, GSK-3 is also
critical for the protein synthesis that is induced in settings such
as skeletal muscle hypertrophy. Its roles as an NFAT kinase also
places it as a key regulator of both differentiation and cellular
proliferation.
[0176] GSK-3 inhibition may refer to inhibition of one or more
GSK-3 enzymes. The family of GSK-3 enzymes is well-known and a
number of variants have been described (see e.g. Schaffer et al.,
2003). In specific embodiments GSK3-.beta. is inhibited.
GSK3-.alpha. inhibitors are also suitable, and in certain aspects
inhibitors for use in the invention inhibit both GSK3-.alpha. and
GSK3-.beta..
[0177] Inhibitors of GSK-3 can include antibodies that bind,
dominant negative variants of, and siRNA and antisense nucleic
acids that target GSK3. Examples of GSK-3 inhibitors are described
in Bennett et al. (2002) and in Ring et al. (2003).
[0178] Specific examples of GSK-3 inhibitors include, but are not
limited to, Kenpaullone, 1-Azakenpaullone, CHIR99021, CHIR98014,
AR-A014418 (see, e.g., Gould et al., 2004), CT 99021 (see, e.g.,
Wagman, 2004), CT 20026 (see, Wagman, supra), SB415286, SB216763
(see, e.g., Martin et al., 2005), AR-A014418 (see, e.g., Noble et
al., 2005), lithium (see, e.g., Gould et al., 2003), SB 415286
(see, e.g., Frame et al., 2001) and TDZD-8 (see, e.g., Chin et al.,
2005). Further exemplary GSK-3 inhibitors available from Calbiochem
(see, e.g., Dalton et al., WO2008/094597, herein incorporated by
reference), include but are not limited to BIO (2'Z,3'.English
Pound.)-6-Bromomdirubm-3'-oxime (GSK-3 Inhibitor IX); BIO-Acetoxime
(2'Z,3'E)-6-Bromoindirubin-3'-acetoxime (GSK-3 Inhibitor X);
(5-Methyl-1H-pyrazol-3-yl)-(2-phenylquinazolin-4-yl)amine (GSK-3
Inhibitor XIII); Pyridocarbazole-cyclopenadienylruthenium complex
(GSK-3 Inhibitor XV); TDZD-8
4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (GSK-3beta
Inhibitor I); 2-Thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxadiazole
(GSK-3beta Inhibitor II); OTDZT
2,4-Dibenzyl-5-oxothiadiazolidine-3-thione (GSK-3beta Inhibitor
III); alpha-4-Dibromoacetophenone (GSK-3beta Inhibitor VII);
AR-AO14418 N-(4-Methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea
(GSK-3beta Inhibitor VIII);
3-(1-(3-Hydroxypropyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-4-pyrazin-2-yl-pyrr-
ole-2,5-dione (GSK-3beta Inhibitor XI); TWS1 19 pyrrolopyrimidine
compound (GSK-3beta Inhibitor XII); L803 H-KEAPP APPQSpP-NH2 or its
Myristoylated form (GSK-3beta Inhibitor XIII);
2-Chloro-1-(4,5-dibromo-thiophen-2-yl)-ethanone (GSK-3beta
Inhibitor VI); AR-AO144-18; SB216763; and SB415286.
[0179] GSK-3 inhibitors can activate, for example, the
Wnt/.beta.-catenin pathway. Many of .beta.-catenin downstream genes
co-regulate pluripotency gene networks. For example, a GSK-3
inhibitor activates c-Myc expression as well as enhances its
protein stability and transcriptional activity. Thus, in some
embodiments, GSK-3 inhibitors can be used to stimulate endogenous
Myc polypeptide expression in a cell, thereby eliminating the need
for Myc expression to induce pluripotency.
[0180] In addition, the structure of the active site of GSK-3.beta.
has been characterized and key residues that interact with specific
and non-specific inhibitors have been identified (Bertrand et al.,
2003). This structural characterization allows additional GSK
inhibitors to be readily identified.
[0181] The inhibitors used herein are preferably specific for the
kinase to be targeted. The inhibitors of certain embodiments are
specific for GSK-3.beta. and GSK-3.alpha., substantially do not
inhibit erk2 and substantially do not inhibit cdc2. Preferably the
inhibitors have at least 100 fold, more preferably at least 200
fold, very preferably at least 400 fold selectivity for human GSK-3
over mouse erk2 and/or human cdc2, measured as ratio of IC.sub.50
values; here, reference to GSK-3 IC.sub.50 values refers to the
mean values for human GSK-3.beta. and GSK-3.alpha.. Good results
have been obtained with CHIR99021 which is specific for GSK-3.
Suitable concentrations for use of CHIR99021 are in the range 0.01
to 100, preferably 0.1 to 20, more preferably 0.3 to 10
micromolar.
[0182] 2. MEK Inhibitor
[0183] MEK inhibitors, which include inhibitors of
mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) or
its related signaling pathways like MAPK cascade, may be used in
certain aspects of the invention. Mitogen-activated protein kinase
kinase (sic) is a kinase enzyme which phosphorylates
mitogen-activated protein kinase. It is also known as MAP2K.
Extracellular stimuli lead to activation of a MAP kinase via a
signaling cascade ("MAPK cascade") composed of MAP kinase, MAP
kinase kinase (MEK, MKK, MEKK, or MAP2K), and MAP kinase kinase
kinase (MKKK or MAP3K).
[0184] A MEK inhibitor herein refers to MEK inhibitors in general.
Thus, a MEK inhibitor refers to any inhibitor of a member of the
MEK family of protein kinases, including MEK1, MEK2 and MEK5.
Reference is also made to MEK1, MEK2 and MEK5 inhibitors. Examples
of suitable MEK inhibitors, already known in the art, include the
MEK1 inhibitors PD184352 and PD98059, inhibitors of MEK1 and MEK2
U0126 and SL327, and those discussed in Davies et al. (2000).
[0185] In particular, PD184352 and PD0325901 have been found to
have a high degree of specificity and potency when compared to
other known MEK inhibitors (Bain et al., 2007). Other MEK
inhibitors and classes of MEK inhibitors are described in Zhang et
al. (2000).
[0186] Inhibitors of MEK can include antibodies to, dominant
negative variants of, and siRNA and antisense nucleic acids that
suppress expression of MEK. Specific examples of MEK inhibitors
include, but are not limited to, PD0325901 (see, e.g., Rinehart et
al., 2004), PD98059 (available, e.g., from Cell Signaling
Technology), U0126 (available, for example, from Cell Signaling
Technology), SL327 (available, e.g., from Sigma-Aldrich), ARRY-162
(available, e.g., from Array Biopharma), PD184161 (see, e.g., Klein
et al., 2006), PD184352 (CI-1040) (see, e.g., Mattingly et al.,
2006), sunitinib (see, e.g., Voss, et al., US2008004287
incorporated herein by reference), sorafenib (see, Voss supra),
Vandetanib (see, Voss supra), pazopanib (see, e.g., Voss supra),
Axitinib (see, Voss supra) and PTK787 (see, Voss supra).
[0187] Currently, several MEK inhibitors are undergoing clinical
trial evaluations. CI-1040 has been evaluated in Phase I and II
clinical trials for cancer (see, e.g., Rinehart et al., 2004).
Other MEK inhibitors being evaluated in clinical trials include PD
184352 (see, e.g., English et al., 2002), BAY 43-9006 (see, e.g.,
Chow et al., 2001), PD-325901 (also PD0325901), GSK1 120212,
ARRY-438162, RDEA1 19, AZD6244 (also ARRY-142886 or ARRY-886),
R05126766, XL518 and AZD8330 (also ARRY-704).
[0188] Inhibition of MEKs can also be conveniently achieved using
RNA-mediated interference (RNAi). Typically, a double-stranded RNA
molecule complementary to all or part of a MEK gene is introduced
into pluripotent cells, thus promoting specific degradation of
MEK-encoding mRNA molecules. This post-transcriptional mechanism
results in reduced or abolished expression of the targeted MEK
gene. Suitable techniques and protocols for achieving MEK
inhibition using RNAi are known.
[0189] A number of assays for identifying kinase inhibitors,
including GSK-3 inhibitors and MEK inhibitors, are known. For
example, Davies et al. (2000) describes kinase assays in which a
kinase is incubated in the presence of a peptide substrate and
radiolabeled ATP. Phosphorylation of the substrate by the kinase
results in incorporation of the label into the substrate. Aliquots
of each reaction are immobilized on phosphocellulose paper and
washed in phosphoric acid to remove free ATP. The activity of the
substrate following incubation is then measured and provides an
indication of kinase activity. The relative kinase activity in the
presence and absence of candidate kinase inhibitors can be readily
determined using such an assay. Downey et al. (1996) also describes
assays for kinase activity which can be used to identify kinase
inhibitors.
[0190] 3. TGF-.beta. Receptor Inhibitor
[0191] TGF-.beta. receptor inhibitors may include any inhibitors of
TGF signaling in general or inhibitors specific for TGF-.beta.
receptor (e.g., ALK5) inhibitors, which can include antibodies to,
dominant negative variants of, and siRNA and antisense nucleic
acids that suppress expression of, TGF beta receptors (e.g., ALK5).
Exemplary TGF-.beta. receptor/ALK5 inhibitors include, but are not
limited to, SB431542 (see, e.g., Inman et al., 2002), A-83-01, also
known as
3-(6-Methyl-2-pyridinyl)-N-phenyl-4-(4-quinolinyl)-1H-pyrazole-1-carbothi-
oamide (see, e.g., Tojo et al., 2005, and commercially available
from, e.g., Toicris Bioscience);
24346-Methylpyridin-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine,
Wnt3a/BIO (see, e.g., Dalton, et al., WO2008/094597, herein
incorporated by reference), BMP4 (see, Dalton, supra), GW788388
(-(4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridm-2-yl}-N-(tetrahydro-2H-pyra-
n-4-yl)benzamide) (see, e.g., Gellibert et al., 2006), SM16 (see,
e.g., Suzuki et al., 2007), IN-1130
(3((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)-
benzamide) (see, e.g., Kim et al., 2008), GW6604
(2-phenyl-4-(3-pyridin-2-yl-1H-pyrazol-4-yl)pyridine) (see, e.g.,
de Gouville et al., 2006), SB-505124
(2-(5-benzo[1,3]dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridi-
ne hydrochloride) (see, e.g., DaCosta et al., 2004) and pyrimidine
derivatives (see, e.g., those listed in Stiefl et al.,
WO2008/006583, herein incorporated by reference).
[0192] Further, while an "ALK5 inhibitor" is not intended to
encompass non-specific kinase inhibitors, an "ALK5 inhibitor"
should be understood to encompass inhibitors that inhibit ALK4
and/or ALK7 in addition to ALK5, such as, for example, SB-431542
(see, e.g., Inman et al., 2002). Without intending to limit the
scope of the invention, it is believed that ALK5 inhibitors affect
the mesenchymal to epithelial conversion/transition (MET) process.
TGF-.beta./activin pathway is a driver for epithelial to
mesenchymal transition (EMT). It is contemplated that inhibiting
the TGF-.beta./activin pathway can facilitate MET (i.e.,
reprogramming) process.
[0193] It is believed that inhibition of the TGF-.beta./activin
pathway will have similar effects. Thus, any inhibitor (e.g.,
upstream or downstream) of the TGF-.beta./activin pathway can be
used in combination with, or instead of, TGF-.beta./ALK5 inhibitors
as described herein. Exemplary TGF-.beta./activin pathway
inhibitors include but are not limited to: TGF beta receptor
inhibitors, inhibitors of SMAD 2/3 phosphorylation, inhibitors of
the interaction of SMAD 2/3 and SMAD 4, and activators/agonists of
SMAD 6 and SMAD 7. Furthermore, the categorizations described
herein are merely for organizational purposes and one of skill in
the art would know that compounds can affect one or more points
within a pathway, and thus compounds may function in more than one
of the defined categories.
[0194] TGF beta receptor inhibitors can include antibodies to,
dominant negative variants of, and siRNA or antisense nucleic acids
that target TGF beta receptors. Specific examples of inhibitors
include but are not limited to SU5416;
2-(5-benzo[1,3]dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridin-
e hydrochloride (SB-505124); lerdelimumb (CAT-152); metelimumab
(CAT-192); GC-1008; ID1 1; AP-12009; AP-11014; LY550410; LY580276;
LY364947; LY2109761; SB-505124; SB-431542; SD-208; SM16; NPC-30345;
Ki26894; SB-203580; SD-093; Gleevec;
3,5,7,2',4'-pentahydroxyfiavone (Morin); activin-M108A; P144;
soluble TBR2-Fc; and antisense transfected tumor cells that target
TGF beta receptors (See, e.g., Wrzesinski et al., 2007; Kaminska et
al., 2005; and Chang et al., 2007.)
[0195] C. Culturing of Reprogrammed Cells
[0196] After immortalized somatic cells are introduced with
reprogramming factors using the disclosed methods, these cells may
be cultured in a medium sufficient to maintain the pluripotency.
Culturing of induced pluripotent stem (iPS) cells generated in this
invention can use various media and techniques developed to culture
primate pluripotent stem cells, more specially, embryonic stem
cells, as described in U.S. Pat. App. 20070238170 and U.S. Pat.
App. 20030211603. It is appreciated that additional methods for the
culture and maintenance of human pluripotent stem cells, as would
be known to one of skill, may be used with the present
invention.
[0197] In certain embodiments, undefined conditions may be used;
for example, pluripotent cells may be cultured on fibroblast feeder
cells or a medium which has been exposed to fibroblast feeder cells
in order to maintain the stem cells in an undifferentiated state.
Alternately, pluripotent cells may be cultured and maintained in an
essentially undifferentiated state using defined,
feeder-independent culture system, such as a TeSR medium (Ludwig et
al., 2006a; Ludwig et al., 2006b). Feeder-independent culture
systems and media may be used to culture and maintain pluripotent
cells. These approaches allow iPS cells to remain in an essentially
undifferentiated state without the need for mouse fibroblast
"feeder layers." As described herein, various modifications may be
made to these methods in order to reduce costs as desired.
[0198] For example, like human embryonic stem (hES) cells, iPS
cells can be maintained in 80% DMEM (Gibco #10829-018 or
#11965-092), 20% defined fetal bovine serum (FBS) not heat
inactivated (or human AB serum), 1% non-essential amino acids, 1 mM
L-glutamine, and 0.1 mM .beta.-mercaptoethanol. Alternatively, iPS
cells can be maintained in serum-free medium, made with 80%
Knock-Out DMEM (Gibco #10829-018), 20% serum replacement (Gibco
#10828-028), 1% non-essential amino acids, 1 mM L-glutamine, and
0.1 mM .beta.-mercaptoethanol. Just before use, human bFGF may be
added to a final concentration of about 4 ng/mL (WO 99/20741) or
zebrafish bFGF may be used instead as in the Examples.
[0199] Various matrix components may be used in culturing and
maintaining human pluripotent stem cells, preferably in the place
of feeder cells. For example, Matrigel.TM., collagen IV,
fibronectin, laminin, and vitronectin in combination may be used to
coat a culturing surface as a means of providing a solid support
for pluripotent cell growth, as described in Ludwig et al. (2006a;
2006b), which are incorporated by reference in their entirety.
Particularly, Matrigel.TM. may be used to provide a substrate for
cell culture and maintenance of human pluripotent stem cells.
Matrigel.TM. is a gelatinous protein mixture secreted by mouse
tumor cells and is commercially available from BD Biosciences (New
Jersey, USA). This mixture resembles the complex extracellular
environment found in many tissues and is used by cell biologists as
a substrate for cell culture.
[0200] iPS cells, like ES cells, have characteristic antigens that
can be identified or confirmed by immunohistochemistry or flow
cytometry, using antibodies for SSEA-1, SSEA-3 and SSEA-4
(Developmental Studies Hybridoma Bank, National Institute of Child
Health and Human Development, Bethesda Md.), and TRA-1-60 and
TRA-1-81 (Andrews et al., 1987). Pluripotency of embryonic stem
cells can be confirmed by injecting approximately
0.5-10.times.10.sup.6 cells into the rear leg muscles of 8-12 week
old male SCID mice. Teratomas develop that demonstrate at least one
cell type of each of the three germ layers.
V. Reprogramming Factors Expression and Transduction
[0201] In certain aspects of the present invention, reprogramming
factors are expressed from expression cassettes comprised in one or
more vectors. The vectors may be an integrating vector or an
episomal vector. In a further aspect, reprogramming proteins could
be introduced directly into somatic cells by protein transduction
(see U.S. Application No. 61/172,079, incorporated herein by
reference).
[0202] A. Integrating and Episomal Vectors
[0203] iPS cells may be generated by integration of certain nucleic
acids or genes encoding reprogramming proteins into non-pluripotent
cells, such as transformed B cells, in the present invention. DNA
delivery is typically achieved through integrating viral vectors in
the current practice, such as retroviruses. Transduced genes may
include the master transcriptional regulators Oct4 (Pouf51) and
Sox2, although it is suggested that other genes enhance the
efficiency of induction. After a critical period, small numbers of
transduced cells may begin to become morphologically and
biochemically similar to pluripotent stem cells, and could be
isolated through morphological selection, doubling time, or through
a reporter gene and antibiotic selection.
[0204] In November 2007, a milestone was achieved by creating iPS
from adult human fibroblasts from two independent research teams'
studies (Yu et al., 2007; Yamanaka et al., 2007). With the same
principle used earlier in mouse models, Yamanaka had successfully
transformed human fibroblasts into pluripotent stem cells using the
same four pivotal genes: Oct4, Sox2, Klf4, and c-Myc with a
retroviral system but c-Myc is oncogenic. Thomson and colleagues
used Oct4, Sox2, Nanog, and a different gene Lin28 using a
lentiviral system avoiding the use of c-Myc.
[0205] As described above, induction of pluripotent stem cells from
human dermal fibroblasts has been achieved using retroviruses or
lentiviral vectors for ectopic expression of reprogramming genes.
Recombinant retroviruses such as the Moloney murine leukemia virus
(MMLV) have the ability to integrate into the host genome in a
stable fashion. They contain a reverse transcriptase that allows
integration into the host genome. Lentiviruses are a subclass of
Retroviruses. They are widely adapted as vectors thanks to their
ability to integrate into the genome of non-dividing as well as
dividing cells. The viral genome in the form of RNA is
reverse-transcribed when the virus enters the cell to produce DNA,
which is then inserted into the genome at a random position by the
viral integrase enzyme.
[0206] Introduction of reprogramming factor genes may also be
accomplished by using a transposon-transposase system. Such
transposon-transposase systems that could be used are the Sleeping
Beauty system, the Frog Prince system (for the description of the
latter see e.g. EP1507865), or the TTAA-specific piggyBac
system.
[0207] Transposons are sequences of DNA that can move around to
different positions within the genome of a single cell, a process
called transposition. In the process, they can cause mutations and
change the amount of DNA in the genome. Transposons were also once
called jumping genes, and are examples of mobile genetic
elements.
[0208] There are a variety of mobile genetic elements, and they can
be grouped based on their mechanism of transposition. Class I
mobile genetic elements, or retrotransposons, copy themselves by
first being transcribed to RNA, then reverse transcribed back to
DNA by reverse transcriptase, and then being inserted at another
position in the genome. Class II mobile genetic elements move
directly from one position to another using a transposase to "cut
and paste" them within the genome.
[0209] These reprogramming methods may also make use of
extra-chromosomally replicating vectors (i.e., episomal vectors)
which are vectors capable of replicating episomally to make iPS
cells essentially free of exogenous vector or viral elements (see
U.S. Publication No. 2010/0003757, incorporated herein by
reference; Yu et al., 2009), as has been previously described
herein.
[0210] B. Protein Transduction
[0211] One possible way to avoid introducing exogenous genetic
modifications to target cells would be to deliver the reprogramming
proteins directly into cells, rather than relying on the
transcription from delivered genes. Previous studies have
demonstrated that various proteins can be delivered into cells in
vitro and in vivo by conjugating them with a short peptide that
mediates protein transduction, such as HIV Tat and poly-arginine. A
recent study demonstrated that murine fibroblasts can be fully
reprogrammed into pluripotent stem cells by direct delivery of
recombinant reprogramming proteins (Zhou et al., 2009). More
details of the methods for reprogramming cells with protein
transduction have been disclosed in U.S. Application No. 61/172,079
incorporated herein by reference.
[0212] In certain aspects of the present invention, protein
transduction domains could be used to introduce reprogramming
proteins directly into immortalized somatic cells. Protein
transduction could be a method for enhancing the delivery of
reprogramming proteins into cells. For example, a region of the Tat
protein, which is derived from the HIV Tat protein, can be fused to
a target protein allowing the entry of the target protein into the
cell. The advantages of using fusions of these transduction domains
are that protein entry is rapid, concentration-dependent and appear
to work with different cell types.
[0213] In a further aspect of the present invention, nuclear
localization sequence may also be used to facilitate nuclear entry
of reprogramming proteins. Nuclear localization signals (NLS) have
been described for various proteins. The mechanism of protein
transport to the nucleus is through the binding of a target protein
containing a nuclear localization signal to alpha subunit of
karyopherin. This is followed by transport of the target
protein:karyopherin complex through the nuclear pore and into the
nucleus. However, reprogramming proteins are often transcription
factors that may have endogenous nuclear localization sequences.
Therefore, nuclear localization sequences may not be necessary.
[0214] The direct introduction of reprogramming proteins into
somatic cells may be used in the present invention, with
reprogramming proteins operatively linked to a protein transduction
domain (PTD), either by creating a fusion protein comprising such a
domain or by chemically cross-linking the reprogramming protein and
PTD via functional groups on each molecule.
[0215] Standard recombinant nucleic acid methods can be used to
express one or more transducible reprogramming proteins used
herein. In one embodiment, a nucleic acid sequence encoding the
transducible protein is cloned into a nucleic acid expression
vector, e.g., with appropriate signal and processing sequences and
regulatory sequences for transcription and translation. In another
embodiment, the protein can be synthesized using automated organic
synthetic methods.
[0216] In addition, there have been several methods that may also
help the transport of proteins into cells, one or more of which can
be used alone or in combination with the methods using the protein
transduction domains, including, but not limited to,
microinjection, electroporation, and the use of liposomes. Most of
these methods may need a purified preparation of protein.
Purification of recombinant proteins is often facilitated by the
incorporation of an affinity tag into the expression construct,
making the purification step fast and efficient.
VI. Vector Construction and Delivery
[0217] In certain embodiments, vectors for immortalizing and/or
reprogramming could be constructed to comprise additional elements
in addition to nucleic acid sequences encoding various components
such as immortalizing genes or reprogramming factors as described
above in cells. Details of components of these vectors and delivery
methods are disclosed below.
[0218] A. Vector
[0219] One of skill in the art would be well equipped to construct
a vector through standard recombinant techniques (see, for example,
Maniatis et al., 1988 and Ausubel et al., 1994, both incorporated
herein by reference).
[0220] Vectors can also comprise other components or
functionalities that further modulate gene delivery and/or gene
expression, or that otherwise provide beneficial properties to the
targeted cells. Such other components include, for example,
components that influence binding or targeting to cells (including
components that mediate cell-type or tissue-specific binding);
components that influence uptake of the vector nucleic acid by the
cell; components that influence localization of the polynucleotide
within the cell after uptake (such as agents mediating nuclear
localization); and components that influence expression of the
polynucleotide.
[0221] Such components also might include markers, such as
detectable and/or selection markers that can be used to detect or
select for cells that have taken up and are expressing the nucleic
acid delivered by the vector. Such components can be provided as a
natural feature of the vector (such as the use of certain viral
vectors which have components or functionalities mediating binding
and uptake), or vectors can be modified to provide such
functionalities. A large variety of such vectors are known in the
art and are generally available. When a vector is maintained in a
host cell, the vector can either be stably replicated by the cells
during mitosis as an autonomous structure, incorporated within the
genome of the host cell, or maintained in the host cell nucleus or
cytoplasm.
[0222] B. Regulatory Elements
[0223] Eukaryotic expression cassettes included in the vectors
preferably contain (in a 5'-to-3' direction) a eukaryotic
transcriptional promoter operably linked to a protein-coding
sequence, splice signals including intervening sequences, and a
transcriptional termination/polyadenylation sequence.
[0224] 1. Promoter/Enhancers
[0225] A "promoter" is a control sequence that is a region of a
nucleic acid sequence at which initiation and rate of transcription
are controlled. It may contain genetic elements at which regulatory
proteins and molecules may bind, such as RNA polymerase and other
transcription factors, to initiate the specific transcription a
nucleic acid sequence. The phrases "operatively positioned,"
"operatively linked," "under control," and "under transcriptional
control" mean that a promoter is in a correct functional location
and/or orientation in relation to a nucleic acid sequence to
control transcriptional initiation and/or expression of that
sequence.
[0226] Promoters suitable for use in EBNA-1-encoding vectors of the
invention are those that direct the expression of the expression
cassettes encoding the EBNA-1 protein to result in sufficient
steady-state levels of EBNA-1 protein to stably maintain EBV
oriP-containing vectors. Promoters are also used for efficient
expression of expression cassettes encoding reprogramming
factors.
[0227] A promoter generally comprises a sequence that functions to
position the start site for RNA synthesis. The best known example
of this is the TATA box, but in some promoters lacking a TATA box,
such as, for example, the promoter for the mammalian terminal
deoxynucleotidyl transferase gene and the promoter for the SV40
late genes, a discrete element overlying the start site itself
helps to fix the place of initiation. Additional promoter elements
regulate the frequency of transcriptional initiation. Typically,
these are located in the region 30-110 bp upstream of the start
site, although a number of promoters have been shown to contain
functional elements downstream of the start site as well. To bring
a coding sequence "under the control of" a promoter, one positions
the 5' end of the transcription initiation site of the
transcriptional reading frame "downstream" of (i.e., 3' of) the
chosen promoter. The "upstream" promoter stimulates transcription
of the DNA and promotes expression of the encoded RNA.
[0228] The spacing between promoter elements frequently is
flexible, so that promoter function is preserved when elements are
inverted or moved relative to one another. For example, in the
HSV-tk promoter, the spacing between promoter elements can be
increased to 50 bp apart before activity begins to decline.
Depending on the promoter, it appears that individual elements can
function either cooperatively or independently to activate
transcription. A promoter may or may not be used in conjunction
with an "enhancer," which refers to a cis-acting regulatory
sequence involved in the transcriptional activation of a nucleic
acid sequence.
[0229] A promoter may be one naturally associated with a nucleic
acid sequence, as may be obtained by isolating the 5' non-coding
sequences located upstream of the coding segment and/or exon. Such
a promoter can be referred to as "endogenous." Similarly, an
enhancer may be one naturally associated with a nucleic acid
sequence, located either downstream or upstream of that sequence.
Alternatively, certain advantages will be gained by positioning the
coding nucleic acid segment under the control of a recombinant or
heterologous promoter, which refers to a promoter that is not
normally associated with a nucleic acid sequence in its natural
environment. A recombinant or heterologous enhancer refers also to
an enhancer not normally associated with a nucleic acid sequence in
its natural environment. Such promoters or enhancers may include
promoters or enhancers of other genes, and promoters or enhancers
isolated from any other virus, or prokaryotic or eukaryotic cell,
and promoters or enhancers not "naturally occurring," i.e.,
containing different elements of different transcriptional
regulatory regions, and/or mutations that alter expression. For
example, promoters that are most commonly used in recombinant DNA
construction include the .beta.-lactamase (penicillinase), lactose
and tryptophan (trp) promoter systems. In addition to producing
nucleic acid sequences of promoters and enhancers synthetically,
sequences may be produced using recombinant cloning and/or nucleic
acid amplification technology, including PCR.TM., in connection
with the compositions disclosed herein (see U.S. Pat. Nos.
4,683,202 and 5,928,906, each incorporated herein by reference).
Furthermore, it is contemplated the control sequences that direct
transcription and/or expression of sequences within non-nuclear
organelles such as mitochondria, chloroplasts, and the like, can be
employed as well.
[0230] Naturally, it will be important to employ a promoter and/or
enhancer that effectively direct the expression of the DNA segment
in the organelle, cell type, tissue, organ, or organism chosen for
expression. Those of skill in the art of molecular biology
generally know the use of promoters, enhancers, and cell type
combinations for protein expression, (see, for example Sambrook et
al. 1989, incorporated herein by reference). The promoters employed
may be constitutive, tissue-specific, inducible, and/or useful
under the appropriate conditions to direct high level expression of
the introduced DNA segment, such as is advantageous in the
large-scale production of recombinant proteins and/or peptides. The
promoter may be heterologous or endogenous.
[0231] Additionally any promoter/enhancer combination (as per, for
example, the Eukaryotic Promoter Data Base EPDB, through world wide
web at epd.isb-sib.ch/) could also be used to drive expression. Use
of a T3, T7 or SP6 cytoplasmic expression system is another
possible embodiment. Eukaryotic cells can support cytoplasmic
transcription from certain bacterial promoters if the appropriate
bacterial polymerase is provided, either as part of the delivery
complex or as an additional genetic expression construct.
[0232] Non-limiting examples of promoters include early or late
viral promoters, such as, SV40 early or late promoters,
cytomegalovirus (CMV) immediate early promoters, Rous Sarcoma Virus
(RSV) early promoters; eukaryotic cell promoters, such as, e.g.,
beta actin promoter (Ng, 1989; Quitsche et al., 1989), GADPH
promoter (Alexander et al., 1988, Ercolani et al., 1988),
metallothionein promoter (Karin et al., 1989; Richards et al.,
1984); and concatenated response element promoters, such as cyclic
AMP response element promoters (cre), serum response element
promoter (sre), phorbol ester promoter (TPA) and response element
promoters (tre) near a minimal TATA box. It is also possible to use
human growth hormone promoter sequences (e.g., the human growth
hormone minimal promoter described at Genbank, accession no.
X05244, nucleotide 283-341) or a mouse mammary tumor promoter
(available from the ATCC, Cat. No. ATCC 45007). A specific example
could be a phosphoglycerate kinase (PGK) promoter.
[0233] 2. Initiation Signals and Internal Ribosome Binding
Sites
[0234] A specific initiation signal also may be required for
efficient translation of coding sequences. These signals include
the ATG initiation codon or adjacent sequences. Exogenous
translational control signals, including the ATG initiation codon,
may need to be provided. One of ordinary skill in the art would
readily be capable of determining this and providing the necessary
signals. It is well known that the initiation codon must be
"in-frame" with the reading frame of the desired coding sequence to
ensure translation of the entire insert. The exogenous
translational control signals and initiation codons can be either
natural or synthetic. The efficiency of expression may be enhanced
by the inclusion of appropriate transcription enhancer
elements.
[0235] In certain embodiments of the invention, the use of internal
ribosome entry sites (IRES) elements are used to create multigene,
or polycistronic, messages. IRES elements are able to bypass the
ribosome scanning model of 5' methylated Cap dependent translation
and begin translation at internal sites (Pelletier and Sonenberg,
1988). IRES elements from two members of the picornavirus family
(polio and encephalomyocarditis) have been described (Pelletier and
Sonenberg, 1988), as well an IRES from a mammalian message (Macejak
and Sarnow, 1991). IRES elements can be linked to heterologous open
reading frames. Multiple open reading frames can be transcribed
together, each separated by an IRES, creating polycistronic
messages. By virtue of the IRES element, each open reading frame is
accessible to ribosomes for efficient translation. Multiple genes
can be efficiently expressed using a single promoter/enhancer to
transcribe a single message (see U.S. Pat. Nos. 5,925,565 and
5,935,819, each herein incorporated by reference).
[0236] In certain embodiments of the invention, the use of a
sequence coding for at least one protease cleavage site and/or
self-cleaving peptide for polycistronic transcription can be used.
For example, there are several self-cleaving peptides such as a
viral 2A peptide.
[0237] 3. Multiple Cloning Sites
[0238] Vectors can include a multiple cloning site (MCS), which is
a nucleic acid region that contains multiple restriction enzyme
sites, any of which can be used in conjunction with standard
recombinant technology to digest the vector (see, for example,
Carbonelli et al., 1999, Levenson et al., 1998, and Cocea, 1997,
incorporated herein by reference.) "Restriction enzyme digestion"
refers to catalytic cleavage of a nucleic acid molecule with an
enzyme that functions only at specific locations in a nucleic acid
molecule. Many of these restriction enzymes are commercially
available. Use of such enzymes is widely understood by those of
skill in the art. Frequently, a vector is linearized or fragmented
using a restriction enzyme that cuts within the MCS to enable
exogenous sequences to be ligated to the vector. "Ligation" refers
to the process of forming phosphodiester bonds between two nucleic
acid fragments, which may or may not be contiguous with each other.
Techniques involving restriction enzymes and ligation reactions are
well known to those of skill in the art of recombinant
technology.
[0239] 4. Splicing Sites
[0240] Most transcribed eukaryotic RNA molecules will undergo RNA
splicing to remove introns from the primary transcripts. Vectors
containing genomic eukaryotic sequences may require donor and/or
acceptor splicing sites to ensure proper processing of the
transcript for protein expression (see, for example, Chandler et
al., 1997, herein incorporated by reference).
[0241] 5. Termination Signals
[0242] The vectors or constructs of the present invention will
generally comprise at least one termination signal. A "termination
signal" or "terminator" is comprised of the DNA sequences involved
in specific termination of an RNA transcript by an RNA polymerase.
Thus, in certain embodiments a termination signal that ends the
production of an RNA transcript is contemplated. A terminator may
be necessary in vivo to achieve desirable message levels.
[0243] In eukaryotic systems, the terminator region may also
comprise specific DNA sequences that permit site-specific cleavage
of the new transcript so as to expose a polyadenylation site. This
signals a specialized endogenous polymerase to add a stretch of
about 200 A residues (polyA) to the 3' end of the transcript. RNA
molecules modified with this polyA tail appear to more stable and
are translated more efficiently. Thus, in other embodiments
involving eukaryotes, it is preferred that the terminator comprises
a signal for the cleavage of the RNA, and it is more preferred that
the terminator signal promotes polyadenylation of the message. The
terminator and/or polyadenylation site elements can serve to
enhance message levels and to minimize read through from the
cassette into other sequences.
[0244] Terminators contemplated for use in certain aspects of the
invention include a known terminator of transcription described
herein or a terminator known to one of ordinary skill in the art,
including but not limited to, for example, the termination
sequences of genes, such as for example the bovine growth hormone
terminator or viral termination sequences, such as for example the
SV40 terminator. In certain embodiments, the termination signal may
be a lack of transcribable or translatable sequence, such as due to
a sequence truncation.
[0245] 6. Polyadenylation Signals
[0246] In expression, particularly eukaryotic expression, one will
typically include a polyadenylation signal to effect proper
polyadenylation of the transcript. The nature of the
polyadenylation signal is not believed to be crucial to the
successful practice of the invention, and any such sequence may be
employed. Preferred embodiments include the SV40 polyadenylation
signal or the bovine growth hormone polyadenylation signal,
convenient and known to function well in various target cells.
Polyadenylation may increase the stability of the transcript or may
facilitate cytoplasmic transport.
[0247] 7. Origins of Replication
[0248] In order to propagate a vector in a host cell, it may
contain one or more origins of replication sites (often termed
"ori"), for example, a nucleic acid sequence corresponding to oriP
of EBV as described above or a genetically engineered oriP with a
similar or elevated function in differentiation programming, which
is a specific nucleic acid sequence at which replication is
initiated. Alternatively a replication origin of other
extra-chromosomally replicating virus as described above or an
autonomously replicating sequence (ARS) can be employed.
[0249] 8. Selection and Screenable Markers
[0250] In certain embodiments of the invention, cells containing a
nucleic acid construct of the present invention may be identified
in vitro or in vivo by including a marker in the expression vector.
Such markers would confer an identifiable change to the cell
permitting easy identification of cells containing the expression
vector. Generally, a selection marker is one that confers a
property that allows for selection. A positive selection marker is
one in which the presence of the marker allows for its selection,
while a negative selection marker is one in which its presence
prevents its selection. An example of a positive selection marker
is a drug resistance marker.
[0251] Usually the inclusion of a drug selection marker aids in the
cloning and identification of transformants, for example, genes
that confer resistance to neomycin, puromycin, hygromycin, DHFR,
GPT, zeocin and histidinol are useful selection markers. In
addition to markers conferring a phenotype that allows for the
discrimination of transformants based on the implementation of
conditions, other types of markers including screenable markers
such as GFP, whose basis is colorimetric analysis, are also
contemplated. Alternatively, screenable enzymes as negative
selection markers such as herpes simplex virus thymidine kinase
(tk) or chloramphenicol acetyltransferase (CAT) may be utilized.
One of skill in the art would also know how to employ immunologic
markers, possibly in conjunction with FACS analysis. The marker
used is not believed to be important, so long as it is capable of
being expressed simultaneously with the nucleic acid encoding a
gene product. Further examples of selection and screenable markers
are well known to one of skill in the art. One feature of the
present invention includes using selection and screenable markers
to select vector-free cells after the differentiation programming
factors have effected a desired altered differentiation status in
those cells.
[0252] C. Vector Delivery
[0253] Introduction of a vector into cells with the current
invention may use any suitable methods for nucleic acid delivery
into cells, as described herein (e.g., viral transduction) or as
would be known to one of ordinary skill in the art. Such methods
include, but are not limited to, direct delivery of DNA such as by
ex vivo transfection (Wilson et al., 1989, Nabel et al, 1989), by
injection (U.S. Pat. Nos. 5,994,624, 5,981,274, 5,945,100,
5,780,448, 5,736,524, 5,702,932, 5,656,610, 5,589,466 and
5,580,859, each incorporated herein by reference), including
microinjection (Harland and Weintraub, 1985; U.S. Pat. No.
5,789,215, incorporated herein by reference); by electroporation
(U.S. Pat. No. 5,384,253, incorporated herein by reference;
Tur-Kaspa et al., 1986; Potter et al., 1984); by calcium phosphate
precipitation (Graham and Van Der Eb, 1973; Chen and Okayama, 1987;
Rippe et al., 1990); by using DEAE-dextran followed by polyethylene
glycol (Gopal, 1985); by direct sonic loading (Fechheimer et al.,
1987); by liposome mediated transfection (Nicolau and Sene, 1982;
Fraley et al., 1979; Nicolau et al., 1987; Wong et al., 1980;
Kaneda et al., 1989; Kato et al., 1991) and receptor-mediated
transfection (Wu and Wu, 1987; Wu and Wu, 1988); by microprojectile
bombardment (PCT Application Nos. WO 94/09699 and 95/06128; U.S.
Pat. Nos. 5,610,042; 5,322,783 5,563,055, 5,550,318, 5,538,877 and
5,538,880, and each incorporated herein by reference); by agitation
with silicon carbide fibers (Kaeppler et al., 1990; U.S. Pat. Nos.
5,302,523 and 5,464,765, each incorporated herein by reference); by
Agrobacterium-mediated transformation (U.S. Pat. Nos. 5,591,616 and
5,563,055, each incorporated herein by reference); by PEG-mediated
transformation of protoplasts (Omirulleh et al., 1993; U.S. Pat.
Nos. 4,684,611 and 4,952,500, each incorporated herein by
reference); by desiccation/inhibition-mediated DNA uptake (Potrykus
et al., 1985), and any combination of such methods. Through the
application of techniques such as these, organelle(s), cell(s),
tissue(s) or organism(s) may be stably or transiently
transformed.
[0254] 1. Liposome-Mediated Transfection
[0255] In a certain embodiment of the invention, a nucleic acid may
be entrapped in a lipid complex such as, for example, a liposome.
Liposomes are vesicular structures characterized by a phospholipid
bilayer membrane and an inner aqueous medium. Multilamellar
liposomes have multiple lipid layers separated by aqueous medium.
They form spontaneously when phospholipids are suspended in an
excess of aqueous solution. The lipid components undergo
self-rearrangement before the formation of closed structures and
entrap water and dissolved solutes between the lipid bilayers
(Ghosh and Bachhawat, 1991). Also contemplated is a nucleic acid
complexed with Lipofectamine-2000 (Gibco BRL) or Superfect
(Qiagen). The amount of liposomes used may vary upon the nature of
the liposome as well as the, cell used, for example, about 5 to
about 20 ng vector DNA per 1 to 10 million of cells may be
contemplated.
[0256] Liposome-mediated nucleic acid delivery and expression of
foreign DNA in vitro has been very successful (Nicolau and Sene,
1982; Fraley et al., 1979; Nicolau et al., 1987). The feasibility
of liposome-mediated delivery and expression of foreign DNA in
cultured chick embryo, HeLa and hepatoma cells has also been
demonstrated (Wong et al., 1980).
[0257] In certain embodiments of the invention, a liposome may be
complexed with a hemagglutinating virus of Japan (HVJ). This has
been shown to facilitate fusion with the cell membrane and promote
cell entry of liposome-encapsulated DNA (Kaneda et al., 1989). In
other embodiments, a liposome may be complexed or employed in
conjunction with nuclear non-histone chromosomal proteins (HMG-1)
(Kato et al., 1991). In yet further embodiments, a liposome may be
complexed or employed in conjunction with both HVJ and HMG-1. In
other embodiments, a delivery vehicle may comprise a ligand and a
liposome.
[0258] 2. Electroporation
[0259] In certain embodiments of the present invention, a nucleic
acid is introduced into a cell via electroporation. Electroporation
involves the exposure of a suspension of cells and DNA to a
high-voltage electric discharge. Recipient cells can be made more
susceptible to transformation by mechanical wounding. Also the
amount of vectors used may vary upon the nature of the cells used,
for example, about 5 to about 20 .mu.g vector DNA per 1 to 10
million of cells may be contemplated.
[0260] Transfection of eukaryotic cells using electroporation has
been quite successful. Mouse pre-B lymphocytes have been
transfected with human kappa-immunoglobulin genes (Potter et al.,
1984), and rat hepatocytes have been transfected with the
chloramphenicol acetyltransferase gene (Tur-Kaspa et al., 1986) in
this manner.
[0261] 3. Calcium Phosphate
[0262] In other embodiments of the present invention, a nucleic
acid is introduced to the cells using calcium phosphate
precipitation. Human KB cells have been transfected with adenovirus
5 DNA (Graham and Van Der Eb, 1973) using this technique. Also in
this manner, mouse L(A9), mouse C127, CHO, CV-1, BHK, NIH3T3 and
HeLa cells were transfected with a neomycin marker gene (Chen and
Okayama, 1987), and rat hepatocytes were transfected with a variety
of marker genes (Rippe et al., 1990).
[0263] 4. DEAE-Dextran
[0264] In another embodiment, a nucleic acid is delivered into a
cell using DEAE-dextran followed by polyethylene glycol. In this
manner, reporter plasmids were introduced into mouse myeloma and
erythroleukemia cells (Gopal, 1985).
[0265] 5. Sonication Loading
[0266] Additional embodiments of the present invention include the
introduction of a nucleic acid by direct sonic loading. LTK.sup.-
fibroblasts have been transfected with the thymidine kinase gene by
sonication loading (Fechheimer et al., 1987).
[0267] 6. Receptor Mediated Transfection
[0268] Still further, a nucleic acid may be delivered to a target
cell via receptor-mediated delivery vehicles. These take advantage
of the selective uptake of macromolecules by receptor-mediated
endocytosis that will be occurring in a target cell. In view of the
cell type-specific distribution of various receptors, this delivery
method adds another degree of specificity to the present
invention.
[0269] Certain receptor-mediated gene targeting vehicles comprise a
cell receptor-specific ligand and a nucleic acid-binding agent.
Others comprise a cell receptor-specific ligand to which the
nucleic acid to be delivered has been operatively attached. Several
ligands have been used for receptor-mediated gene transfer (Wu and
Wu, 1987; Wagner et al., 1990; Perales et al., 1994; Myers, EPO
0273085), which establishes the operability of the technique.
Specific delivery in the context of another mammalian cell type has
been described (Wu and Wu, 1993; incorporated herein by reference).
In certain aspects of the present invention, a ligand will be
chosen to correspond to a receptor specifically expressed on the
target cell population.
[0270] In other embodiments, a nucleic acid delivery vehicle
component of a cell-specific nucleic acid targeting vehicle may
comprise a specific binding ligand in combination with a liposome.
The nucleic acid(s) to be delivered are housed within the liposome
and the specific binding ligand is functionally incorporated into
the liposome membrane. The liposome will thus specifically bind to
the receptor(s) of a target cell and deliver the contents to a
cell. Such systems have been shown to be functional using systems
in which, for example, epidermal growth factor (EGF) is used in the
receptor-mediated delivery of a nucleic acid to cells that exhibit
upregulation of the EGF receptor.
[0271] In still further embodiments, the nucleic acid delivery
vehicle component of a targeted delivery vehicle may be a liposome
itself, which will preferably comprise one or more lipids or
glycoproteins that direct cell-specific binding. For example,
lactosyl-ceramide, a galactose-terminal asialganglioside, have been
incorporated into liposomes and observed an increase in the uptake
of the insulin gene by hepatocytes (Nicolau et al., 1987). It is
contemplated that the tissue-specific transforming constructs of
the present invention can be specifically delivered into a target
cell in a similar manner.
[0272] 7. Microprojectile Bombardment
[0273] Microprojectile bombardment techniques can be used to
introduce a nucleic acid into at least one, organelle, cell, tissue
or organism (U.S. Pat. No. 5,550,318; U.S. Pat. No. 5,538,880; U.S.
Pat. No. 5,610,042; and PCT Application WO 94/09699; each of which
is incorporated herein by reference). This method depends on the
ability to accelerate DNA-coated microprojectiles to a high
velocity allowing them to pierce cell membranes and enter cells
without killing them (Klein et al., 1987). There are a wide variety
of microprojectile bombardment techniques known in the art, many of
which are applicable to the invention.
[0274] In this microprojectile bombardment, one or more particles
may be coated with at least one nucleic acid and delivered into
cells by a propelling force. Several devices for accelerating small
particles have been developed. One such device relies on a high
voltage discharge to generate an electrical current, which in turn
provides the motive force (Yang et al., 1990). The microprojectiles
used have consisted of biologically inert substances such as
tungsten or gold particles or beads. Exemplary particles include
those comprised of tungsten, platinum, and preferably, gold. It is
contemplated that in some instances DNA precipitation onto metal
particles would not be necessary for DNA delivery to a recipient
cell using microprojectile bombardment. However, it is contemplated
that particles may contain DNA rather than be coated with DNA.
DNA-coated particles may increase the level of DNA delivery via
particle bombardment but are not, in and of themselves,
necessary.
[0275] For the bombardment, cells in suspension are concentrated on
filters or solid culture medium. Alternatively, immature embryos or
other target cells may be arranged on solid culture medium. The
cells to be bombarded are positioned at an appropriate distance
below the macroprojectile stopping plate.
VII. Differentiation of iPS Cells
[0276] Various approaches may be used with the present invention to
differentiate iPS cells into cell lineages including, but not
limited to, hematopoietic cells, myocytes (e.g., cardiomyocytes),
neurons, fibroblasts and epidermal cells, and tissues or organs
derived therefrom. Exemplary methods of hematopoietic
differentiation of iPS cells may include, for example, methods
disclosed by U.S. Application No. 61/088,054 and No. 61/156,304,
both incorporated herein by reference in their entirety, or
embryoid body (EB) based methods (Chadwick et al., 2003; Ng et al.,
2005). Fibronectin differentiation methods may also be used for
blood lineage differentiation, as exemplified in Wang et al., 2007.
Exemplary methods of cardiac differentiation of iPS cells may
include embryoid body (EB) methods (Zhang, et al., 2009), OP9
stroma cell methods (Narazaki et al., 2008), or growth
factor/chemical methods (see U.S. Patent Publn. 20080038820,
20080226558, 20080254003 and 20090047739, all incorporated herein
by reference in their entirety).
[0277] A. Liver Cells
[0278] Hepatocytes can be differentiated from pluripotent stem
cells such as hES cells using an inhibitor of histone deacetylase,
as described in U.S. Pat. No. 6,458,589 and PCT publication WO
01/81549 (Geron Corporation). Undifferentiated pluripotent stem
cells may be cultured in the presence of an inhibitor of histone
deacetylase. In an exemplary method, differentiation is initiated
with 1% DMSO, then with 2.5 mM of the histone deacetylase inhibitor
n-butyrate. The cells obtained can be matured by culturing 4 days
in a hepatocyte culture medium containing n-butyrate, DMSO, plus
growth factors such as EGF, hepatocyte growth factor, and
TGF-.alpha..
[0279] Staged protocols for differentiating pluripotent stem cells
such as hES cells into hepatocytes are described in US 2005/0037493
A1 (Geron Corp.). Cells are cultured with several combinations of
differentiation and maturation agents in sequence, causing the
pluripotent stem cells such as hES cells to differentiate first
into early endoderm or hepatocyte precursors, and then to mature
hepatocyte-like cells.
[0280] Differentiation into endoderm-like cells can be initiated
using either butyrate, DMSO or fetal bovine serum, optionally in
combination with fibroblast growth factors. Differentiation can
then continue using a commercially available hepatocyte culture
medium, including factors such as hepatocyte growth factor (HGF),
epidermal growth factor (EGF), and/or bone morphogenic protein
(e.g., BMP-2, 4, or 7) in various combinations. Final maturation
may be enhanced by the presence of agents such as dexamethazone or
Oncostatin M. An illustration of the "DMSO Protocol" from US
2005/0037493 A1, as applied to the reporter hepatocytes of this
invention, is provided below in Example 3. In a refined hepatocyte
differentiation protocol, differentiation is initiated using a
protein with Activin activity, typically in the presence of or
sequentially with other factors like butyrate and/or DMSO (Example
6). The cells can then be matured in stages, using HGF, EGF, and/or
BMP, enhanced by the presence of agents such as dexamethazone
followed by Oncostatin M.
[0281] Hepatocytes in certain aspects of this invention can be made
by culturing pluripotent stem cells or other non-hepatocytes in a
medium under conditions that increase the intracellular level of
hepatocyte programming factors to be sufficient to promote
programming of the cells into hepatocytes (see U.S. Application No.
61/323,689, incorporated herein by reference). The medium may also
contain one or more hepatocyte differentiation and maturation
agents, like various kinds of growth factors. However, by
increasing the intracellular level of hepatocyte programming
transcription factors, aspects of the present invention bypass most
stages toward mature hepatocytes without the need to change the
medium for each of the stages. Therefore, in view of the advantages
provided by the present invention, in particular aspects, the
medium for culturing cells under hepatocyte programming may be
essentially free of one or more of the hepatocyte differentiation
and maturation agents, or may not undergo serial change with media
containing different combination of such agents.
[0282] These agents may either help induce cells to commit to a
more mature phenotype--or preferentially promote survival of the
mature cells--or have a combination of both these effects.
Hepatocyte differentiation and maturation agents illustrated in
this disclosure may include soluble growth factors (peptide
hormones, cytokines, ligand-receptor complexes, and other
compounds) that are capable of promoting the growth of cells of the
hepatocyte lineage. Non-limiting examples of such agents include
but are not limited to epidermal growth factor (EGF), insulin,
TGF-.alpha., TGF-.beta., fibroblast growth factor (FGF), heparin,
hepatocyte growth factor (HGF), Oncostatin M (OSM), IL-1, IL-6,
insulin-like growth factors I and II (IGF-I, IGF-2), heparin
binding growth factor 1 (HBGF-1), and glucagon. The skilled reader
will already appreciate that Oncostatin M is structurally related
to Leukemia inhibitory factor (LIF), Interleukin-6 (IL-6), and
ciliary neurotrophic factor (CNTF).
[0283] An additional example is n-butyrate, as described in
previous patent disclosures (U.S. Pat. No. 6,458,589, U.S. Pat. No.
6,506,574; WO 01/81549). Homologs of n-butyrate can readily be
identified that have a similar effect, and can be used as
substitutes in the practice of this invention. Some homologs have
similar structural and physicochemical properties to those of
n-butyrate: acidic hydrocarbons comprising 3-10 carbon atoms, and a
conjugate base selected from the group consisting of a carboxylate,
a sulfonate, a phosphonate, and other proton donors. Examples
include isobutyric acid, butenoic acid, propanoic acid, other
short-chain fatty acids, and dimethylbutyrate. Also included are
isoteric hydrocarbon sulfonates or phosphonates, such as
propanesulfonic acid and propanephosphonic acid, and conjugates
such as amides, saccharides, piperazine and cyclic derivatives. A
further class of butyrate homologs is inhibitors of histone
deacetylase. Non-limiting examples include trichostatin A,
5-azacytidine, trapoxin A, oxamflatin, FR901228, cisplatin, and
MS-27-275. Another class of agents is organic solvents like DMSO.
Alternatives with similar properties include but are not limited to
dimethylacetamide (DMA), hexmethylene bisacetamide, and other
polymethylene bisacetamides. Solvents in this class are related, in
part, by the property of increasing membrane permeability of cells.
Also of interest are solutes such as nicotinamide.
[0284] The term "hepatocyte" or "hepatocyte lineage cell" as used
in this disclosure means a cell that has one or more, preferably at
least three, and more preferably five or seven of the following
characteristics: .alpha..sub.1-antitrypsin; asialoglycoprotein,
glycogen storage, cytochrome P450 enzyme expression;
glucose-6-phosphatase activity, low to negligible
.alpha.-fetoprotein, and morphological features of hepatocytes
(cuboidal cells, possibly with canalicular spaces between them).
Other features of mature hepatocytes isolated from human liver may
be present, but are not required to qualify cells as hepatocytes
within this definition. Assay methods for identifying cell markers
are detailed in U.S. Pat. No. 6,458,589. A "hepatocyte" of this
invention may be but is not necessarily obtained by differentiating
human embryonic stem cells, unless this is explicitly required.
[0285] In the context of drug screening, the user may also wish to
test the activity of particular drug metabolizing enzymes, such as
cytochrome P450 enzymes. A convenient way of surveying the activity
of cytochrome P450 is to combine the cells with a "cassette" of
substrates: such as midazolam (metabolized by CYP3A4), tolbutamide
(metabolized by CYP2C9), phenacetin (CYP1A2), and bufuralol
(CYP2D6). Activity can be quantitated as being about 0.1, 1, or 10
times that of a reference cell line, such as HepG2 cells. A
convenient way of monitoring metabolites of all the drugs in the
cassette simultaneously is by GCMS. If desirable, the cells can be
treated with compounds such as dexamethazone or Rifampicin before
or during use in drug screening, so as to increase cytochrome P450
expression or activity in the cells.
[0286] B. Nerve Cells
[0287] Neural cells can be generated from pluripotent stem cells
such as hES cells according to the method described in U.S. Pat.
No. 6,833,269; Carpenter et al., 2001; and WO 03/000868 (Geron
Corporation). Undifferentiated hES cells or embryoid body cells are
cultured in a medium containing one or more neurotrophins and one
or more mitogens, generating a cell population in which at least
.sup..about.60% of the cells express A2B5, polysialylated NCAM, or
Nestin and which is capable of at least 20 doublings in culture.
Exemplary mitogens are EGF, basic FGF, PDGF, and IGF-1. Exemplary
neurotrophins are NT-3 and BDNF. The use of TGF-.beta. Superfamily
Antagonists, or a combination of cAMP and ascorbic acid, can be
used to increase the proportion of neuronal cells that are positive
for tyrosine hydroxylase, a characteristic of dopaminergic neurons.
The proliferating cells can then be caused to undergo terminal
differentiation by culturing with neurotrophins in the absence of
mitogen.
[0288] Oligodendrocytes can be generated from pluripotent stem
cells such as hES cells by culturing them as cell aggregates,
suspended in a medium containing a mitogen such as FGF, and
oligodendrocyte differentiation factors such as triiodothyronine,
selenium, and retinoic acid. The cells are then plated onto a solid
surface, the retinoic acid is withdrawn, and the population is
expanded. Terminal differentiation can be effected by plating on
poly-L-lysine, and removing all growth factors. Populations can be
obtained in which over 80% of the cells are positive for
oligodendrocyte markers NG2 proteoglycan, A2B5, and PDGFR.alpha.,
and negative for the neuronal marker NeuN. See PCT publication WO
04/007696 and Keirstead et al., 2005. Derivation of retinal pigment
epithelial cells has also been reported (Klimanskaya et al.,
2004).
[0289] C. Heart Cells
[0290] The iPS cells provided herein may be differentiated into
cardiomyocytes according to methods described in US 2011/0097799
(incorporated herein by reference). Cardiomyocytes or cardiomyocyte
precursors can be generated from pluripotent stem cells such as hES
cells according to the method provided in WO 03/006950. In a
similar fashion, the iPS cells may be cultured in suspension with
fetal calf serum or serum replacement, and optionally a
cardiotrophic factor that affects DNA-methylation, such as
5-azacytidine. Alternatively, cardiomyocyte clusters can be
generated by culturing on a solid substrate with Activin A,
followed by culturing with a bone morphogenic protein like BMP4,
and optionally by further culturing with an insulin-like growth
factor like IGF-1. If desired, spontaneously contracting cells can
then be separated from other cells in the population, by density
centrifugation.
[0291] Further process steps can include culturing the cells so as
to form clusters known as Cardiac Bodies.TM., removing single
cells, and then dispersing and reforming the Cardiac Bodies.TM. in
successive iterations. Populations are obtained with a high
proportion of cells staining positive for cTnI, cTnT,
cardiac-specific myosin heavy chain (MHC), and the transcription
factor NR.times.2.5. See WO 03/006950, Xu et al., 2002; and US
2005/0214939 A1 (Geron Corporation).
[0292] D. Other Cell Types
[0293] Islet cells can be differentiated from pluripotent stem
cells such as hES cells (WO 03/050249, Geron Corp.) by initiating
differentiation by culturing in a medium containing a combination
of several factors selected from Activin A, a histone deacetylase
inhibitor (such as butyrate), a mitogen (such as bFGF); and a
TGF-.beta. Superfamily antagonist (such as noggin). The cells can
then be matured by culturing with nicotinamide, yielding a cell
population in which at least 5% of the cells express Pdx1, insulin,
glucagon, somatostatin, and pancreatic polypeptide. Cell clusters
may form buds enriched for insulin producing cells, which can be
recovered by filtering. See WO 03/050249 (Geron Corp.).
[0294] Hematopoietic cells can be made by coculturing pluripotent
stem cells such as hES cells with murine bone marrow cells or yolk
sac endothelial cells was used to generate cells with hematopoietic
markers (U.S. Pat. No. 6,280,718). Hematopoietic cells can also be
made by culturing stem cells with hematogenic cytokines and a bone
morphogenic protein, as described in US 2003/0153082 A1 and WO
03/050251 (Robarts Institute). Method for hematopoietic cell
differentiation from iPS cells provided herein may be described in
US 2010/0216181 and US 2010/0279403 (all incorporated herein by
reference).
[0295] Mesenchymal progenitors and fibroblasts can be generated
from pluripotent stem cells such as hES cells according to the
method described in WO 03/004605. hES-derived mesenchymal cells can
then be further differentiated into osteoblast lineage cells in a
medium containing an osteogenic factor, such as bone morphogenic
protein (particularly BMP4), a ligand for a human TGF-.beta.
receptor, or a ligand for a human vitamin D receptor (WO 03/004605
Sotile et al., 2003). US 2004/0009589 A1 (Iskovitz-Elder et al.)
and US 2003/0166273 A1 (Kaufman et al., Wisconsin) report
endothelial cells derived from human embryonic stem cells.
Chondrocytes or their progenitors can be generated by culturing
stem cells in microaggregates with effective combinations of
differentiation factors listed in WO 03/050250 (Geron Corp.).
[0296] Other differentiation methods known in the art or
subsequently developed can be used in conjunction with this
invention to create engineered cells representative of other
tissues.
VIII. Examples
[0297] The following examples are included to demonstrate preferred
embodiments of the invention. It should be appreciated by those of
skill in the art that the techniques disclosed in the examples
which follow represent techniques discovered to function well in
the practice of the invention, and thus can be considered to
constitute preferred modes for its practice. However, those of
skill in the art should, in light of the present disclosure,
appreciate that many changes can be made in the specific
embodiments which are disclosed and still obtain a like or similar
result without departing from the spirit and scope of the
invention.
Example 1
Engineering Maxi EBV Particles for Reprogramming
[0298] If EBV-positive B cells prove more receptive to
reprogramming, then B cells negative for EBV may be made more
susceptible by infecting them with engineered EBV particles that
may encode reprogramming factors. EBV is a member of the human
herpesvirus family that is capable of packaging very large amounts
of DNA (.ltoreq.165 kb), a desirable feature from the standpoint of
molecular engineering. We can take advantage of the features of EBV
to generate recombinant EBV-based vectors that, in combination with
a helper cell line, can be used to create Maxi-EBV particles that
serve as vehicles for delivering proteins essential for
reprogramming, transformation, etc. (Wendtner et al., 2003;
Delecluse et al., 1999; Delecluse et al., 1998; Hettich et al.,
2006). The following is an outline of the process that may be
needed to derive such particles:
[0299] First, to generate an infection B cell line, a
virus-defective helper cell line is created from 293 cells:
complete EBV genome (165 kb) is cloned onto a prokaryotic replicon
that also carries marker genes driven by eukaryotic promoters (8-10
wks); extrachromosomal EBV genome devoid of TR sequence is
introduced into 293 cells that provides all the packaging functions
for the EBV vector; and a population of clones resulting from
transfection is maintained. A "non-transforming" mini EBV plasmid
is engineered to encode the following: Selection (Hygromycin, GFP,
etc), Terminal repeats of EBV (TR), two origins of replication
(oriLyt and oriP), EBNA-1. The mini EBV plasmid may optionally
include reprogramming genes and/or dominant negative derivatives of
EBNA-1 with/without conditional operators or promoters. Then
packaged mini EBVs are created by: transiently transfecting
engineered virus-defective cells (above) with mini EBV plasmid and
a viral transactivator; harvesting, purifying, and concentrating
supernatant; establishing a test cell line for infection and
screening for Hyg-resistance and/or GFP-positive clones; and
establishing larger scale production and determining viral titers.
After that primary B cells are infected by incubating primary B
cells with mini EBV virions followed by assessing efficiency of
infection 48 hours post (if fluorescence is used as an
indicator)
Example 2
Reprogramming Lymphoblastoid Cells Lines (LCLs) and Standard B
Cells
1) Drive Mature B Cell Population Towards a Progenitor State or
Isolate a Pax-5--Pro-B Cell Progenitor Cell Type for Reprogramming
Trials.
[0300] Dedifferentiation of a mature B cell population to a
progenitor cell type might need inhibition of Pax-5, Blimp1, Oct2
and Bob-1 or up-regulation of C/EBP.alpha..
[0301] The following reagents/treatments are used to down regulate
Pax-5 expression:
[0302] Cells are treated with Glucocorticoids (GCs) like
Prednisolone sodium succinate or SN38 or SU11274 (Kanteti et al.,
2009; Marie-Cardine et al., 2008) to down regulate Pax-5 expression
(Rahman et al., 2001). The surviving cells are placed in IL-7
containing media to support the growth of pro-B cells.
[0303] B cells are treated with antisense RNA, small interfering
RNA, ribozymes or transfected with expression cassettes encoding
Pax-5-inhibiting oligonucleotide molecules. The same approach can
be used for Blimp1, Oct2 and Bob-1. Down regulating one or more of
these genes may enhance reprogramming.
[0304] As an alternative to or in addition to downregulation of
Pax-5, Blimp1, Oct2 or Bob-1, mature adult B cells are infected
with retrovirus encoding C/EBP.alpha. gene. C/EBP.alpha.
up-regulation can steer the cells to a myeloid progenitor like
state and more receptive to reprogramming factors. This strategy
has been outlined by Jaenisch et al. Alternatively, an expression
cassette for C/EBP.alpha. could be introduced by
electroporation.
2) Identify and Isolate a Pax-5 Devoid Pro-B Cell Progenitor Cell
Type for Reprogramming Trials.
[0305] This approach could involve the isolation and purification
of a lymphoid progenitor cells co-expressing the antigens CD34,
CD38 and CD10.
[0306] CD34.sup.+CD10.sup.+CD19.sup.- progenitor B cells are devoid
of Pax-5 expression. Hence this population could be a target cell
type for reprogramming.
[0307] The pro-B cells can be expanded in culture utilizing a
combination of stem cell factor (SCF), interleukin-2 (IL-2),
interleukin-7 (IL 7), interleukin-15 (IL-15), Flt3 ligand (FL) and
thymic stromal lymphopoietin (TSLP).
[0308] A second strategy will involve the isolation of transitional
B cells from peripheral blood. Transitional B cells mark the
crucial link between bone-marrow (BM) immature and peripheral
mature B cells that are identified as CD19(+) CD24(high) CD38(high)
expressing cells. These cells represent approximately 4% of B cells
in healthy adult peripheral blood (Chung et al., 2003).
[0309] The frequency of transitional B cells is upregulated in
immune disorders and in HIV patients. This cell type can be a
target cell for generating iPS cells from disease specific
donors.
[0310] Transfection of immature B cell (Pax-5.sup.-) cells, or a
lymphoid progenitor cells or transitional B cells with plasmids
containing the reprogramming factors (Oct4, Sox2, Nanog or Klf4,
optionally Lin28 or c-Myc; see FIGS. 1A-1B) can be used for
generating iPSCs.
3) Reprogramming Primary B Cells Transformed with EBV:
[0311] The efficient transformation capacity of EBV of primary B
cells is routinely performed to establish and bank lymphoblastoid
cell lines (LCLs) in vitro. The Epstein-Barr virus (EBV) latency
III program imposed by viral proteins EBNA-2 and LMP-1 is directly
responsible for transformation of B cells in vitro.
[0312] LCLs express increased levels of c-Myc, which is at least in
part responsible for EBV-driven B-cell proliferation. LCLs also
reveal induction of NF-KappaB which in turn is responsible for
protection from apoptosis.
[0313] c-Myc is a reprogramming factor. Transfection of LCLs with
reprogramming factors without c-Myc or SV40-T antigen can be used
to generate iPSCs.
[0314] Inhibitors of NF-KappaB and p53 can be used as supplements
for reprogramming trials with LCLs.
4) Post Transfection Care of Recipient Cells
[0315] Recipient B cells can be placed in media supporting
surviving B Addition of BLyS, BAFF (members of the TNF family of
cytokines, essential survival factor for B cells) or CD40 ligand
could also augment the proliferation of B cells containing the
reprogramming, factors for the first few days post transfection (Fu
et al., 2009).
[0316] Reprogramming trials using LCLs could be performed under
Serum Free conditions. The cells can be placed on irradiated. MEFs
or on Matrigel and fed for 30 days using conditioned media from
MEFs or under MEF-free conditions using enriched media containing
small molecules.
[0317] Several conditions that can be used to facilitate chemical
MEF-Free reprogramming methods can be included.
Example 3
Reprogramming Lymphoblastoid Cell Lines (LCLs) without Preemptive
Inhibition of Pax-5 or Over-Expression of C/EBP.alpha.-R Gene Using
Defined Feeder-Free Conditions
[0318] The primary LCLs were obtained and expanded in RPMI medium
containing 10-20% FBS. The cultured LCLs were transfected via
electroporation with EBV-based episomal vectors containing
reprogramming factors as described below.
[0319] The reprogramming was performed using three LCL cell lines
transduced with three sets of reprogramming factors: 7
reprogramming factors (Oct4, Sox2; Nanog, Lin28, Klf4, c-Myc, SV40
Large T antigen), 5 reprogramming factors (Oct4, Sox2; Nanog, Lin28
and SV40 Large T antigen) or 4 reprogramming factors (Oct4, Sox2;
Nanog and SV40 Large T antigen).
[0320] The optimal concentration of DNA for reprogramming was
between 1-2 .mu.g. The efficiency of transfection was estimated by
using a relevant plasmid backbone containing a fluorescent marker
like GFP.
[0321] The efficiency of transfection for GFP-containing plasmids
was between 40-95%. The efficiency of transfection for plasmids
containing GFP along with the reprogramming factors was between
2-20%. The LCLs are a very favorable cell type for oriP-containing
plasmids.
[0322] Presence of MEFs resulted in uncontrolled proliferation of
untransfected cells. Therefore, the entire process was performed
under feeder-free conditions. After transfection, cells were placed
on a feeder-free matrix to promote attachment. The matrix component
may comprise Matrigel.TM., fibronectin, RetroNectin.RTM. (a
fragment of fibronectin), combination of retronectin with Matrigel,
CellStart.TM., collagen or any component that could replace a
feeder layer. The viability of cells post-transfection was about
5-50%.
[0323] The transfected cells were placed in media containing
DMEM/F12, N2 supplement, B27 supplement, 1% NEAA, 1% Glutamax, 0.1
mM .beta.-mercaptoethanol, 100 ng/mL zebrafish basic fibroblast
growth factor (zbFGF), 0.5 .mu.M PD0325901, 3 .mu.M CHIR99021, 0.5
.mu.M A-83-01, 1000 U/mL human recombinant LIF, and 10 .mu.M HA100
(CHALP medium). The cells were fed with fresh media every other day
for the first week post transfection. During the second week, half
of the spent media was gently removed from each well and the cells
were fed with fresh media every other day. The media exchanges were
performed very gently to prevent dislodging of cells that were
attached to the culture vessel surface. Two to three weeks post
transfection, the cultures were slowly transitioned to mTeSR1 or
TeSR2. The cultures were fed with fresh TeSR media every other day
for the next 2-3 weeks
[0324] The levels of Pax-5 expression were determined in
untransfected and transfected LCLs. Pax-5 levels were quantified by
intracellular flow cytometry 4-6 days post transfection. Pax-5
expression in untransfected LCLs was between 60-85%. LCLs
transfected with reprogramming plasmids revealed a decreased
expression of Pax-5 (10-60%). Various combinations of plasmids
displayed varying levels of Pax-5 downregualtion (FIGS. 6A-6D). The
combinations displaying the highest inhibition of Pax-5 expression
generated iPSCs. The exact mechanism by which the reprogramming
factors downregulate Pax-5 is not known. Episomal feeder-free
reprogramming in the presence of small molecules leads to
downregulation of endogenous Pax-5 expression, which in turn may
facilitate the generation of LCL derived iPSCs. A closer analysis
revealed the threshold of Pax-5 expression that favors the
reprogramming process is between 10-30%. Reprogramming conditions
that led to a 65-90% Pax-5 inhibition resulted in iPSCs, while
suboptimal inhibition between 20-50% did not favor reprogramming of
LCLs to iPSCs.
[0325] LCL cultures were transfected with plasmids encoding the
C/EBP.alpha. gene. The presence of the transfected gene was
confirmed by PCR. C/EBP.alpha. over-expressing cells were selected
by placing the cells in G418 containing media. Following selection,
the cells were transfected with reprogramming factors. A second
strategy was to transfect LCLs with plasmids encoding C/EBP.alpha.
gene along with the reprogramming factors.
[0326] Adherent colonies appeared in the wells and the morphology
of LCLs transitioned from a suspension cell type to an adherent
cell type. The adherent colonies were picked and propagated on
Matrigel coated plates. The colonies slowly began to acquire the
classic morphology of iPS-like colonies. Live staining with
Tra-1-60 was performed and confirmed the iPS status of the colony
(FIGS. 2A-2B, 3A-3B, 4A-4B, and 4A-5B). LCLs transfected with the
reprogramming factors alone revealed iPS colonies. Over-expression
of the C/EBP.alpha. gene prior to or inhibition of Pax-5 expression
prior to reprogramming was not essential to reprogram LCLs.
[0327] Placing transfected LCLs on irradiated MEFs in the presence
of hESC media or MEF conditioned medium resulted in the
proliferation of untransfected LCLs. The cultures expanded rapidly
post transfection in the presence of feeders and KOSR-containing
media. Feeder-free conditions favored the reprogramming of B
cells.
Example 4
Strategies to Remove Residual EBV from the iPS Colonies
[0328] EBV preferentially infects B cells (e.g., producing
lymphoblastoid lines) and must provide a selective advantage to the
host cell because it is not lost from them. Therefore, one
possibility is that plasmids bearing the oriP replicon of EBV may
promote gene expression and plasmid retention more optimally within
these cells than other cell types for reprogramming. For example,
the EBNA-1 already present within these infected cells would
complement the newly introduced oriP plasmid encoding the
reprogramming factors by promoting its retention and ensure
sufficient time for expression to ensure reprogramming. Once the
transition to iPS cells occur, it is likely that the endogenous EBV
and the transfected oriP-based plasmid would be lost from the cells
naturally since they are not likely to provide a selective
advantage to the cells. On the other hand, the rate of loss of
those episomes may be too slow to be desirable.
[0329] There are three potential ways to address either of these
possibilities and force the loss of EBV and its cognate oriP-based
DNA from cells. First, the transfected oriP-based plasmid will
likely not provide a selective advantage to resulting iPS clones
and therefore will be naturally lost from cells over time during
cell division. A molecular screen would be used to identify clones
that are successfully free of the plasmid. Second, the plasmids can
be fitted with a cassette to select against cells that still retain
the transfected oriP-based plasmid by encoding a selection marker
such as drug resistance, fluorescence, or cell surface marker (i.e.
hygromycin, GFP, CD4, etc). This approach, however, will not remove
the endogenous EBV that may still reside in the host cell.
[0330] Therefore, the third approach is to fit the transfected DNA
with a cassette encoding a derivative of EBNA-1 that functions as a
dominant negative to inhibit the function of wild-type EBNA-1.
Alternatively, EBNA-1 dominant negative Tat-Fusion protein (Tat is
a protein transduction domain) could be engineered and supplemented
to the iPS cells.
[0331] A derivative of EBNA-1 that lacks its amino-terminal half
but retains its ability to localize to the nucleus and bind DNA is
a well-studied inhibitor of EBNA-1 that facilitates the loss of
oriP-containing plasmids from cells (Kirchmaier and Sugden, 1997;
Kennedy et al., 2003; Mack and Sugden, 2008). This EBNA-1 DNA
binding domain (DBD) mutant competes with wild-type EBNA-1 by
forming heterodimers, binds to sites within the oriP DNA, and
inhibits wild-type EBNA-1's ability to support replication of the
oriP-containing plasmids resulting in loss of the plasmid DNA.
Because the oriP replicon is found within wild-type EBV plasmids,
they too will be lost from cells in the presence of the DBD
protein. Therefore, once reprogramming has successfully occurred,
the residual oriP-based plasmid from the initial transfection can
be induced to express the EBNA-1 DBD domain (FIGS. 1A-1B) or it can
be introduced from an independent plasmid.
[0332] The expression of cassettes encoding selection or a dominant
negative derivative of EBNA-1 will be driven by a conditional
promoter (FIGS. 1A-1B). The promoter will be responsive to
estrogen, tetracycline, or the presence of Nanog or Oct4 proteins.
The estrogen receptor functions as a transcriptional regulator that
translocates to the nucleus in response to estrogen where it binds
to responsive elements within the DNA. It has the potential to be
leaky but responds quickly in comparison to the tetracycline-based
systems. The Tet-based system is advantageous due to its high
degree of regulation and is less prone to leakiness. For example,
the level of expression of our gene of interest would correlate
with the level of doxycycline that is added to the system. An
expression system that is conditionally based on the presence of
Nanog or Oct4 ensures that the cell has acquired properties that
are associated with pluripotency. Presumably, the higher the Oct4
or Nanog, then the higher the level of expression from the cassette
encoding drug selection or the dominant negative derivative of
EBNA-1.
Example 5
Additional Strategies to Remove Residual EBV from the iPS
Colonies
[0333] Once the iPS colonies are formed, residual EBV can also be
removed by a fourth approach by supplementing the media with the
reagents and using the methods as detailed below. The surviving
clones can be screened to demonstrate the absence of EBV.
[0334] The following strategies could be used to remove residual
EBV from the iPS colonies:
[0335] Acyclovir [9-(2-hydroxyethoxymethyl) guanine], the first
clinically useful drug effective against lytic replication of
EBV.
[0336] Three nucleoside analogs,
E-5-(2-bromovinyl)-2'-deoxyuridine,
1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine, and
1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-methyluracil are
potent inhibitors of EBV replication in vitro (Lin et al.,
1983).
[0337] beta-L-5-Iododioxolane uracil has potent anti-Epstein-Barr
virus (EBV) activity (50% effective concentration=0.03 microM) with
low cytotoxicity (50% cytotoxic concentration=1,000 microM). It
exerts its antiviral activity by suppressing replicative EBV DNA
and viral protein synthesis (Kira et al., 2000).
[0338] A combination of 3'-azido-3'-deoxythymidine, along with
alpha and gamma interferon could be used to cure EBV from the
recipient cells.
[0339] Supplementation of media with G-quadruplex-specific
compounds TMPyP3, TMPyP4, and BRACO-19 can be used. These compounds
block EBV proliferation and disrupt the ability of EBNA-1 to tether
to metaphase chromosomes (Norseen et al., 2009).
[0340] Hsp90 inhibitors induce the death of established,
EBV-transformed lymphoblastoid cell lines at doses nontoxic to
normal cells, and this effect is substantially reversed when
lymphoblastoid cell lines are stably infected with a retrovirus
expressing a functional EBNA-1 mutant lacking the Gly-Ala repeats
(Sun et al., 2010). iPS cells which retain EBV and wild-type EBNA-1
would be specifically targeted and selected against.
[0341] Since LCLs overexpress c-Myc, residual un-reprogrammed cells
and partially reprogrammed iPS colonies can continue to express
c-Myc. Inactivation of c-Myc by a chemical inhibitor (10058-F4) or
conditional expression of dominant-negative c-Myc can be used to
remove cells that have any expression of c-Myc.
Example 6
Lymphoblastoid B Cell Lines Reprogrammed to EBV-Free Induced
Pluripotent Stem Cells
[0342] Briefly, lymphoblastoid cell lines (LCLs) were obtained from
Coriell Cell Repositories and maintained using RPMI1640
(Invitrogen) with 15% FBS (Hyclone). The cells were transfected
using oriP/EBNA-1-based episomal vectors previously described (Yu
et al., 2009; Yu et al., 2007). Post transfection the cells were
placed in Matrigel-coated tissue culture plates (BD Biosciences) in
reprogramming medium (RM) for 2-3 weeks Yu et al. (manuscript
submitted December 2010) followed by maintenance in TeSR-2 Medium
(Stem Cell Technologies) for additional 2 weeks. The iPSC-like
colonies were initially handpicked and propagated using TeSR-2
medium on Matrigel coated plates. Characterization of four
LCL-iPSCs was performed by flow cytometry, PCR and teratoma
analysis (Yu et al., 2009). In vitro differentiations were
performed to neural, hematopoietic, cardiac, and hepatocyte
lineages, were performed according to protocols established during
the development of iCell Cardiomyocytes.TM., iCell Hepatocytes.TM.
and iCell Neurons.TM. (Cellular Dynamics International). The
presence of EBV was assessed by RT-PCR, genomic DNA PCR and
immunohistochemistry to detect the presence of EBNA-1 protein. The
karyotype of LCL-iPSCs was analyzed by G banding (WiCell Research
Institute). The genetic identity to the parental line confirmed by
short tandem repeat (STR) analysis (Cell Line Genetics). IgGH
receptor rearrangement analysis was performed on parental and
LCL-iPSCs (Hematologics).
[0343] LCLs were reprogrammed via a single transfection of
oriP/EBNA-1 plasmids encoding reprogramming genes under feeder-free
conditions outlined by Yu et al. (manuscript submitted December
2010). Transfection efficiencies of 50-80% with a viability ranging
from 50-70% were recorded with LCLs transfected with
oriP/EBNA-1-GFP plasmids (data not shown). LCLs were placed on
Matrigel-coated plates immediately after transfection, and cultured
with reprogramming medium for 2-3 weeks. Adherent colonies were
visible around 2 weeks post transfection (FIG. 7A) and the medium
was then transitioned to TeSR-2. After culturing in TeSR-2 medium
for about 2 weeks, the pluripotent status of the colonies was
confirmed by live-cell staining of Tra-1-60 expression (FIG. 7Ci).
Various doses and combinations of the reprogramming plasmids can
reprogram LCLs (FIG. 7B). L-Myc and c-Myc demonstrated similar
efficiencies of iPSC generation from LCLs. 3-11% of the total
adherent colonies were confirmed to be iPSCs by Tra-1-60 staining.
The number of Tra-1-60 positive colonies scored at 7 weeks was
greater than the colonies scored at 5 weeks post transfection
supporting the conversion of adherent colonies to authentic iPSCs.
This was further confirmed by alkaline phosphatase staining (data
not shown). Generation of LCL-iPSC by this method was more
efficient than the average efficiency of iPSC generation from
fibroblasts and keratinocytes by episomal reprogramming (Okita et
al., 2010; Carey et al., 2009; Okita et al., 2008) as well as viral
reprogrammed terminally differentiated murine B cells (Hanna et
al., 2008), but not as efficient as episomal reprogramming of cord
blood (Yu et al. manuscript submitted December 2010). Recent
findings indicate that an `open` chromatin state contributes to
maintenance of pluripotency (Gaspar-Maia et al., 2011). EBNA-1 has
been shown to orchestrate a broad rearrangement of the cellular
transcriptional factors that maintain chromatin architecture and
control viral replication. The pleotrophic effects of EBNA-1
induced during B-cell transformation and expression of other viral
proteins may favor the reprogramming process in LCLs compared to
primary cells (Sompallae et al., 2010).
[0344] Extensive characterization was performed on two clones
derived from each LCL. iPSCs derived from LCL-1 were termed,
LCL-iPS1a and 1b while those derived from LCL-2, LCL-iPS2a and
iPS2b. All LCL-iPS clones had greater than 90% expression of
SSEA-4, Tra-1-81 and OCT3/4 (FIG. 7Cii) and a normal karyotype
(FIG. 7Ciii). RT-PCR analysis demonstrated robust expression of
pluripotency-associated transcripts (FIG. 7Civ) and absence of
reprogramming elements (FIGS. 7E-7F). All 4 LCL-iPSCs generated
well-differentiated teratomas and revealed the presence of mesoderm
(cartilage), goblet cells (endoderm) and neural rosettes (ectoderm)
(FIG. 7D). In vitro differentiation of LCL-iPSCs was performed
using 3D suspension cultures. Endodermal potential was confirmed by
generating hepatocyte-like cells and quantifying Alpha1-Antitrypsin
positive cells (FIG. 8Di). Ectodermal potential was confirmed by
development of .beta.3-tubulin/Nestin double-positive neural
precursor cells and the presence of .beta.3-tubulin positive neural
cultures (FIG. 8D iii-iv). Mesodermal potential was confirmed by
generating cardiomyocytes and multipotent HPCs. LCL-iPSCs generated
beating aggregates expressing 2-15% cardiac troponin T positive
cells on day 14 of differentiation (FIG. 8Dii). LCL-iPSCs generated
CD34+, CD45+, CD43+, CD41+ and CD235a expressing HPCs and formed
colonies in methylcellulose based colony forming assays and
subsequently generated defined cell types like megakaryocytes,
macrophages and granulocytes (FIG. 8Dv-vii). Thus LCLs-iPSCs are
capable of generating terminally differentiated lineages. LCL-iPSCs
maintained identity to the parental LCLs and have been successfully
propagated for at least 50 passages. LCL-iPSCs displayed a clonal
IgGH rearrangement profile (FIG. 8E) similar to the parental LCLs.
The IgGH spectrum can serve as a clone tracking tool for LCL-iPSCs
(Kuppers, 2009; van Dongen et al., 2003).
[0345] Since EBNA-1 is required for establishment of episomal
latent infection, long-term survival of LCLs (Leight and Sugden,
2000; Altmann et al., 2006) and is the only viral protein
absolutely required for persistence of EBV infection in host cells.
LCL-iPSCs were tested for the presence of EBNA-1 at early and late
passages. No expression of EBNA-1 was detectable at the
genomic/episomal, transcriptional (FIGS. 8A-8B) and protein levels
(FIG. 8C) in the LCL-iPSCs after 25 passages. However, EBV can
persist in quiescent cells in latency type 0 without any detectable
EBNA-1 expression (Thorley-Lawson and Gross, 2004). Therefore
absence of EBNA-1 expression (FIG. 8A) alone does not indisputably
indicate a loss of EBV. The absence of detectable EBNA-1 and oriP
sequence along with absence of additional viral latency genes,
EBNA-2 and LMP-2A as well as lytic gene BZLF-1 (FIGS. 8A-8B)
further confirmed the loss of viral elements as a result of the
reprogramming process. Although a thorough analysis is needed to
document the complete loss of EBV in LCL-iPSCs, the generation of
EBV free LCL-iPSCs or defined cell types derived from EBV-free
LCL-iPSCs leads us to speculate on the potential clinical
application of these cells for future transplantation studies.
[0346] Cell Culture and Maintenance of iPSCs.
[0347] Lymphoblastoid cell lines (LCLs) were maintained with
RPMI1640 containing 15% FBS at 37.degree. C. and 5% CO.sub.2 in a
humidified incubator. The derivation of iPSCs from LCLs was
performed on Matrigel-coated tissue culture plates. The cells were
transitioned to reprogramming medium 12 hours post transfection.
The reprogramming medium consisted of DMEM/F12 supplemented with
non-essential amino acids (NEAA), Glutamax, N2, B27 (all from
Invitrogen), 0.1 mM .beta.-mercaptoethanol, 100 ng/mL zebrafish
basic fibroblast growth factor (zbFGF), 0.5 .mu.M PD0325901, 3
.mu.M CHIR99021, 0.5 .mu.M A-83-01 (all from Stemgent), 1000
units/mL hLIF (Millipore) and 10 .mu.M HA-100 (Santa Cruz). The
cells were fed with fresh medium every other day for two weeks.
Between days 14-20 the culture medium was transitioned to TesR-2
medium. Colonies with morphology similar to iPS colonies were
readily visible between days 14-20 post-transfection. The presence
of true-iPS colonies was confirmed by morphology and live-cell
staining with Tra-1-60 antibody. All LCL derived iPS cells were
maintained on Matrigel-coated tissue culture dishes in TeSR-2
Complete Medium (Stem cell Technologies).
[0348] Episomal Vectors.
[0349] Construction of the oriP/EBNA-1-based episomal vectors is
described by Yu et al. (Yu et al., 2009). Six of the reprogramming
plasmids were used for the generation of LCL-iPSCs. Briefly, OSNK
is an oriP/EBNA-1 plasmid which uses the internal ribosome entry
site 2 (IRES2) mediated expression of OCT4, SOX2, NANOG and KLF4.
The following plasmids use the same backbone for expression: OSTK
encodes OCT4, SOX2, SV40 Large T antigen and KLF4, OSNL encodes
OCT4, SOX2, NANOG and Lin28 OSTN encodes OCT4, SOX2, SV40 Large T
antigen and NANOG, c-mL encodes c-MYC and LIN28 and L-mL encodes
L-MYC and LIN28.
[0350] Reprogramming LCLs.
[0351] Reprogramming LCLs with various combinations of episomal
vectors described above and outlined in FIG. 8B was performed via
nucleofection using the Human B Cell 96-well Nucleofector Kit
(Lonza) and program E0-100 with 1-2 .mu.g of DNA per reaction.
Nucleofected cells (.about.1.0E+06 cells per condition) were
allowed to recover a few hours and directly plated to
Matrigel-coated 6-well plates in reprogramming medium.
[0352] Immunofluorescence, Immunoperoxidase and Alkaline
Phosphatase Staining.
[0353] Tra-1-60 live-cell staining was performed by incubating
cells with 10 .mu.g of Tra-1-60 primary antibody (R&D Systems)
for 1 hour, washing briefly three times with DMEM/F12 then
incubating with 1:100 dilutions of IgM AlexaFluor488-conjugated
secondary antibody (Invitrogen) for 30 minutes. Stained cells were
washed and Tra-1-60 colonies were visualized by fluorescent
microscopy. Alkaline Phosphatase (AP) staining was performed using
the Vector Blue Alkaline Phosphatase Substrate Kit III (Vector
Laboratories) according to the manufacturer's instructions.
[0354] Cytospin cell preps were made from cell suspensions of
parental LCLs and LCL-iPSCs and fixed with acetone. Slides were
next rehydrated in PBS, permeabilized with 0.5% triton in PBS and,
blocked with 10% bovine serum albumin (BSA) for 1 hour at room
temperature. The cytospins were stained using anti-EBNA-1 (Santa
Cruz, clone 0211) overnight at 4.degree. C. Sections were washed
and stained with goat anti-mouse IgG HRP or the relevant isotype
control antibody. The signal was visualized with diaminobenzidine
and the slides were counterstained with hematoxylin for
contrast.
[0355] Images were captured using an Olympus IX-71 with an Olympus
DP-70 camera.
[0356] RT-PCR.
[0357] Total RNA and cDNA for each sample were prepared using the
RNeasy Mini Plus kit (Qiagen) and the Improm II Reverse
Transcription kit (Promega), respectively, following the
manufacturer's instructions. RT-PCR to analyze transgene and
endogenous mRNA expression was carried out using primers previous
described by Yu et al (2007). Primers used to detect additional EBV
genes are as follows: EBNA-2 F 5'-CAT AGA AGA AGA AGA GGA TGA
AGA-3' (SEQ ID NO:1) and EBNA-2 R 5'-GTA GGG ATT CGA GGG AAT TAC
TGA-3' (SEQ ID NO:2), LMP-2A F 5'-AGG AAC GTG AAT CTA ATG AAG A-3'
(SEQ ID NO:3) and LMP-2A R 5'-AAG TGA CAA CCG CAG TAA GCA-3',
BZLF-1 F 5' (SEQ ID NO:4)-CAC GGT AGT GCT GCA GTT GC-3' (SEQ ID
NO:5) and BZLF-1 R 5'-CCC AGA ATC AAC AGA CTA ACC AAG CCG-3' (SEQ
ID NO:6). PCR was run using 1 .mu.L of diluted cDNA template (1:2)
for 30 to 35 cycles at 95.degree. C. for 30 s, 55.degree. C. for 30
s, and 72.degree. C. for 30 s.
[0358] Genomic/Episomal DNA PCR.
[0359] Total cellular and viral DNA was isolated using the DNeasy
Blood and Tissue kit (Qiagen) according to the manufacturer's
instructions. PCR to detect episomal reprogramming vector and viral
DNA was performed using primers previous described (Yu et al.,
2009; Yu et al., 2007) or the primer sets listed above. PCR was run
using 150 ng of gDNA per reaction for 30 to 35 cycles at 95.degree.
C. for 30 s, 55.degree. C. for 30 s, and 72.degree. C. for 30
s.
[0360] In Vitro Differentiation.
[0361] LCL-iPSCs maintained for over 25 passages on Matrigel were
used for all in vitro differentiation experiments.
[0362] Endodermal, neural, cardiac and hematopoietic cultures were
dissociated into single-cell suspension using TrypLE (Invitrogen),
and the first step included the formation of aggregates in
ultra-low attachment flasks in the presence of a rock inhibitor,
H1152 (EMD Biosciences), for 24 hours.
[0363] Hematopoietic differentiation was performed by placing the
cells in IMDM medium supplemented with NEAA, Glutamine (Invitrogen)
and 2% SR3 (Sigma) in the presence of 25 ng/mL zbFGF, 50 ng/mL
rhBMP4 (R&D Systems), 50 ng/ml rhVEGF, 25 ng/mL, rhFlt-3
ligand, 25 ng/mL rhSCF, 25 ng/mL rhIL-3, and 25 ng/mL rhIL-6 (All
from ProSpec-Tany TechnoGene Ltd.) for 12 days. The cells were
harvested and the stained for the presence of CD31, CD34, CD43,
CD45, CD41 and CD235a and assayed by flow cytometry. The
individualized cells were placed in MethoCult (Stem Cell
Technologies) media for quantifying colony-forming units per the
manufacturer's instructions
[0364] HPCs derived from LCL-iPSCs were placed in MegaCult.RTM.-C
collagen-based medium (Stem Cell Technologies) to detect
megakaryocyte progenitors. Megacult cultures were stained after 10
days to detect the presence of Mk-specific antigen GP11b/111a
(CD41) on megakaryocytes according to the manufacturer's
instructions.
[0365] HPCs derived from LCL-iPSCs were expanded for 10 days to
enrich the myeloid cells. The cells were placed in SFEM media (Stem
Cell Technologies) supplemented with 1% Excyte (Serologicals),
monothioglycerol (450 .mu.M, Sigma), NEAA (0.1 mM), L-glutamine (2
mM), GM-CSF (100 ng/mL, ProSpec-Tany TechnoGene Ltd.). Wright stain
was performed on cytospins to detect the presence of different cell
types. The cultures were also stained for the presence of
macrophage (CD68), granulocytic (CD15) and monocytic (CD14)
specific antigens by flow cytometry (data not shown).
[0366] Cardiac differentiation was performed by placing the
aggregates in DMEM/F12 supplemented with 10% FBS and zbFGF-2 for 7
days and transitioning to DMEM/F12 supplemented with 10% FBS for
the next 8 days. Beating aggregates were dissociated and stained
for the presence of cardiac troponin T (cTnT) (Abcam) on day 14 of
differentiation.
[0367] Neural differentiation was induced by placing the aggregates
in DMEM/F12 supplemented with 1% N2 supplement, 0.5-1 .mu.M
dorsomorphin and 5 .mu.M SB 431542 (both Sigma Aldrich) for one
week, followed by transition to DMEM/F12 containing N2 and B27
supplements alone for additional two weeks. The neural aggregates
were individualized around day 20 of differentiation and plated on
Matrigel coated plates for additional 1-2 weeks. The expression of
.beta.3-tubulin and nestin was quantified by flow cytometry. The
cells were also stained to detect the presence of .beta.3-tubulin
by immunofluorescence, and the nuclei were counterstained with
Hoechst for DNA staining Anti-tubulin and anti-nestin antibodies
were purchased from BD Pharmingen.
[0368] Endodermal differentiation was induced by placing the
aggregates in RPMI1640 media supplemented with 2% N2 supplement and
50-100 ng/mL of activin A (Invitrogen) for the first 3-4 days
followed by the addition of 10-50 ng/mL of BMP4 (R&D Systems),
zbFGF-2 and HGF2 (R&D Systems) for the next two weeks. The
hepatocyte-like cells were matured in the presence of oncostatin M
(R&D Systems) and dexamethasone (Sigma), and the cultures were
harvested at day 33 of differentiation.
[0369] Teratoma Formation.
[0370] LCL-iPSCs maintained on Matrigel-coated plates in the
presence of TeSR-2 were harvested using collagenase IV and injected
intramuscularly into the hind limb of SCID/beige mice (Harlan
Laboratories, Madison, Wis.). Three mice were injected per cell
line, each with one 6-well plate of cells. Matrigel was added at
1/3 total volume to the cell suspension prior to injection. Tumors
formed at 8-10 weeks and were processed for hematoxylin and eosin
staining and histological analysis by the Immunohistochemical Core
Service affiliated with the Department of Surgery located at the
University of Wisconsin-Madison. All animal work was conducted
according to relevant national and international guidelines under
the approval of the Cellular Dynamics International Animal Care and
Use Committee.
[0371] DNA Fingerprinting.
[0372] Genomic DNA was isolated from LCL-iPSCs and parental LCLs
using the DNeasy Blood and Tissue kit (Qiagen). The samples were
sent to WiCell Research Institute and Cell Line Genetics for short
tandem repeat (STR) analysis. Genotypes for 8 STR loci were
analyzed on the parental and LCL-iPSCs.
[0373] Karyotyping.
[0374] G-banding analysis was conducted by WiCell Research
Institute.
[0375] IgGH Rearrangement Analysis.
[0376] Genomic DNA was isolated per manufacturer's protocol (using
the DNeasy Blood and Tissue kit) from parental LCLs and the
LCL-iPSCs. The IgG heavy chain gene rearrangement assays were
performed by a multiplexed PCR reaction by Hematologics to detect
distinct monoclonal amplicons for the three immunoglobulin heavy
chain framework regions.
[0377] Flow Cytometry Analysis.
[0378] LCL-iPSCs maintained on Matrigel were harvested and stained
for the presence of Tra-1-81 (AlexaFluor488-conjugated TRA-1-81,
Millipore), and SSEA-4 (BD Pharmingen, clone MC813-70). Dead cells
stained by propidium-iodide were excluded from the analysis.
Intracellular OCT3/4 (BD, clone 40/OCT-3) staining was performed on
cells fixed with 2% paraformaldehyde and permeablized with PBS+0.1%
saponin. Cells were stained overnight and analyzed the next day on
a flow cytometer (Accuri). Isotype antibodies (BD Pharmingen) were
used as controls.
[0379] For in vitro differentiation studies, LCL-iPSCs were stained
using polyclonal Alpha1-Antitrypsin antibody (Bethyl Laboratories)
to quantify hepatocyte-like cells. Neural precursor cells derived
from LCL-iPSCs were stained using anti-tubulin (TUJ1) and nestin
(25/NESTIN), BD Pharmingen. For cardiac differentiation the cells
were stained using anti-cardiac troponin T antibody (Abcam, clone
1C11). LCL derived HPCs were quantified by surface staining of
hematopoietic precursors with: pan CD45 (clone HI30); CD43
(clone1G10); CD34 (clone 581); CD41 (clone HIPS); CD235a (clone
HIR2) antibodies (all from BD Biosciences).
[0380] All of the methods disclosed and claimed herein can be made
and executed without undue experimentation in light of the present
disclosure. While the compositions and methods of this invention
have been described in terms of preferred embodiments, it will be
apparent to those of skill in the art that variations may be
applied to the methods and in the steps or in the sequence of steps
of the method described herein without departing from the concept,
spirit and scope of the invention. More specifically, it will be
apparent that certain agents which are both chemically and
physiologically related may be substituted for the agents described
herein while the same or similar results would be achieved. All
such similar substitutes and modifications apparent to those
skilled in the art are deemed to be within the spirit, scope and
concept of the invention as defined by the appended claims.
REFERENCES
[0381] The following references, to the extent that they provide
exemplary procedural or other details supplementary to those set
forth herein, are specifically incorporated herein by reference.
[0382] U.S. Appln. 61/258,120 [0383] U.S. Appln. 61/088,054 [0384]
U.S. Appln. 61/156,304 [0385] U.S. Appln. 61/172,079 [0386] U.S.
Appln. 61/323,689 [0387] U.S. Pat. No. 4,683,202 [0388] U.S. Pat.
No. 4,684,611 [0389] U.S. Pat. No. 4,952,500 [0390] U.S. Pat. No.
5,302,523 [0391] U.S. Pat. No. 5,322,783 [0392] U.S. Pat. No.
5,384,253 [0393] U.S. Pat. No. 5,464,765 [0394] U.S. Pat. No.
5,538,877 [0395] U.S. Pat. No. 5,538,880 [0396] U.S. Pat. No.
5,550,318 [0397] U.S. Pat. No. 5,563,055 [0398] U.S. Pat. No.
5,580,859 [0399] U.S. Pat. No. 5,589,466 [0400] U.S. Pat. No.
5,591,616 [0401] U.S. Pat. No. 5,610,042 [0402] U.S. Pat. No.
5,656,610 [0403] U.S. Pat. No. 5,702,932 [0404] U.S. Pat. No.
5,736,524 [0405] U.S. Pat. No. 5,780,448 [0406] U.S. Pat. No.
5,789,215 [0407] U.S. Pat. No. 5,925,565 [0408] U.S. Pat. No.
5,928,906 [0409] U.S. Pat. No. 5,935,819 [0410] U.S. Pat. No.
5,945,100 [0411] U.S. Pat. No. 5,981,274 [0412] U.S. Pat. No.
5,994,624 [0413] U.S. Pat. No. 6,280,718 [0414] U.S. Pat. No.
6,458,589 [0415] U.S. Pat. No. 6,506,574 [0416] U.S. Pat. No.
6,833,269 [0417] U.S. Pubin. 2003/0166273 A1 [0418] U.S. Pubin.
2003/0153082 A1 [0419] U.S. Pubin. 2003/0211603 [0420] U.S. Pubin.
2004/0009589 A1 [0421] U.S. Pubin. 2005/0037493 A1 [0422] U.S.
Pubin. 2005/0214939 A1 [0423] U.S. Pubin. 2007/0238170 [0424] U.S.
Pubin. 2008/0038820 [0425] U.S. Pubin. 2008/004287 [0426] U.S.
Pubin. 2008/0226558 [0427] U.S. Pubin. 2008/0254003 [0428] U.S.
Pubin. 2009/0047739 [0429] U.S. Pubin. 2010/0003757 [0430] Adams,
J. Virol., 61(5):1743-1746, 1987. [0431] Aiyar et al., EMBO J.,
17(21):6394-6403, 1998. [0432] Alexander et al., Proc. Nat. Acad.
Sci. USA, 85:5092-5096, 1988. [0433] Altmann et al., Proc. Natl.
Acad. Sci. USA, 103(38):14188-14193, 2006. [0434] Amoli et al. Int.
J. Epidemiol., 37(Suppl 1):41-45, 2008. [0435] Andrews et al., In:
Teratocarcinomas and Embryonic Stem Cells, Robertson (Ed.), IRL
Press, 207-246, 1987. [0436] Aravind and Landsman, Nucleic Acids
Res., 26(19):4413-4421, 1998. [0437] Ausubel et al., In: Current
Protocols in Molecular Biology, John, Wiley & Sons, Inc, New
York, 1994. [0438] Baer et al., Nature, 310(5974):207-211, 1984.
[0439] Bain et al., Biochem. J., 408(3):297-315, 2007. [0440]
Bennett et al, J. Biol. Chem., 277:34, 2002. [0441] Bertrand et
al., J. MoI Biol., 333(2):393-407, 2003. [0442] Bode et al., Gene
Ther. Mol. Biol., 6:33-46, 2001. [0443] Bode et al., Science,
255(5041):195-197, 1992. [0444] Brown et al. PLoS One, 5:e11373,
2010. [0445] Cahir-McFarland et al., J. Virol., 78(8):4108-19,
2004. [0446] Cahir-McFarland et al., Proc. Natl. Acad. Sci. USA,
97(11):6055-60, 2000. [0447] Carbonelli et al., FEMS Microbiol.
Lett., 177(1):75-82, 1999. [0448] Carey et al., Proc. Natl. Acad.
Sci. USA, 106:157-162, 2009. [0449] Carpenter et al., Exp Neurol.,
172(2):383-97, 2001. [0450] Chadwick et al., Blood, 102(3):906-15,
2003. [0451] Chandler et al., Proc. Natl. Acad. Sci. USA,
94(8):3596-601, 1997. [0452] Chang, et al., Frontiers in
Bioscience, 12:4393-4401, 2007. [0453] Chaudhuri et al., Proc.
Natl. Acad. Sci. USA, 98(18):10085-10089, 2001. [0454] Chen and
Okayama, Mol. Cell. Biol., 7(8):2745-2752, 1987. [0455] Chin et
al., Molecular Brain Res., 137(1-2):193-201, 2005. [0456] Chow et
al., Cytometry Commun. Clinical Cytometry, 46:72-78, 2001. [0457]
Chung et al., Trends Immunol., 24(6):343-9, 2003. [0458] Cobaleda
and Busslinger, Curr. Opin. Immunol., 20:139-148. 2008. [0459]
Cobaleda, Methods Mol. Biol., 636:233-250., 2010 [0460] Cocea,
Biotechniques, 23(5):814-816, 1997. [0461] DaCosta et al., Molec.
Pharmacol., 65(3):744-752, 2004. [0462] Davies et al., Biochem J.,
351:95-105, 2000. [0463] De Benedetti and Rhoads, Nucleic Acids
Res., 19:1925-1931, 1991. [0464] de Gouville et al., Drug News
Perspective, 19(2):85-90, 2006. [0465] Delecluse et al., Proc.
Natl. Acad. Sci. USA, 95(14):8245-50, 1998. [0466] Delecluse et
al., Proc. Natl. Acad. Sci. USA, 96(9):5188-93, 1999. [0467] Dhar
et al., Cell, 106(3):287-296, 2001. [0468] Downey et al., J. Biol.
Chem., 271(35):21005-21011, 1996. [0469] English et al., Trends in
Pharmac. Sci., 23(1):40-45, 2002. [0470] Ercolani et al., J. Biol.
Chem., 263:15335-15341, 1988. [0471] Ermakova et al., J. Biol.
Chem., 271(51):33009-33017, 1996. [0472] European Appln. EP1507865
[0473] European Appln. EPO 0273085 [0474] Evans et al., In: Cancer
Principles and Practice of Oncology, Devita et al. (Eds.),
Lippincot-Raven, NY, 1054-1087, 1997. [0475] Fechheimer et al.,
Proc Natl. Acad. Sci. USA, 84:8463-8467, 1987. [0476] Fraley et
al., Proc. Natl. Acad. Sci. USA, 76:3348-3352, 1979. [0477] Frame
et al, Biochemical J., 359:1-16, 2001. [0478] Frappier and
O'Donnell, Proc. Natl. Acad. Sci. USA, 88(23):10875-10879, 1991.
[0479] Fu et al., Blood, 113(19):4627-36, 2009. [0480] Gahn and
Schildkraut, Cell, 58(3):527-535, 1989. [0481] Gahn and Sugden, J.
Virol., 69(4):2633-2636, 1995. [0482] Gaspar-Maia et al., Nat. Rev.
Mol. Cell. Biol., 12:36-47, 2011. [0483] Gassmann et al., Proc.
Natl. Acad. Sci. USA, 92:1292-1296, 1995. [0484] Gellibert, et al.,
J. Med. Chem., 49(7):2210-2221, 2006. [0485] Ghosh and Bachhawat,
In: Liver Diseases, Targeted Diagnosis and Therapy Using Specific
Receptors and Ligands, Wu et al. (Eds.), Marcel Dekker, NY, 87-104,
1991. [0486] Gopal, Mol. Cell. Biol., 5:1188-1190, 1985. [0487]
Gorman et al., Cell, 42(2):519-26, 1985. [0488] Gould et al, Intl.
J. Neuropsychopharmacology, 7:387-390, 2004. [0489] Gould et al,
Pharmacological Res., 48:49-53, 2003. [0490] Graham and Van Der Eb,
Virology, 52:456-467, 1973. [0491] Hanna et al., Cell, 133:250-264,
2008. [0492] Harada and Kieff, J. Virol., 71(9):6611-8, 1997.
[0493] Harland and Weintraub, J. Cell Biol., 101(3):1094-1099,
1985. [0494] Hettich et al., Gene Ther., 13(10):844-56, 2006.
[0495] Hudson et al., Virology, 147(1):81-98, 1985. [0496] Inman et
al., Molec. Pharmacol., 62(1):65-74, 2002. [0497] Jenke et al.,
Proc. Natl. Acad. Sci. USA, 101 (31), 11322-11327, 2004. [0498] Jia
et al. Nat. Methods, 7:197-199, 2010. [0499] Julien et al.,
Virology, 326(2):317-328, 2004. [0500] Kaeppler et al., Plant Cell
Rep., 8:415-418, 1990. [0501] Kaji et al., Nature, 458, 771-775,
2009. [0502] Kaminska et al., Acta Biochimica Polonica,
52(2):329-337, 2005. [0503] Kanda et al., Mol. Cell. Biol.,
21(10):3576-3588, 2001. [0504] Kaneda et al., Science, 243:375-378,
1989. [0505] Kanteti et al., Lab Invest., 89(3):301-14, 2009.
[0506] Karin et al. Cell, 36: 371-379, 1989. [0507] Kato et al, J.
Biol. Chem., 266:3361-3364, 1991. [0508] Keirstead et al., J.
Neurosci., 25(19):4694-705, 2005. [0509] Kennedy and Sugden, Mol.
Cell. Biol., 23(19):6901-6908, 2003. [0510] Kennedy et al., Proc.
Natl. Acad. Sci. USA, 100:14269-14274, 2003. [0511] Kilger et al,
EMBO J., 17(6):1700-9, 1998. [0512] Kim et al., Xenobiotica,
38(3):325-339, 2008. [0513] Kira et al., Antimicrob. Agents
Chemother., 44(12):3278-84, 2000. [0514] Kirchmaier and Sugden, J.
Virol., 69(2):1280-1283, 1995. [0515] Kirchmaier and Sugden, J.
Virol., 71(3):1766-75, 1997. [0516] Kirchmaier and Sugden, J.
Virol., 72(6):4657-4666, 1998. [0517] Klein et al, Neoplasia,
8:1-8, 2006. [0518] Klein et al., Nature, 327:70-73, 1987. [0519]
Klimanskaya et al., Cloning Stem Cells, 6(3):217-45, 2004. [0520]
Knight and Robertson, J. Virol., 78(4):1981-91, 2004. [0521]
Kuppers, Blood, 114:3970-3971, 2009. [0522] Langle-Rouault et al.,
J. Virol., 72(7):6181-6185, 1998. [0523] Leblois et al., Mol.
Ther., 1(4):314-22, 2000. [0524] Leight and Sugden, Rev. Med.
Virol., 10:83-100, 2000. [0525] Levenson et al., Hum. Gene Ther.,
9(8):1233-1236, 1998. [0526] Levitskaya et al., Proc. Natl. Acad.
Sci. USA, 94(23):12616-12621, 1997. [0527] Lin et al., Nat.
Methods, 6:805-808, 2009. [0528] Lin et al., Science,
221(4610):578-9, 1983. [0529] Lindner and Sugden, Plasmid, 58:1-12,
2007. [0530] Ludwig et al., Nat. Biotechnol., 24(2):185-187, 2006b.
[0531] Ludwig et al., Nat. Methods, 3(8):637-46, 2006a. [0532]
Macejak and Sarnow, Nature, 353:90-94, 1991. [0533] Mack and
Sugden, Cancer Res., 68(17):6963-8, 2008. [0534] Mackey and Sugden,
Mol. Cell. Biol., 19(5):3349-3359, 1999. [0535] Mackey et al., J.
Virol., 69(10):6199-6208, 1995. [0536] Maniatis, et al., Molecular
Cloning, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring
Harbor, N.Y., 1988. [0537] Manzini et al., Proc. Natl. Acad. Sci.
USA, 103(47):17672-17677, 2006. [0538] Marechal et al., J. Virol.,
73(5):4385-4392, 1999. [0539] Margolskee et al., Mol. Cell. Biol.,
8:2837-2847, 1988. [0540] Marie-Cardine et al., Clin. Immunol.,
127(1):14-25, 2008. [0541] Martin, et al., Nature Immunology,
6:111-184, 2005. [0542] Mattingly et al, J. Pharmacol. Experimen.
Therap., 316:456-465, 2006. [0543] Middleton and Sugden, J. Virol.,
66(1):489-495, 1992. [0544] Munsie et al., Curr. Biol., 10:989,
2000. [0545] Nabel et al., Science, 244(4910):1342-1344, 1989.
[0546] Nanbo et al., EMBO J., 26:4252-62, 2007. [0547] Narazaki, et
al., Circulation, 118(5):498-506, 2008. [0548] Ng et al.,
Development, 132(5):873-84, 2005. [0549] Ng, Nuc. Acid Res.,
17:601-615, 1989. [0550] Nicolau and Sene, Biochim. Biophys. Acta,
721:185-190, 1982. [0551] Nicolau et al., Methods Enzymol.,
149:157-176, 1987. [0552] Niller et al., J. Biol. Chem.,
270(21):12864-12868, 1995. [0553] Noble et al, Proc. Natl. Acad.
Science, USA, 102:6990-6995, 2005. [0554] Norseen et al., J.
Virol., 83(20):10336-46, 2009. [0555] Ohe et al., Hum. Gene Ther.,
6:325-333, 1995. [0556] Okita and Yamanaka, Exp. Cell Res.,
316:2565-2570, 2010. [0557] Okita et al., Nat. Protoc., 5:418-428,
2010. [0558] Okita et al., Science, 322:949-953, 2008. [0559]
Omirulleh et al., Plant Mol. Biol., 21(3):415-428, 1993. [0560]
Pannell et al., EMBO J., 19(21):5884-94, 2000. [0561] Parcells et
al., J. Virol., 73(2):1362-1373, 1999. [0562] Parker et al., J.
Virol., 70(8):5731-4, 1996. [0563] PCT Appln. WO 01/81549 [0564]
PCT Appln. WO 03/000868 [0565] PCT Appln. WO 03/004605 [0566] PCT
Appln. WO 03/006950 [0567] PCT Appln. WO 03/050249 [0568] PCT
Appln. WO 03/050250 [0569] PCT Appln. WO 03/050251 [0570] PCT
Appln. WO 04/007696 [0571] PCT Appln. WO 07/113,505 [0572] PCT
Appln. WO 08/006,583 [0573] PCT Appln. WO 08/094,597 [0574] PCT
Appln. WO 94/09699 [0575] PCT Appln. WO 95/06128 [0576] PCT Appln.
WO 99/20741 [0577] Pelletier and Sonenberg, Nature, 334:320-325,
1988. [0578] Perales et al., Proc. Natl. Acad. Sci. USA,
91:4086-4090, 1994. [0579] Piechaczek et al., Nucleic Acids Res.,
27:426-428, 1999. [0580] Potrykus et al., Mol. Gen. Genet.,
199(2):169-177, 1985. [0581] Potter et al., Proc. Natl. Acad. Sci.
USA, 81:7161-7165, 1984. [0582] Quitsche et al., J. Biol. Chem.,
264:9539-9545, 1989. [0583] Rahman et al., J. Exp. Med.,
193(3):237-44, 2001. [0584] Rawlins et al., Cell, 42((3):859-868,
1985. [0585] Reisman and Sugden, Mol. Cell. Biol., 6(11):3838-3846,
1986. [0586] Reisman et al., Mol. Cell. Biol., 5(8):1822-1832,
1985. [0587] Richards et al., Cell, 37:263-272, 1984. [0588]
Rinehart et al., J. Clinical Oncol., 22:4456-4462, 2004. [0589]
Ring et al., Diabetes, 52:588-595, 2003. [0590] Rippe, et al., Mol.
Cell. Biol., 10:689-695, 1990. [0591] Ritzi et al., J. Cell Sci.,
116(Pt 19):3971-3984, 2003. [0592] Sambrook et al., Molecular
Cloning: A Laboratory Manual, Cold Spring Harbor, Cold Spring
Harbor Press, 1989. [0593] Schaarschmidt et al., EMBO J.,
23(1):191-201, 2004. [0594] Schaffer et al.; Gene, 302(1-2):73-81,
2003. [0595] Schepers et al., EMBO J., 20(16):4588-4602, 2001.
[0596] Sears et al., J. Virol., 78(21):11487-11505, 2004. [0597]
Sinclair et al, EMBO J., 13(14):3321-8, 1994, [0598] Sompallae et
al., PLoS One, 5:e12052, 2010. [0599] Su et al., Proc. Natl. Acad.
Sci. USA, 88(23):10870-19874, 1991. [0600] Sugden and Warren, J.
Virol., 63(6):2644-2649, 1989. [0601] Sun et al., Proc. Natl. Acad.
Sci. USA, 107(7):3146-51, 2010. [0602] Suzuki et al., Cancer Res.,
67(5):2351-2359, 2007. [0603] Thorley-Lawson and Gross, N. Engl. J.
Med., 350:1328-1337, 2004. [0604] Tojo et al., Cancer Science,
96(11):791-800, 2005, [0605] Tur-Kaspa et al., Mol. Cell. Biol.,
6:716-718, 1986. [0606] van Dongen et al., Leukemia, 17:2257-2317,
2003. [0607] Wada et al., Int. Immunol., 23:65-74, 2011. [0608]
Wagman, Current Pharmaceutical Design, 10:1105-1137, 2004. [0609]
Wagner et al., Proc. Natl. Acad. Sci. USA 87(9):3410-3414, 1990.
[0610] Wang et al., Mol. Cell. Biol., 26(3):1124-1134, 2006. [0611]
Wang et al., Mol. Cell. Biol., 26(3):1124-1134, 2006. [0612] Wang
et al., Proc. Natl. Acad. Sci. USA, 104:7612-7616, 2007. [0613]
Warren et al., Cell Stem Cell, 7:618-630, 2010. [0614] Wendtner et
al., Exp. Hematol., 31(2):99-108, 2003. [0615] Wilson et al.,
Science, 244:1344-1346, 1989. [0616] Woltjen et al., Nature, 458,
766-770, 2009. [0617] Woltjen et al., Nature, 458:766-770, 2009.
[0618] Wong et al., Gene, 10:87-94, 1980. [0619] Wrzesinski et al.,
Clinical Cancer Res., 13(18):5262-5270, 2007. [0620] Wu and Wu,
Adv. Drug Delivery Rev., 12:159-167, 1993. [0621] Wu and Wu,
Biochemistry, 27: 887-892, 1988. [0622] Wu and Wu, J. Biol. Chem.,
262:4429-4432, 1987. [0623] Wysokenski and Yates, J. Virol.,
63(6):2657-2666, 1989. [0624] Xu et al., Dev. Cell, 2:251-252,
2002. [0625] Yamanaka et al., Cell, 131(5):861-72, 2007. [0626]
Yamanaka, Cell Stem Cell, 1:39-49, 2007. [0627] Yang and Russell,
Proc. Natl. Acad. Sci. USA, 87:4144-4148, 1990. [0628] Yates and
Guan, J. Virol., 65(1):483-488, 1991. [0629] Yates et al., J.
Virol., 74(10):4512-4522, 2000. [0630] Yates et al., Nature,
313:812-815, 1985. [0631] Yates et al., Nature, 313:812-815, 1985.
[0632] Yates et al., Proc. Natl. Acad. Sci. USA, 81:3806-3810,
1984. [0633] Yates, Cancer Cells, (6)197-205, 1988. [0634] Ying,
Nature, 453:519-23, 2008. [0635] Yu et al., Antimicrob. Agents
Chemo., 53(10):4311-4319, 2009. [0636] Yu et al., Science,
318:1917-1920, 2007. [0637] Yu et al., Science, 318:1917-1920,
2007. [0638] Yu et al., Science, 324:797-801, 2009. [0639] Zhang et
al., Angew. Chem., Int. Ed., 48:2542-2545, 2009. [0640] Zhang et
al., Bioorganic Med. Chem. Letters; 10:2825-2828, 2000. [0641] Zhou
et al., Cell Stem Cell, 4:381-384, 2009. [0642] Zhou et al., EMBO
J., 24(7):1406-1417, 2005. [0643] Zhou et al., Nature,
462(7276):1070-4, 2009. [0644] Zimber-Strobl et al., J. Virol.,
65(1):415-23, 1991.
Sequence CWU 1
1
6124DNAArtificial SequenceSynthetic primer 1catagaagaa gaagaggatg
aaga 24224DNAArtificial SequenceSynthetic primer 2gtagggattc
gagggaatta ctga 24322DNAArtificial SequenceSynthetic primer
3aggaacgtga atctaatgaa ga 22421DNAArtificial SequenceSynthetic
primer 4aagtgacaac cgcagtaagc a 21520DNAArtificial
SequenceSynthetic primer 5cacggtagtg ctgcagttgc 20627DNAArtificial
SequenceSynthetic primer 6cccagaatca acagactaac caagccg 27
* * * * *